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ABSTRACT 
 
A NEW MOUSE MODEL OF METASTATIC GASTRIC CANCER AND 
E-CADHERIN PRIMARY TUMOR SUPPRESSION  
Jacob Till 
Sandra Ryeom 
Gastric cancer is the fifth most common cancer and the third leading cause of cancer 
death worldwide. The majority of patients with gastric cancer are diagnosed with 
disseminated disease and even patients diagnosed with early stage disease have high rates 
of recurrence. The utility of current mouse models of gastric cancer is limited by slow 
development of gastric tumors and lack of metastasis.  Here I describe a new mouse 
model of gastric cancer driven by p53 loss, Cdh1 loss, and oncogenic Kras expression in 
gastric parietal cells (referred to as ACKPY mice). I generated these mice to investigate 
the contribution of oncogenic Kras to the progression of gastric cancer given the high rate 
of mutation and amplification of the RTK/Ras pathway identified in gastric cancer 
patients. These mice develop mixed-type gastric adenocarcinomas with metastases to 
lymph nodes, lung, and liver. Oncogenic Kras and loss of Trp53 is sufficient to drive 
rapid carcinogenesis in a variety of models. Therefore, I tested if loss of E-cadherin was 
necessary for the onset of gastric adenocarcinoma in gastric parietal cells by generating 
ACKPY mice with one or two alleles of wild-type Cdh1 (E-cadherin). E-cadherin 
expression significantly increased survival and the limited number of mice with gastric 
tumors have tumors that were focal in nature, suggesting an additional event was 
necessary for gastric tumorigenesis. Loss of E-cadherin expression was observed in some 
 vi 
of these tumors, suggesting that its loss may be necessary for gastric tumorigenesis in this 
model. I show that loss of E-cadherin in our model increases β-catenin signaling and that 
inhibition of β-catenin signaling prolonged survival of ACKPY mice. Microarray data 
comparing gene expression in stomachs harvested from Cdh1fl/fl and Cdh1fl/+ mice 
showed a correlation between E-cadherin loss and upregulation of oncogenic Kras 
signaling. Gene sets regulated by each of the main Kras effector pathways were over-
represented in our microarray data. Examination of ERK phosphorylation revealed that 
E-cadherin likely does not regulate MAPK activity in our model. The upregulation of 
oncogenic Kras target genes that result from the loss of E-cadherin may alternatively be 
explained by E-cadherin regulation of other Kras effector pathways. 
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CHAPTER 1 INTRODUCTION 
i. Abstract 
The term gastric cancer generally refers to adenocarcinoma of the stomach, as 
approximately 95% of all gastric cancers are adenocarcinomas. Gastric cancer is the fifth 
most common cancer worldwide and the third leading cause of cancer death (Jacques 
Ferlay et al. 2015; J Ferlay et al. 2013). The majority of gastric cancers are diagnosed 
after they have progressed to disseminated disease (Surveillance Research Program, n.d.) 
and even patients diagnosed with early stage gastric cancer have relatively poor survival 
due to high rates of recurrence (Washington 2010). Since 1965, gastric adenocarcinoma 
has been commonly been divided into two main subcategories: intestinal-type and 
diffuse-type (Lauren 1965). The progression to intestinal-type gastric cancer follows a 
well-described sequence known as the Correa Pathway: inflammation leads to atrophy, 
followed by metaplasia, then dysplasia, and finally carcinoma (Correa 1992; Fox and 
Wang 2007). While little is known about the histologic and pathologic changes that occur 
during the progression to diffuse-type gastric cancer, both sporadic and hereditary forms 
are associated with loss of expression of E-cadherin (Graziano, Humar, and Guilford 
2003). The mouse has long been used as a model of gastric cancer; initially chemically 
induced models and Helicobacter infection models were used, which was followed by the 
development of genetically engineered mouse models (Poh et al. 2016; Hayakawa et al. 
2013; Yu, Yang, and Nam 2014; Giraud and Judd 2009). 
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ii. Gastric Cancer Epidemiology 
Gastric cancer is the fifth most common cancer worldwide (fourth among men) 
with almost 1 million new cases in 2012 (Table 1-1). The 952,000 new cases diagnosed 
in 2012 (6.8% of all malignancies) put it behind only cancers of the lung, breast, 
colorectum, and prostate. Greater than 70% of gastric cancer cases occur in the 
developing world (677,000 cases in 2012) with more than half in Eastern Asia (549,000 
cases in 2012). Incidence rates among men (631,000 cases in 2012) are about twice as 
high as those among women (320,000 cases in 2012). Though it ranks as the fifth most 
common cancer, with 723,000 deaths (8.8% of all cancer deaths) in 2012 (Table 1-1), it is 
the second most deadly among the top 5 cancers, behind lung cancer (Jacques Ferlay et 
al. 2015; J Ferlay et al. 2013). 
Cancer Incidence Mortality 
Lung 1824701 1589925 
Breast 1671149 521907 
Colorectum 1360602 693933 
Prostate 1094916 307481 
Stomach 951594 723073 
Liver 782451 745533 
Cervix uteri 527624 265672 
Oesophagus 455784 400169 
Bladder 429793 165084 
Non-Hodgkin lymphoma 385741 199670 
Leukaemia 351965 265471 
Pancreas 337872 330391 
Kidney 337860 143406 
Corpus uteri 319605 76160 
Lip, oral cavity 300373 145353 
Thyroid 298102 39771 
Brain, nervous system 256213 189382 
Ovary 238719 151917 
Melanoma of skin 232130 55488 
Gallbladder 178101 142823 
Larynx 156877 83376 
Other pharynx 142387 96105 
Multiple myeloma 114251 80019 
Nasopharynx 86691 50831 
Hodgkin lymphoma 65950 25469 
Testis 55266 10351 
Kaposi sarcoma 44247 26974 
Table 1-1. Global cancer incidence and mortality by cancer type (2012). 
(J Ferlay et al. 2013) 
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The incidence of gastric cancer worldwide has declined significantly since 1975 
(the first time such statistics were compiled) when it was the most common malignancy 
(J Ferlay et al. 2013). In the US, this decline can be observed in the decrease in gastric 
cancer mortality since the 1930s (Siegel, Naishadham, and Jemal 2012). Many studies 
have shown that this decline is due specifically to a decrease in intestinal-type gastric 
cancer, which has been hypothesized to be highly associated with environmental risks. 
This decline predates the discovery and treatment of the specific pathogen H. pylori 
(which I will discuss later). One hypothesis explaining the decreased incidence in gastric 
cancer is the rise in popularity of refrigeration technology (Howson, Hiyama, and 
Wynder 1986; La Vecchia et al. 1990). This improved food storage, reduced salt-based 
preservation, prevented bacterial and fungal contamination, and allowed greater 
incorporation of fresh food and vegetables into the diet. 
iii. Gastric Cancer in the Clinic 
The signs and symptoms of gastric cancer, if present at all, tend to be vague and 
nonspecific in nature. Patients may experience weight loss, anorexia, fatigue, epigastric 
discomfort, pain, postprandial fullness, heartburn, indigestion, nausea, or vomiting. None 
of these signs and symptoms unequivocally indicates gastric cancer and more commonly 
indicate other benign disease. As a result, many patients are diagnosed at late stage. Signs 
and symptoms of incurable disease include ascites, jaundice, palpable mass, intestinal 
obstruction, ovarian mass (Krukenber’s tumor), peritoneal implant in the pelvis 
(Blumer’s shelf), and nodal metastasis around the umbilicus (Sister Mary Joseph’s 
Node), to a supraclavicular lymph node (Vichow’s node) or an axillary node (Irish node) 
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(Avital et al. 2015). Data from the Surveillance, Epidemiology, and End Results (SEER) 
Program of the National Cancer Institute (NCI) compiled from 2004-2013 show that at 
least 60% of patients present with at least regionally invasive disease (Surveillance 
Research Program, n.d.). 
 
Figure 1-1. Stage distribution of Surveillance, Epidemiology, and End Results (SEER) 
data on gastric cancer from 2004-2013. 
(Surveillance Research Program, n.d.) 
 
There are a number of known risk factors for gastric cancer ranging from 
environmental to genetic factors. Nutritional risk factors include high salt and nitrate 
diets, low dietary vitamin A and C, poor food preparation (smoking, curing), lack of 
refrigeration, and poor drinking water (well water). Rubber and coal workers are at 
increased risk due to their occupational exposures. Other environmental factors include 
H. pylori infection, cigarette smoking, Epstein-Barr virus, radiation exposure, benign 
gastric ulcers, and prior treatment for MALT lymphoma. Type A blood, pernicious 
anemia, family history (without known genetic factors), Hereditary Nonpolyposis Colon 
Cancer, Familial Adenomatous Polyposis, Li-Fraumeni Syndrome, BRCA1/2 mutation, 
and Hereditary Diffuse Gastric Cancer are all genetic risk factors for gastric cancer. 
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Finally, several precursor lesions increase the risk of progression to gastric cancer 
including adenomatous gastric polyps, dysplasia, chronic gastritis, intestinal metaplasia, 
and Menetrier disease (Avital et al. 2015). 
In the US, staging follows the traditional TNM staging as defined by the 
American Joint Committee on Cancer (AJCC). Increasing stage correlates with increased 
mortality. Staging is determined through the use of multiple modalities including physical 
exam, endoscopy, biopsy, imaging, and surgery. Notably, stage 1A patients, considered 
“curable,” have only a 71% 5-year survival rate (Washington 2010). Recommended 
therapy for patients with stage 1 disease is total or sub-total gastrectomy with 
lymphadenoectomy. Postoperative chemoradiation is recommended for patients with 
stage 1B disease. For all other patients, a combination of palliation, neoadjuvant 
chemoradiation, surgery, and adjuvant chemoradiation is recommended based on stage 
and medical fitness (Waddell et al. 2013). 
iv. Human Gastric Histology 
To understand the biology of gastric cancer, it is important to understand the 
anatomy and histology of the stomach. The stomach is a large, saccular organ with a 
volume of 1.2-1.5 liters and a capacity of more than 3 liters. Food enters the stomach 
from the esophagus passing through the gastro-esophageal junction and exits the stomach 
via the pyloric sphincter where it enters the duodenum. The stomach is subdivided into 5 
regions: the cardia, the fundus, the corpus (body), the antrum, and the pyloruos (Figure 
1-2A). The gastric wall (from inner to outer) is composed of the mucosa, submucosa, 
muscularis propria, and serosa. The mucosa and submucosa are thrown into folds called 
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rugae. The inner surface of the mucosa is perforated by millions of foveollae or gastric 
pits that lead to the gastric glands.  The mucosa is composed of the surface epithelium, 
lamina propria, and muscularis mucosa. Gastric adenocarcinoma arises from this surface 
epithelium (Figure 1-2B). 
The more superficial compartment of the gastric mucosa is called the foveolar 
compartment. It is primarily composed of columnar mucous cells and is relatively 
uniform through the stomach. The foveolar layer consists of the more superficial mucous 
cells, which secrete mucins and the deeper, less mucinous, mucous neck cells, which are 
thought to give rise to both the foveolar and the deeper glandular compartments (Figure 
1-2C). 
The deeper glandular compartment is composed of gastric glands. The glands 
vary in their composition of four main cell types depending on the region of the stomach. 
The four main cell types are mucous cells, parietal cells, chief cells, and endocrine cells. 
Parietal cells are the acid producing cells, pumping hydrogen ions out into the lumen in 
exchange for potassium ions. Parietal cells are also important for their production of 
secreted signals that regulate the differentiation and maintenance of gastric progenitors. 
They are typically located in the superficial half of the glandular layer, appearing large 
and pale pink on hematoxylin & eosin (H&E) staining. Chief cells produce and secrete 
pepsinogens (proteolytic proenzymes). They are typically located in the lower half of the 
glandular layer, appearing smaller and dark purple on H&E stain. Endocrine cells are 
scattered throughout the gastric glands and appear triangular shaped with brightly pink 
granules on H&E stain. They are characterized by the hormones they secrete; some of the 
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most common endocrine cells are gastrin-producing G cells, somatostatin-producing D 
cells, and endothelin-producing X cells (Adler, Farraye, and Crawford 2015) (Figure 
1-2C). 
 
Figure 1-2 Normal gastric histology. 
(A) Schematic view of human stomach regions 
(B) Schematic diagram of stomach wall 
(C) Schematic diagram of a gastric pit/gland 
v. Mouse Gastric Histology 
The mouse stomach has some notable differences from the human stomach that 
must be kept in mind when discussing mouse models of gastric cancer. Whereas the 
human stomach is relatively uniform in its histology, the mouse stomach is subdivided 
into two sections. The proximal third comprises the non-glandular forestomach that is 
squamous and esophageal in morphology. The distal two-thirds is referred to as the 
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glandular stomach and is analogous to the human stomach. A projecting fold, called the 
limiting ridge, demarcates these two regions. The glandular stomach is analogous to the 
human stomach and is similarly divided into anatomic regions that differ in their 
glandular cellular content: cardia, corpus, pyloric antrum (Scudamore 2013) (Figure 1-3). 
 
Figure 1-3. Schematic view of mouse stomach regions 
vi. Gastric Cancer Histologic Classification 
The term gastric cancer refers to adenocarcinoma of the stomach, as 
approximately 95% of all gastric cancers are adenocarcinomas. Since 1965 gastric 
adenocarcinoma has been commonly divided into two main subcategories: intestinal-type 
and diffuse-type (Lauren 1965). The World Health Organization (WHO) subdivides these 
categories further and adds other subtypes. The intestinal-type is characterized by the 
formation of glands or tubules. WHO tubular and papillary adenocarcinoma fall into this 
category. The diffuse-type is characterized by single cells or small clusters of cells that 
are poorly cohesive and do not form glands. Signet ring cells, so called for the large 
mucin droplet that displaces and flattens the nucleus to one side, are pathognomonic of 
diffuse-type gastric cancer. WHO poorly cohesive carcinoma and mucinous 
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adenocarcinoma fall into this category. More recently, a third category referred to as 
“mixed-type” has been added to the Lauren classification to include neoplasms with both 
intestinal- and diffuse-type characteristics (Lauwers 2015). 
Intestinal-type gastric cancer is found more commonly in areas of the world with 
a higher incidence of gastric cancer and is the subtype that has declined the most rapidly 
in the past few decades. Additionally, it is more common among older individuals and 
men. Diffuse-type gastric cancer rates are more homogenous across the world, the 
incidence has declined more slowly, and it occurs with similar frequency between the 
sexes and throughout all age groups. These data suggest that the intestinal-type is more 
highly associated with environmental factors, whereas the diffuse-type is less 
environmentally associated (Muñoz and Asvall 1971). 
Though both types are associated with H. pylori infection, little else is known 
about the histologic and pathologic changes that occur during the progression to diffuse-
type gastric cancer. The progression to intestinal-type gastric cancer follows a well-
described sequence known as the Correa Pathway (Figure 1-4) (Correa 1992; Fox and 
Wang 2007). This progression begins with chronic inflammation (gastritis) often due to 
the specific pathogen H. pylori. The inflammation leads to epithelial defects including 
gland dilation and mineralization in addition to the infiltration of lymphocytes. It is 
followed by an atrophic gastritis that is characterized by loss of parietal cells and focal 
fibrosis. The definitions of atrophic gastritis and intestinal metaplasia often overlap; 
however, the loss of parietal cells in atrophic gastritis is considered mechanistically 
important. Loss of acid production (achlorhydria) leads to bacterial overgrowth and loss 
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of secreted signals dysregulates growth and differentiation of progenitors. This is 
followed by intestinal and/or pseudopyloric/spasmolytic polypeptide-expressing 
metaplasia (SPEM). Intestinal metaplasia is characterized by a transition from normal cell 
architecture to an elongated intestinal phenotype with mucous droplets and occasionally 
the formation of goblet cells. SPEM has recently been recognized as more closely 
associated with progression to gastric cancer and it has been suggested to be the true 
precursor lesion. It is a type of mucous metaplasia that, as the name suggests, is 
characterized by expression of spasmolytic polypeptide. This is followed by dysplasia 
with irregular glandular architecture characterized by infolding and branching as well as 
cellular and nuclear atypia. The final stage is frank carcinoma with invasion (Fox and 
Wang 2007) (Figure 1-4). 
 
Figure 1-4. Correa pathway (Fox and Wang 2007).  
vii. Hereditary Diffuse Gastric Cancer 
Genetically engineered mouse models are generated utilizing common or 
hereditary genetic lesions to induce cancer; this has been the case with gastric cancer as 
well. In 1964, Jones reported on the case of a 21-year-old Maori male with an inoperable 
carcinoma of the stomach. This was particularly interesting because of the man’s young 
age and the high incidence of the disease in close relatives (five with proven gastric 
cancer and several others suspected) (Jones 1964). This kindred was updated in 1998 by 
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Guilford et al to include an additional 25 cases of gastric cancer that had occurred since 
the initial report (Guilford et al. 1998). Jones termed this phenomenon “early onset 
familial gastric cancer,” but it would come to be known as “Hereditary Diffuse Gastric 
Cancer” (HDGC). The inheritance pattern observed in the Maori kindred was one of 
dominant inheritance with incomplete penetrance (Guilford et al. 1998), consistent with a 
susceptibility gene as observed in other hereditary cancer syndromes (Nagy, Sweet, and 
Eng 2004). 
Using classical genetic mapping techniques, Guilford and colleagues mapped the 
genetic locus to chromosome 16q22.1, which contains the candidate gene for E-cadherin 
(CDH1). E-cadherin is a calcium dependent cell-cell adhesion protein important for 
establishing cellular polarity and maintaining normal tissue morphology. Loss of 
expression of E-cadherin is found in many cancers and correlates with infiltrative and 
metastatic ability; therefore, it has been termed an “invasion suppressor gene” (A. O. O. 
Chan 2006). Single-stranded conformational polymorphism screening of coding exons 
revealed a band shift in exon 7 in two affected and 4 obligate carriers that was not present 
in 150 unrelated chromosomes. Upon direct sequencing, the first causal mutation 
(G1008T) was identified. This mutation, in the final nucleotide of an exon, removes the 
splice site. Guilford et al identified an additional frame shift mutation and premature stop 
codon in two additional families with HDGC. The disease appears to follow a classic 
two-hit sequence as expression of E-cadherin is lost in HDGC tumors. However, unlike 
many other inherited cancer syndromes, this loss is frequently due to promoter 
hypermethylation rather than loss of heterozygosity. Further, CDH1 hypermethylation 
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and loss of expression is found in the majority of sporadic cases of diffuse-type gastric 
cancer (Graziano, Humar, and Guilford 2003). Interestingly, H. pylori infection has been 
shown to modulate promoter methylation of CDH1 (Liu et al. 2014). 
The risk of gastric cancer in patients with HDGC-associated mutations has been 
estimated at approximately 70% (67% in men and 83% in women) with an additional risk 
of lobular breast adenocarcinoma in women of 52% (Guilford, Humar, and Blair 2010; 
Kaurah et al. 2007). Over 100 different CDH1 mutations have been identified with no 
characteristic mutational types or hotspots. HDGC patients typically present with diffuse-
type gastric adenocarcinoma with signet ring cells and linitis plastica (at late stage) that is 
indistinguishable from sporadic forms of diffuse-type gastric cancer. The only option for 
patients with known HDGC to prevent cancer is prophylactic total gastrectomy. 
However, this option comes with significant morbidity including alteration of eating 
habits, dumping syndrome, diarrhea, and weight loss. Surveillance endoscopy is a poorly 
favored option as even advanced diffuse-type gastric cancer can be missed due to its 
often-subtle appearance. Current recommendations are for prophylactic total gastrectomy 
prior to 20 years of age when mortality risk from surgery and mortality risk from HDGC 
are about equal at <1% (Guilford, Humar, and Blair 2010). 
While E-cadherin has been identified as the genetic hit in HDGC, the exact 
mechanism by which a mutation leads to gastric cancer is still not known. Several 
mechanisms have been proposed to explain E-cadherin’s tumor suppressor activity 
including sequestration of β-catenin, regulation of Rho GTPases, interaction with EGFR, 
and inhibition NF-κB. E-cadherin sequesters β-catenin at the adherens junction in the 
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cadherin-catenin complex that links the adherens junction to the cytoskeleton. Loss of E-
cadherin may lead to increased free β-catenin, which can translocate to the nucleus, bind 
its transcription factor partners and transcribe classical WNT pathway target genes. 
Further, E-cadherin regulates Rho GTPases involved in cell motility and migration. E-
cadherin has also been shown to interact with EGFR and act in a context-dependent 
manner to activate or inhibit its signaling. Finally, E-cadherin can inhibit the activity of 
NF-κB likely through binding and sequestering its p65 subunit (Liu et al. 2014). 
viii. Gastric Cancer Molecular Classification 
Two recent studies have attempted to molecularly classify gastric 
adenocarcinomas using high-throughput genomic technologies. The Cancer Genome 
Atlas Research Network (TCGA) analyzed a panel of 295 treatment-naïve gastric 
adenocarcinoma samples for: copy number variation, whole-exome sequencing, 
methylation profiling, RNA sequencing, microRNA sequencing, and reverse-phase 
protein array, and microsatellite instability (MSI). Integration of the results of 
unsupervised clustering on each platform classified the samples into four groups (Bass et 
al. 2014). The first TCGA group was associated with high Epstein-Bar virus (EBV) 
burden and promoter hypermethylation. The second group had high MSI, mutation rates, 
and promoter hypermethylation. The remaining samples were divided into two groups 
based on the degree of copy number variation. Further analysis defined four similar sub-
types based on EBV positivity (9%), high MSI (22%), genomic stability (GS, 20%), or 
chromosomal instability (CIN, 50%). Each sub-type was further characterized by its 
associated mutational spectrum, notable pathway/gene activation or inactivation, and 
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histologic type. The GS sub-type contained 73% of the diffuse-type gastric cancer 
samples and was associated with CDH1 and RHOA mutations. The CIN group was 
associated with intestinal morphology, TP53 mutation, and receptor tyrosine kinase 
(RTK)-RAS activation (Figure 1-5) (Bass et al. 2014). 
Figure 1-5. Summary of The Cancer Genome Atlas (TCGA) gastric cancer subtypes 
(Poh et al. 2016; Bass et al. 2014). 
 
The Asian Cancer Research Group (ACRG) analyzed a panel of 291 primary 
gastric tumors for: expression profiling, copy number variation, and targeted gene 
sequencing. For this classification, principal components analysis separated the samples 
into three clusters. The first was positively correlated with an epithelial-to-mesenchymal 
transition (EMT) signature and negatively correlated with a cell proliferation signature. 
The second correlated with MSI, cytokine signaling, cell proliferation, and methylation 
signatures. The remaining cluster of samples were subdivided based on their TP53 
activation status, resulting in four subtypes: MSI, microsatellite stable (MSS)/EMT, 
MSS/TP53+, and MSS/TP53-. Each sub-type had distinct genomic alterations, survival 
outcomes, and recurrence rates. The authors note that the MSS/EMT subtype was 
predominantly (80%) diffuse-type. However, it only contained 27% of the diffuse-type 
samples and the highest rate of CDH1 mutation was in the MSI group. The highest 
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percentage of EGFR and ERBB2 (HER2) amplifications were found in the MSS/TP53- 
group, but the highest rate of KRAS mutation was in the MSI group (Figure 1-6) 
(Cristescu et al. 2015). 
Figure 1-6. Summary of Asian Cancer Research Group (ACRG) gastric cancer subtypes 
(Poh et al. 2016; Cristescu et al. 2015). 
ix. Animal Models of Gastric Cancer 
To advance our understanding of the cellular and molecular mechanisms 
underlying gastric cancer progression and to develop new treatments, there is a need for a 
mouse model that better replicates advanced human disease. Three types of mouse 
models have traditionally been used: chemically induced models, helicobacter induced 
models, and genetically engineered models. These models have also been combined into 
hybrid models to study their interactions and to accelerate or advance disease 
progression. However, current animal models of gastric cancer do not adequately 
recapitulate advanced disease because of long latency periods and the lack of metastatic 
disease or the presence of metastasis only to regional nodes (Hayakawa et al. 2013; 
Giraud and Judd 2009; Poh et al. 2016; Yu, Yang, and Nam 2014). 
The earliest mouse model of gastric cancer is the N-methyl-N-nitrosourea (MNU) 
induced model (Tatematsu et al. 1992). However, most mice died due to squamous cell 
carcinomas (SCC) of the forestomach prior to adenocarcinoma development in the 
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glandular stomach. Reducing the dose of MNU in the drinking water produced 
adenocarcinomas without the confounding forestomach SCCs (Tatematsu et al. 1993; 
Yamachika et al. 1998). The MNU model has been utilized in combination with 
genetically engineered mice to investigate many signaling pathways involved in gastric 
cancer, including p53 (Yamamoto et al. 2000), E-cadherin (Humar et al. 2009), β-catenin 
(Takasu et al. 2008), and NF-κB (Sakamoto et al. 2010) (Table 1-2). More recently, two 
chemically induced models of precancerous change have come into use: the parietal cell 
specific protonophore DMP-777 and the structurally related L-635 (Hayakawa et al. 
2013). DMP-777 was first used in rats (Goldenring et al. 2000), but in both rats and mice 
it causes acute oxyntic atrophy, mucous cell hyperplasia, and SPEM (Goldenring et al. 
2000; Nomura et al. 2005). In contrast, treatment with L-635 is more rapid and has the 
additional feature of a prominent inflammatory infiltration (Nam et al. 2010). 
Other mouse models of gastric cancer attempted to utilize the specific pathogen 
H. pylori as it is known to contribute to gastric carcinogenesis in humans. In the late 
1980s it was shown that mice are resistant to infection with the human pathogen H. pylori 
(Ehlers, Warrelmann, and Hahn 1988; Cantorna and Balish 1990), so the feline isolate H. 
felis (A Lee et al. 1990) or H. pylori mutant strains have been used instead (Adrian Lee et 
al. 1997). H. felis infection produces gastritis and atrophy with some strain dependence 
(A Lee et al. 1990; A Lee et al. 1993; Sakagami et al. 1996). Prolonged infection leads to 
hyperplasia, metaplasia, and dysplasia leading to adenocarcinoma (Fox et al. 2002). 
Results of infection with the commonly used Sydney strain of H. pylori (SS1) are strain 
specific, it causes gastritis and atrophy but no carcinoma at 23 months in C57BL/6 and 
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Balb/cA mice (Xin Wang et al. 2003) but causes intra-mucosal cancer at 15 months in 
B6.129 mice (Rogers et al. 2005). Infection with H. felis or H. pylori strains have also 
been used in conjunction with MNU (Tomita et al. 2011; Han et al. 2002) and genetic 
models of gastric cancer (T. C. Wang et al. 2000; Fox et al. 2002). 
Genetic Model Finding Ref 
Trp53+/+ vs. +/- vs. -/- Higher incidence of tumors in Trp53-/- mice. 
No Trp53 mutations in the tumors of any group 
(Yamamoto 
et al. 2000) 
Cdh1+/+ vs. Cdh1+/- Equal incidence of intestinal-type adenoCA. 
Diffuse-type was 11x more common in Cdh1+/-.  
(Humar et 
al. 2009) 
K19-C2mE Tg  
± H. pylori SS1 
β-catenin accumulation in pyloric but not fundic 
tumor cell cytoplasm and nuclei. 
β-catenin mutations were more common in H. 
pylori associated tumors. 
(Takasu et 
al. 2008) 
Ikkβfl/fl vs. IkkβΔFoxa3 Decreased tumorigenesis with KO of Ikkβ. 
Increased apoptotic cell death in Ikkβ KO. 
Apoptosis was dependent on decreased IL1α. 
(Sakamoto 
et al. 2010) 
Table 1-2. Relevant compound MNU-induced/genetically engineered models. 
 
The age of transgenic mouse models has seen a plethora of genetically engineered 
mouse models (GEMMs) of gastric cancer. There are 24 models that result in at least 
intra-mucosal gastric cancer and more that model pre-neoplastic changes (Poh et al. 
2016; Hayakawa et al. 2013; Yu, Yang, and Nam 2014; Giraud and Judd 2009). The long 
latency and lack of metastasis in the majority of these models limit their utility. Relevant 
to our studies are the models that utilize deletion of Cdh1 and activate oncogenic Kras as 
well as the more recent models that attempt to define the cell of origin of gastric cancer. 
As described earlier, germline mutations in the Cdh1 gene (encoding E-cadherin) 
are responsible for HDGC. In 2011, Mimata et al attempted to model HDGC using the 
Cdh1 conditional allele and a gastric parietal specific Cre, Atp-4b-Cre. The Atp4b 
promoter was first used in 1995 to drive SV40 T antigen expression to study pre-parietal 
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cell biology (Q. Li, Karam, and Gordon 1995). Similar experiments generated 
neuroendocrine tumors when expression of a conditional SV40 T antigen allele was 
driven by Atp-4b-Cre expression (Syder et al. 2004). 
The Cdh1 conditional deletion resulted in hyperplasia that progressed from 3 
months on but no invasive cancer by two years. However, they did observe signet ring 
cells (pathognomonic of diffuse gastric cancer) at 12 months (Mimata et al. 2011). In 
2012, Shimada et al. added conditional deletion of the tumor suppressor Trp53 and found 
that these double-conditional knockout mice developed intra-mucosal tumors at 6 months 
and invasive tumors at 9 months with a median survival of one year. At this one-year 
time point, 40% of mice had local lymph node metastasis (Shimada et al. 2012). 
Early studies of the role of oncogenic Kras in gastric cancer utilized the Keratin 
19 (CK19) promoter to drive expression throughout the gastrointestinal tract. One report 
described parietal cell atrophy and mucous neck cell hyperplasia at 3-6 months of age 
(Brembeck et al. 2003). At 16 months, invasive intestinal-type adenocarcinomas were 
observed (Okumura et al. 2010). Another group bred the conditional KrasLSL-G12D to a 
CK19-CreERT transgene to produce tamoxifen-inducible oncogenic Kras expression. This 
study observed only hyperplasia, metaplasia, and adenomas of the stomach, however the 
lack of frank carcinomas may have been due to the increased mortality seen in these 
mice. Over half the mice had to be euthanized prior to the 6 month endpoint due to 
weight loss correlated with oral tumors (Ray et al. 2011). Expression of oncogenic 
KrasLSL-G12D under the control of the ubiquitous promoter UBC9-CreERT drove severe 
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inflammation, hyperplasia, metaplasia, and carcinogenesis in the stomach, but other 
organs were devoid of neoplastic changes (Matkar et al. 2011). 
Several groups have recently argued that Mist1+ or Lgr5+ stem cells are the cell of 
origin of both intestinal-type and/or diffuse-type gastric cancer. The evidence they cite is 
their ability to drive tumorigenesis by specific genetic manipulation of these cell types 
using cre/lox technology (Hayakawa et al. 2015; X. Li et al. 2016). However, at least in 
the case of diffuse-type gastric cancer, similar manipulations of gastric parietal cells 
using Atp-4b-Cre results in tumor formation (Shimada et al. 2012). This suggests that 
several cells of origin exist, that this is not the right criterion on which to identify tumor-
initiating cells, or that some overlap may exist between these cell populations. 
x. Conclusion 
Though a plethora of mouse models of gastric cancer exist, none adequately 
recapitulates the advanced disease as is seen in the majority of human patients. These 
models have long latencies, lack metastasis, or metastasize only to regional nodes. To 
advance our understanding of the cellular and molecular mechanisms underlying gastric 
cancer progression and to develop new treatments for gastric cancer, there is a need for a 
mouse model that better recapitulates advanced human disease. 
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Model Incidence Duration Location Type Inv Met (Ref) 
CEA/SV40  100% 50 d Antrum  Intestinal Y N (Thompson et al. 
2000) 
MMTV/Ad12  82%(M) 
17%(F)  
3–4 m  SCJ  Intestinal 
Adenosquamous 
Y N (Koike et al. 
1989) 
HPV-16  100% 246 d(F) 
352 d(M)  
Antrum  Carcinoid Y Y (Searle et al. 
1994) 
CA-AhR 100% 12 m Corpus Intestinal Y N (Andersson et al. 
2002) 
Atp-4b/SV40 100% 12 m Corpus/Antrum Neuroendocrine Y Y (Syder et al. 
2004) 
Atp-4b/Cdx2 100% 100 w Corpus Intestinal Y N (Mutoh et al. 
2004) 
INS-GAS 75% 20 m  Corpus Intestinal Y N (T. C. Wang et 
al. 2000) 
ACT-GAS 100% 20 m Corpus Intestinal N N (Konda et al. 
1999) 
GAS−/− 60% 12 m  Antrum  Intestinal N N (Zavros et al. 
2005) 
MTH1−/− 13% 18 m  Antrum  Intestinal N N (Tsuzuki et al. 
2001)  
TFF1−/− 30% 5 m  Antrum  Intestinal Y N (Lefebvre et al. 
1996) 
Smad4+/− 100% 18 m  Corpus/Antrum  Intestinal Y N (Xu et al. 2000) 
Smad3−/− 100% 10 m  SCJ Intestinal Y N (Nam et al. 
2012) 
Gp130Y757F/Y757F 100% 3 m Antrum  Adenoma N N (Tebbutt et al. 
2002)  
K19/KrasG12V 38% 16 m  Corpus  Intestinal Y N (Okumura et al. 
2010)  
K19/Wnt1 
K19/C2me  
100% 20 w  SCJ  Intestinal Y N (H. Oshima et al. 
2006)  
Atp4b-Cre 
Cdh1fl/fl 
p53fl/fl 
100% 12 m  Corpus  Diffuse Y Y (Shimada et al. 
2012) 
Villin-Cre 
KLF4fl/fl  
29% 20 m Antrum  Intestinal N N (Qiang Li et al. 
2012)  
Elf+/− 
Smad4+/− 
1/6 7 mo Antrum ND Y N 2005(Redman et 
al. 2005) 
Mist1-CreERT2 
KrasLSL-G12D 
Apcfl/fl 
ND 4 mo Corpus Intestinal N N (Hayakawa et al. 
2015) 
Mist1-CreERT2 
Cdh1fl/fl 
H. felis 
78% 18 m ND Diffuse N N (Hayakawa et al. 
2015) 
Mist1-CreERT2 
Cdh1fl/fl 
LSL-p53R172H 
H. felis 
ND 9 m ND Diffuse Y N (Hayakawa et al. 
2015) 
Lgr5-CreERT2 
Smad4fl/fl 
PTENfl/fl 
40% 3 m Corpus Intestinal Y N (X. Li et al. 
2016) 
Gp130Y757F/Y757F 
Tff1-CreERT2 
KrasLSL-G12D 
ND 3 m Corpus/Antrum  Intestinal Y N (Thiem et al. 
2016) 
Table 1-3. Genetically Engineered Mouse Models (GEMMs) of gastric adenocarcinoma. 
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CHAPTER 2 ACKPY METASTATIC MODEL OF GASTRIC CANCER 
i. Abstract 
The utility of current mouse models of gastric cancer is limited by slow 
development and lack of metastasis (Poh et al. 2016; Hayakawa et al. 2013; Yu, Yang, 
and Nam 2014; Giraud and Judd 2009).  Here I describe a new mouse model of gastric 
cancer driven by p53 loss, Cdh1 loss, and oncogenic Kras expression in gastric parietal 
cells. I generated these mice to investigate the contribution of oncogenic Kras to the 
progression of gastric cancer given the high rate of mutation and amplification of the 
receptor tyrosine kinase (RTK)/Ras pathway in gastric cancer. These mice develop 
invasive diffuse and intestinal type gastric adenocarcinomas as early as 6 weeks of age 
and die with metastases to the lymph nodes, lung, and liver by 3 months. The rapid 
disease progression allows for timely analysis of tumor biology, diagnostics, and 
therapeutics while the metastatic phenotype makes it highly relevant to human disease. 
ii. Introduction 
The utility of current mouse models of gastric cancer is limited due to the long 
latency periods for tumor development, the lack of metastasis in these models or 
metastasis only to regional nodes in a few models (Poh et al. 2016; Hayakawa et al. 2013; 
Yu, Yang, and Nam 2014; Giraud and Judd 2009). To date, there are six mouse models of 
metastatic gastric cancer (Table 2-1). However, only one has clinical relevance. Two 
utilize the SV40 transgene that plays no role in human cancer (Thompson et al. 2000; Q. 
Li, Karam, and Gordon 1995; Syder et al. 2004). One utilizes human papilloma virus 
(HPV)-16 (Searle et al. 1994) that is not associated with gastric cancer in humans 
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(Kamangar et al. 2006). A fourth utilized adenovirus 12 (Koike et al. 1989) and a fifth 
utilized a constitutively active dioxin/aryl hydrocarbon receptor (Andersson et al. 2002), 
neither of which has ever been shown to be involved in the development of gastric 
cancer. Further, the lesions found in the adenovirus 12 model were adenosquamous 
lesions of the forestomach, which is consistent with esophageal disease and not 
adenocarcinoma of the stomach (Koike et al. 1989). The only model that contains genetic 
lesions identified in human disease is the double conditional deletion of the Cdh1 and 
Trp53 genes, but only 40% of mice have local nodal metastasis. A mouse model that 
better replicates advanced human disease would advance our understanding of the 
cellular and molecular mechanisms underlying gastric cancer progression. 
Model  Incidence  Duration  Phenotype  Metastasis Reference 
CEA/SV40  100%  50 d  Intestinal Invasion to the 
duodenum 
(Thompson et al. 2000) 
ATP-4b/SV40  12 months Neuroendocrine LN 
Liver 
(Q. Li, Karam, and 
Gordon 1995; Syder et 
al. 2004) 
HPV-16  100%  246–352 d  Carcinoid LN 
Liver 
(Searle et al. 1994) 
MMTV-Ad12 56% 4 months Adenosquamous LN 
Lungs 
(Koike et al. 1989) 
CA-AhR 100% 12 m Intestinal Invasion of 
local organs 
(Andersson et al. 2002) 
CDH1/p53  100%  12 m  Diffuse  LN (40%) (Shimada et al. 2012) 
Table 2-1. Metastatic mouse models of gastric cancer (LN = Lymph Node). 
 
The H+/K+ ATPase pump, found only in gastric parietal cells and pre-parietal cells 
is responsible for the acidification of the stomach. The Atp4b gene encodes the beta 
subunit and has been used to alter expression of various genes in this cell population 
(Syder et al. 2004). One such model is the conditional deletion of the Cdh1 gene in 
gastric parietal cells by use of the Atp4b-Cre allele in Cdh1fl/fl mice. These mice 
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developed signet ring-like cells at 12 months of age but no invasive cancer even at 24 
months (Mimata et al. 2011). Shimada et al added a conditional deletion of Trp53 
resulting in invasive diffuse-type gastric cancer by 9 months, with 40% of mice 
developing metastasis to regional lymph nodes at one year (Shimada et al. 2012). We 
have attempted to overcome the limitations of this model by adding a third genetic hit. 
In the TCGA cohort, the RTK/Ras signaling axis is altered in the majority of 
gastric cancer samples. EGFR family members (EGFR, ERBB2, ERBB3 and ERBB4) are 
amplified or mutated in 44% (126/287) of cases. The Ras family is genetically modified 
in 18% (46) of cases and, of those, 14% (36) are specifically KRAS alterations. In fact, 
KRAS is mutated in 9% (23) of all cases and the vast majority (20) of these mutations are 
known oncogenic mutations (18 in codons 12/13, 2 in codon 61). Additionally, RASA1, a 
negative regulator of Ras, is mutated or deleted in 9% (24) of cases. Finally, the Raf 
family is modified in 14% of cases (Figure 2-1) (Bass et al. 2014; Cerami et al. 2012). 
Activation of this pathway has been modeled in several studies. Oncogenic Kras 
activation has been shown to produce precancerous or cancerous lesions in the mouse 
stomach in a promoter-dependent manner (Ray et al. 2011; Okumura et al. 2010; Matkar 
et al. 2011). 
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Figure 2-1. Genetic alterations of the RTK/Ras/Raf axis in gastric cancer. 
(Bass et al. 2014; Cerami et al. 2012) (A) EGFR family, (B) Ras family, (C) RASA1, (D) 
Raf family, (E) Symbol key. 
  
Based on these data, we investigated the contribution of oncogenic Kras towards 
the progression of gastric cancer. I generated a mouse model of gastric cancer driven by 
gastric parietal cell-specific (Atp-4b-Cre) loss of E-cadherin (Cdh1fl/fl), loss of p53 
(Trp53fl/fl), and expression of oncogenic Kras (KrasLSL-G12D/+). Additionally, I included a 
yellow fluorescent protein (YFP) reporter allele (Rosa26LSL-YFP). These mice will 
hereafter be referred to as ACKPY mice (Figure 2-2). 
 
Figure 2-2. Schematic of ACKPY mouse model genetics. 
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iii. Results 
Addition of oncogenic Kras to Cdh1/Trp53 deletion model decreases survival four-fold 
 
Figure 2-3. Survival and weight phenotypes of ACKPY (KrasG12D/+) mice compared to 
ACPY (Kras+/+) mice. 
(A) Kaplan-Meier survival curve of ACKPY (n=20) and ACPY (n=19) mice (B) Weight 
graph of corresponding mice over time. 
 
Characterization of the ACKPY mouse model revealed a rapid course of disease. 
The mice had a median survival of 76.5 days (range 64-91 days, SD 7.2). This was over 
four times faster than the ACPY controls (wild-type Kras, Cdh1 loss and Trp53), which 
had a 322-day median survival (range 272-386 days, SD 32.8, Figure 2-3A). ACKPY 
mice began to lose weight around 60 days of age and disease progression correlated with 
weight loss (Figure 2-3B).  
ACKPY mice rapidly develop mixed-type gastric cancer with linitis plastica 
At necropsy, stomachs were dramatically enlarged with normal stomach replaced 
by tumor. They displayed classic linitis plastica (i.e. leather bottle stomach) with 
thickened, rigid, and whitened gastric walls (Figure 2-4A). Histologically, the gastric 
cancers that developed in these mice were mixed-type, with regions consistent with both 
diffuse- and intestinal-type morphology (Figure 2-4B). In one human cohort, mixed-type 
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gastric cancer accounted for 15% of cases (with 54% intestinal- and 32% diffuse-type) 
(Polkowski et al. 2016). 
 
Figure 2-4. Gross and histologic phenotype of ACKPY tumors. 
(A) Representative gross images of wild-type and ACKPY stomachs (scale bar: 1 cm). 
(B) Representative images of intestinal- and diffuse-type lesions found in ACKPY mice. 
(C) Representative H&E and immunofluorescent (blue: DAPI, yellow: YFP) images of 
ACKPY and Cre- control stomachs harvested from mice at 3, 6, and 9 weeks of age 
(scale bar: 1 mm). 
 
We examined the kinetics of disease progression in this model by analyzing 
stomachs of ACKPY mice and Cre- (CKPY) controls at 3, 6, and 9 weeks of age. As 
expected, Cre- control stomachs displayed normal architecture at all time points (Figure 
2-4C). ACKPY mice had few or no identifiable gastric parietal cells by 3 weeks of age 
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and 100% of mice demonstrated high-grade dysplastic lesions and/or intra-mucosal 
carcinomas. At this time point, immunofluorescence microscopy for YFP+ recombined 
cells revealed clusters of transformed cells. By 6 weeks of age, there was a dramatic 
increase of these lesions with invasion in 40% of mice. By 9 weeks of age all mice had 
invasive carcinomas (Figure 2-4C). 
Metastatic disease in ACKPY mice  
Ten mice were sacrificed at 64-83 days of age and analyzed for metastasis to local 
lymph nodes, liver, and lungs. Upon gross examination of the abdomen under a 
fluorescent dissecting microscope (Figure 2-5A), the stomach was enlarged and YFP+ 
nodules were apparent within the perigastric fat in all mice. Histologic evaluation of the 
perigastric fat identified these nodules as perigastric lymph node metastases (Figure 
2-5C). Though no gross lesions were observed in the liver, immunofluorescent histologic 
analysis of tissue specimens identified micro-metastatic lesions in 20% of mice (Figure 
2-5D). 
Gross examination of the thoracic cavity identified YFP+ lesions in the 
mediastinum adjacent to the trachea in 50% of mice examined (Figure 2-5B). 
Histologically these were confirmed as mediastinal lymph node metastases (Figure 2-5E). 
YFP+ lung metastases were identified in all mice (Figure 2-5F). In 50% of mice these 
lung metastases could be observed grossly, while the remaining 50% harbored micro-
metastases only identifiable by immunofluorescent microscopy. 
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Figure 2-5. Metastatic phenotype of ACKPY mice. 
(A&B) Representative gross and fluorescent images of the abdomen or thoracic cavity, 
(C,D,E,F) H&E and immunofluorescent (blue: DAPI, yellow: YFP) images of metastatic 
lesions in ACKPY mice. Scale bars are all 1 mm except for the liver that is 0.5 mm. 
 
I successfully isolated four independent cell lines from four different primary 
gastric tumors and one from a local lymph node metastasis. All cell lines tested formed 
flank tumors in wild-type C57BL/6 mice (Figure 2-6A), experimental validation of the 
neoplastic nature of these lesions. One of the two gastric cancer-derived cell lines tested 
metastasized to the lung in an experimental model of spontaneous metastases (Figure 
2-6B). 
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Figure 2-6. Metastatic ACKPY cell line. 
(A) Growth curve of primary tumor cell line injected subcutaneously into the flank of 
naïve mice (5x106 cells/mouse, n=4). Data are presented as the mean tumor volume ± 
SD. (B) H&E image of lung metastases (red arrows) derived from an ACKPY gastric 
cancer flank tumor. 
 
ACKPY model depends on MAPK activity downstream of oncogenic Kras 
 
Figure 2-7. Kaplan-Meier survival curve of ACKPY mice treated with MEK inhibitor. 
Mice were treated beginning at 4 weeks of age with MEK inhibitor PD0325901 
administered ad libitum in the mouse chow at 7 mg/kg of diet. 
 
To test the dependence of our model on oncogenic Kras signaling through the 
MAPK pathway, I treated mice with an inhibitor to the downstream kinase MEK 
(PD0324901). These mice had an increase in median survival of 18.5 days over vehicle 
(p=0.001, n=8). Of note, one mouse survived over 200 days on treatment (Figure 2-7). 
These data support the utility of the ACKPY model for testing preclinical compounds in 
the treatment of gastric cancer. 
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iv. Discussion 
This newly generated ACKPY mouse model of gastric cancer represents a highly 
tractable and clinically relevant mouse model for the field of gastric cancer research. 
More recently, several additional groups have used specific promoters to drive oncogenic 
Kras expression in the stomach (Table 2-2). Of the four studies that expressed oncogenic 
Kras alone, three of them demonstrated precancerous changes (Ray et al. 2011; Matkar et 
al. 2011; Thiem et al. 2016). One group examined mice at 16 months (Okumura et al. 
2010) and found gastric cancer in less than 40% of mice. Two recent genetic models 
utilize oncogenic Kras and an additional genetic lesion (Apc deletion or Gp130 
activation) to drive cancer development (Hayakawa et al. 2015; Thiem et al. 2016). 
However, one does not invade (Hayakawa et al. 2015) and neither metastasizes 
(Hayakawa et al. 2015; Thiem et al. 2016). Our ACKPY model is clinically relevant, 
invasive, and metastasizes widely. 
Model Incidence Duration Location Type Inv Met  (Ref) 
CK19-CreERT 
KrasLSL-G12D 
ND 6 m ND Adenoma N N (Ray et al. 2011) 
UBC9-CreERT 
KrasLSL-G12D 
ND 13-18 d Fore/Glandular 
Stomach 
Junction 
Mucus Gland 
Metaplasia 
N N (Matkar et al. 
2011) 
Tff1-CreERT2 
KrasLSL-G12D 
ND 9 m Corpus/Antrum  Adenoma N N (Thiem et al. 
2016) 
K19/KrasG12V 38% 16 m  Corpus  Intestinal Y N (Okumura et al. 
2010; Brembeck 
et al. 2003)  
Mist1-CreERT2 
KrasLSL-G12D 
Apcfl/fl 
ND 4 mo Corpus Intestinal N N (Hayakawa et al. 
2015) 
Gp130Y757F/Y757F 
Tff1-CreERT2 
KrasLSL-G12D 
ND 3 m Corpus/Antrum  Intestinal Y N (Thiem et al. 
2016) 
Table 2-2. Oncogenic Kras driven mouse models of precancerous and cancerous gastric 
disease. 
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Both the increased rate of tumor formation and the increased metastasis observed 
in the ACKPY model over the ACPY model is genetically attributable to the inclusion of 
an oncogenic Kras allele. To test the dependence of our model on oncogenic Kras 
signaling through the MAPK pathway, I treated mice with an inhibitor to the downstream 
kinase MEK. While this treatment significantly increased survival (median survival of 95 
days compared to 76.5 days for untreated) it did not do so to the level of genetic 
exclusion of the oncogenic Kras allele as seen in ACPY mice (median survival of 1 year). 
This discrepancy may be due to one or more of several explanations. First and 
foremost, inhibitor treatment was initiated at 4 weeks of age, a time at which small 
tumors are already present. Thus, the context of MAPK inhibition is completely different 
than MAPK activity resulting from lifelong germline wild-type Kras activity. For 
example, drug resistance could evolve quickly within already established tumors to 
overcome the MEK inhibition. Second, there is no reason to think the level of 
MEK/MAPK activity in the Kras wild-type context (ACPY) would be equivalent to the 
level of inhibited activity in the oncogenic Kras context (ACKPY+inhibitor). Inhibition 
is not perfect and the dosage may have been too low; allowing for a degree of MAPK 
signaling to still be present in the inhibited ACKPY tumors that is higher than the level of 
MAPK signaling in the ACPY stomachs. Finally, as will be discussed in future chapters, 
the MAPK pathway is not the only pathway downstream of oncogenic KRAS. Simple 
inhibition of one downstream pathway in the context of oncogenic Kras would not be 
expected to be equivalent to the genetic inhibition of all downstream pathways in the 
context of wild-type Kras (as is the case in ACPY mice). 
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Our findings also have implications for the gastric cancer cell of origin debate. 
Hayakawa et al (2015) showed that activation of oncogenic Kras and loss of Apc in 
Mist1+ stem cells was sufficient to drive intestinal-type gastric cancer, indicating that this 
population may be the cell or origin for intestinal-type gastric cancer. Further, because 
they were able to drive tumorigenesis by loss of Cdh1 and H. felis infection in this cell 
population, they argued that Mist1+ stem cells are the cell of origin of diffuse-type gastric 
cancer. However, Li et al (2016) found that Lgr5+ stem cells are the cell of origin of 
intestinal-type gastric cancer by showing that deletion of Smad4 and PTEN in this 
population led to tumor formation. By these criteria, our data driving mixed-type gastric 
cancer in pre-parietal cells or parietal cells (those that express Atp4b) (Q. Li, Karam, and 
Gordon 1995) suggests that they are also a cell of origin for both intestinal-type and 
diffuse-type gastric cancer. 
These conflicting data may be resolved by further investigation of the overlap 
between these lineages and their progeny. Lgr5+ stem cells (Barker et al. 2010) and 
Mist1+/Troy+ stem cells (Stange et al. 2013) have been shown to generate all cell types in 
the gastric glands, including parietal cells. Perhaps it is not the Lgr5+ or Mist1+ stem cells 
that are being transformed, but their parietal cell or pre-parietal cell differentiated 
daughter cells. Further experimentation is necessary to test this hypothesis. 
 
As proof of principle of the model’s utility, we have begun to investigate the role 
of the microbiome in our model. As has been shown in many cancers, but particularly 
those of the alimentary tract, the microbiome plays an important role in the development 
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of disease (Ohtani 2015). We treated our ACKPY model with a commonly utilized 
quadruple antibiotic cocktail to deplete the microbiota. Microbiome depletion was 
confirmed by qPCR for the bacterial 16S ribosomal subunit in stomach and cecal 
contents at necropsy (Figure 2-8B). Though the results are preliminary, microbiome 
depletion resulted in a 7.5-day increase in median survival (p=0.04, n=6) over vehicle 
(n=5) (Figure 2-8A). While the specific pathogen H. pylori is known to contribute to 
pathogenesis of gastric cancer, these data implicate the normal microbiota in gastric 
cancer development. 
 
Figure 2-8. Antibiotic depletion of microbiome increases ACKPY survival. 
(A) Kaplan-Meier curve showing 7.5-day increase in median survival (p=0.04,) for 
antibiotic treated mice (red, n=6) over vehicle (black, n=5). (B) Microbiome depletion as 
measured by qPCR for the bacterial 16S ribosomal subunit (normalized to total DNA 
content) in stomach (p=0.02) and cecal (p<0.0001) contents at necropsy. Antibiotics were 
administered via the drinking water ad libitum at 1 g/L ampicillin, 1 g/L neomycin, 1 g/L 
metronidazole, 0.5 g/L vancomycin, and 4 g/L sucralose. 
 
 
Given the metastatic phenotype of the ACKPY model, we wished to determine if 
we could detect circulating tumor cells (CTCs) and if their presence would correlate with 
any of the metastatic phenotypes. We used flow cytometry to measure CTCs in cardiac 
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blood by counting the number of YFP+ cells present (CTCs defined as DAPI-, CD45-, 
YFP+). These data are preliminary but promising; mice with many CTCs (>90 per 100 μl 
blood) were found to have macro-metastatic disease of the lung, whereas mice with few 
CTCs (<15 per 100 μl blood) did not (Table 2-3). These data indicate a promising avenue 
of future research and the utility of the model in the burgeoning field of CTCs. 
Animal CTCs per 
100 μl  
blood 
Macroscopic 
Lung 
Metastases 
1 338 Yes 
2 111 Yes 
3 95 Yes 
4 13 No 
5 11 No 
6 11 No 
7 2 No 
Table 2-3. Number of circulating tumor cells (CTCs) correlates with lung metastasis 
phenotype.  
CTCs defined as DAPI-, CD45-, YFP+ cells per 100 µl blood. 
 
This model offers the potential to investigate the molecular mechanisms driving 
gastric cancer via both the E-cadherin pathways and the RTK/Ras signaling axis, and 
may also serve as a useful model for testing new therapies targeting both primary gastric 
cancer and metastatic lesions. Both the rapid progression of gastric cancer and 
widespread metastases set it apart from other available mouse models of gastric cancer. 
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CHAPTER 3 E-CADHERIN AS GATEKEEPER TO MUTANT KRAS AND P53 
LOSS-DRIVEN GASTRIC CANCER 
i. Abstract 
Expression of oncogenic Kras and loss of Trp53 is sufficient to drive rapid 
development of lung cancer (Jackson et al. 2005), pancreatic ductal adenocarcinoma 
(Bardeesy et al. 2006), squamous cell carcinoma (Caulin et al. 2007), acute myeloid 
leukemia (Z. Zhao et al. 2010), and undifferentiated pleomorphic sarcoma (Kirsch et al. 
2007; Mito et al. 2009) in the mouse. To determine if loss of E-cadherin was necessary 
for the onset of gastric adenocarcinoma or if oncogenic Kras and loss of Trp53 in gastric 
parietal cells were sufficient to drive tumorigenesis I generated ACKPY mice with either 
one or two alleles of wild-type Cdh1 (E-cadherin). E-cadherin expression significantly 
increased survival and the gastric tumors that did arise were more focal in nature 
compared to Cdh1fl/fl mice, suggesting an additional event is necessary for gastric 
tumorigenesis. Loss of E-cadherin expression was observed in some of these tumors, 
suggesting that its loss may be necessary for gastric tumorigenesis in this model.  
ii. Introduction 
Conditional expression of oncogenic Kras and Trp53 deletion have been used to 
model many types of cancer in the mouse. Expression of oncogenic Kras in the pancreas 
is sufficient to drive carcinogenesis (Hingorani et al. 2003). In the mouse lung, oncogenic 
Kras alone drives adenoma formation that rarely progresses to adenocarcinomas (Johnson 
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et al. 2001). Addition of Trp53 loss or mutation accelerates these processes (Jackson et 
al. 2001; Jackson et al. 2005; Hingorani et al. 2005; Bardeesy et al. 2006). Expression of 
oncogenic Kras alone in the mouse skin (Caulin et al. 2007) and hematopoietic system (I. 
T. Chan et al. 2004; Braun et al. 2004) results in the development of precancerous 
lesions, while addition of Trp53 loss or mutation results in carcinoma and leukemia, 
respectively (Caulin et al. 2007; Z. Zhao et al. 2010). Finally, expression of oncogenic 
Kras and loss of Trp53 can also drive a mouse model of undifferentiated pleomorphic 
sarcoma (Kirsch et al. 2007; Mito et al. 2009) (Table 3-1). Given the sufficiency of 
oncogenic Kras and deletion of Trp53 to drive tumorigenesis in multiple cell types, I 
investigated whether Cdh1 loss was necessary in our ACKPY model to drive 
carcinogenesis in gastric parietal cells or if expression of oncogenic Kras and deletion of 
Trp53 were sufficient for the development of gastric adenocarcinoma.  
There is evidence in other Kras/Raf1 mouse models of cancer that loss of Cdh1 is 
either required for high penetrance tumorigenesis or that its loss enhances tumorigenesis. 
Oncogenic Kras and Cdh1 deletion in combination have been shown to increase tumor 
formation in a liver tumorigenesis model. Though both oncogenic Kras and loss of Cdh1 
individually were sufficient to drive tumor formation in a minority of mice, the 
combination of both lesions resulted in 100% incidence of tumors, higher-grade disease, 
increased invasiveness, and intrahepatic metastasis (Table 3-2). The authors argued that 
loss of E-cadherin leads to an epithelial-mesenchymal transition phenotype, up-regulation 
of stem cell marks, and an increased ERK activation (Nakagawa et al. 2014). In a mutant 
Raf-driven model of non-small cell lung cancer (NSCLC) the additional loss of E-
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cadherin resulted in the progression of adenomas to adenocarcinomas with increased 
vascularity, invasiveness, and micro-metastasis to local lymph nodes (Table 3-2). They 
identified β-catenin signaling resulting in increased vascular endothelial growth factor 
(VEGF) expression as the key mediator of this phenotype (Ceteci et al. 2007). 
Model Genetics Phenotype Reference 
Lung KrasG12D-LA Adenoma, Adenocarcinoma (Johnson et al. 
2001) KrasG12D-LA 
Trp53+/-, -/- 
Accelerated progression 
Adeno-Cre (intra-nasal) 
KrasLSL-G12D 
Adenoma, Adenocarcinoma (Jackson et al. 
2001) 
Adeno-Cre (intra-nasal) 
KrasLSL-G12D 
Trp53fl/+,fl/fl,R172H/+.R172H/fl,R270H/+,R270H/fl 
Accelerated progression (Jackson et al. 
2005) 
Pancreas Pdx1-Cre 
KrasLSL-G12D 
PanIN 
PDAC 
(Hingorani et al. 
2003) 
Pdx1-Cre 
KrasLSL-G12D 
Trp53LSL-R172H/+ 
Accelerated progression (Hingorani et al. 
2005) 
Pdx1-Cre 
KrasLSL-G12D 
Trp53fl/+,fl/fl 
Accelerated progression (Bardeesy et al. 
2006) 
Skin K5.Cre 
KrasLSL-G12D 
TPA 
Benign Papilloma (Caulin et al. 
2007) 
K5.Cre 
KrasLSL-G12D 
Trp53LSL-R172H/+ 
TPA 
Spindle Cell Carcinoma 
K5.Cre 
KrasLSL-G12D 
Trp53fl/fl 
TPA 
Squamous Cell Carcinoma 
Blood Mx1-Cre 
KrasLSL-G12D 
Myeloproliferative Disorder (I. T. Chan et al. 
2004; Braun et 
al. 2004) 
LGshp53CreER 
KrasLSL-G12D 
Acute Myeloid Leukemia (Z. Zhao et al. 
2010) 
Sarcoma Adeno-Cre (intra-muscular) 
KrasLSL-G12D 
Trp53fl/fl 
Undifferentiated 
Pleomorphic Sarcoma 
(Kirsch et al. 
2007; Mito et al. 
2009) 
Table 3-1. Oncogenic Kras and Kras/Trp53 driven mouse models of cancer. 
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Model Genetic Phenotype (Reference) 
Liver 
 
Hepatocellular Carcinoma 
(HCC) 
Alb-Cre 
KrasLSL-G12D 
-4/10 with tumors @ 8 mo 
-dysplastic nodules or 
     well-differentiation HCC 
(Nakagawa et 
al. 2014) 
Alb-Cre 
Cdh1fl/fl 
-2/12 with tumors @ 11 mo 
-HCC (α-fetoprotein+) 
Alb-Cre 
KrasLSL-G12D 
Cdh1fl/fl 
10/10 with tumor @ 8 mo 
-HCC (α-fetoprotein+) 
-typical trabecular type type to 
     poorly differentiated type 
Liver 
 
Intra-hepatic 
cholangiocarcinoma 
(IHCC) 
Alb-Cre 
KrasLSL-G12D 
-1/8 died of IHCC by 75 wks 
-Died at 36 wks 
(O’Dell et al. 
2012) 
Alb-Cre 
KrasLSL-G12D 
Trp53fl/+ 
-75% died of IHCC by 75 wks 
-Median Survival 52 wks 
Alb-Cre 
KrasLSL-G12D 
Trp53fl/fl 
-100% died of IHCC by 30 wks 
-Median Survival 19 wks 
Lung 
 
Non Small Cell Lung 
Cancer (NSCLC) 
 
 
SP-C C-RAF BXB -Adenomas by 6 weeks (Ceteci et al. 
2007) 
SP-C-rtTA 
Tet-O-Cre 
Cdh1fl/fl 
-No tumors @ 10 mo 
-Diffuse hyperplasia 
-Enlarged alveolar spaces 
-No inflammation 
SP-C C-RAF BXB 
SP-C-rtTA 
Tet-O-Cre 
Cdh1fl/fl 
-Increased tumor volume 
-Increased vascularity 
-Increased invasiveness 
-Micro-metastases  
Table 3-2. Kras/Raf and Cdh1 driven models of cancer. 
iii. Results 
Cdh1fl/+ and Cdh1+/+ mice live significantly longer than Cdh1fl/fl mice 
The presence of one or two Cdh1 wild-type alleles dramatically increases survival 
(p<0.0001, Figure 3-1) in comparison to Cdh1fl/fl (ACKPY) mice. Of 37 Cdh1fl/+ mice, 
only 7 died naturally between 67 and 123 days. Similarly, out of 36 Cdh1+/+ mice, only 6 
died naturally between 72 and 133 days. In comparison, a cohort of 20 Cdh1fl/fl mice 
survived to endpoint between 64 and 91 days of age. However, theses data are 
confounded by cutaneous tumors in the remaining 30 Cdh1fl/+ mice and 30 Cdh1+/+ mice. 
These large tumors required euthanasia of the mice prior to gastric cancer endpoints. 
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Figure 3-1. Kaplan-Meier curve showing increased survival of Cdh1fl/+ and Cdh1+/+ as 
compared to Cdh1fl/fl mice. Mice euthanized for cutaneous tumor are displayed as 
censored events. 
 
 
 
Figure 3-2. Weights of Cdh1fl/fl, Cdh1fl/+, and Cdh1+/+ mice. 
(A,B) Cdh1fl/+ and Cdh1+/+ mice euthanized for cutaneous tumors, (C,D) Cdh1fl/+ and 
Cdh1+/+ mice that died naturally. 
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The majority of Cdh1fl/+  (Figure 3-2A) and Cdh1+/+ (Figure 3-2B) mice do not 
undergo the significant weight loss that was observed in gastric cancer-bearing mice on a 
Cdh1fl/fl background. Upon histologic analysis, only 2 of 11 Cdh1fl/+ mice and 1 of 15 
Cdh1+/+ mice with subcutaneous tumors had histologically detectable stomach tumors. 
The 7 Cdh1fl/+ mice and 6 Cdh1+/+ that died naturally lost weight prior to their death, 
suggesting that they had developed gastric cancer (Figure 3-2C,D). 
Cdh1fl/+ and Cdh1+/+ mice develop subcutaneous tumors 
 
Figure 3-3. Subcutaneous tumors in Cdh1fl/+ and Cdh1+/+ mice. 
(A) Gross image of a mouse with large tumors on its chest and pelvis, (B) Normal mouse 
skin histology (http://ctrgenpath.net/), (C) 5x microscopic image of a subcutaneous 
tumor, (D) 20x detail of compressed epidermis and dermis overlaying the subcutaneous 
tumor, (E) 20x detail of thinned skeletal muscle underlying the subcutaneous tumor. 
 
ACKPY mice with one (Cdh1fl/+) or two (Cdh1+/+) copies of wild-type Cdh1 
developed cutaneous tumors throughout their bodies that necessitated euthanasia of the 
animals prior to gastric cancer defined endpoints due to the inability of the mice to 
ambulate (Figure 3-3A). Analysis of more Cdh1fl/fl mice revealed the occurrence of these 
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tumors at a rate of approximately one in twenty. These cutaneous tumors arise in the 
subcutaneous fat; they (Figure 3-3BC) were covered by epidermis and dermis (Figure 
3-3D) and overlaid skeletal muscle (Figure 3-3E).  Initial characterization revealed 
sarcomatoid histology. 
Cdh1fl/+ stomach tumors are more focal and display sarcomatoid features 
Although stomachs isolated from Cdh1fl/+ and Cdh1+/+ mice are enlarged and 
hyperplastic (Figure 3-4C and A), the majority do not harbor tumors. When these mice 
develop gastric tumors, they are more focal in nature (Figure 3-4D), unlike the 
widespread tumors identified in Cdh1fl/fl stomachs (Figure 3-4B). This suggests that a 
secondary event is occurring that is necessary for tumorigenesis to occur at these sites. 
This event could be genetic, epigenetic, pathway upregulation, or other biological 
processes that lead to carcinogenesis. Histologically, Cdh1fl/+ tumors are mixed-type 
gastric cancer with sarcomatoid features. 
 
Figure 3-4. Representative cross-sectional images of wild-type, Cdh1fl/fl, and Cdh1fl/+ 
stomachs. 
(A) wild-type, (B) Cdh1fl/fl, (C) Cdh1fl/+ without tumor, and (D) Cdh1fl/+ with tumor 
(scale bars = 5 mm). 
 
Loss of E-cadherin Expression in Cdh1fl/+ Stomach Tumors 
We hypothesized that the event occurring in these rare, focal, Cdh1fl/+ stomach 
tumors might be loss of E-cadherin. E-cadherin expression was examined by 
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immunofluorescent (IF) staining. E-cadherin is present in wild-type gastric epithelium 
(Figure 3-5A). Similarly, E-cadherin expression is preserved in gastric tissue from 
Cdh1fl/+ stomachs that lack tumors (Figure 3-5C) and in normal tissue of tumor bearing 
Cdh1fl/+ mice (Figure 3-5D). However, in tumors of Cdh1fl/+ mice, E-cadherin expression 
is absent or variable (Figure 3-5E). As expected, E-cadherin is absent in recombined cells 
(YFP+) in Cdh1fl/fl stomachs, but present in adjacent normal (YFP-) tissue (Figure 3-5B). 
Two primary cell lines were derived from independent Cdh1fl/fl stomachs and two 
lines were derived from independent Cdh1fl/+ stomachs. Neither of the cell lines derived 
from Cdh1fl/fl stomachs expressed E-cadherin by Western blot. However, only one of the 
two Cdh1fl/+ gastric cancer cell lines expressed E-cadherin by Western blot (data not 
shown). These data suggest that the hypothetical secondary event leading to tumor 
formation in Cdh1fl/+ mice may be the loss of E-cadherin in some cases. 
 
Figure 3-5. Representative immunofluorescent images of E-cadherin expression (white) 
counter-stained with DAPI (blue) and for YFP (green).  
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Cdh1 loss in a model of lung adenocarcinoma suppresses tumorigenesis 
To determine whether E-cadherin loss accelerates tumorigenesis in all tissues, I 
examined whether Cdh1 loss is necessary for lung cancer development. We administered 
adenoviral Cre intratracheally to Cre negative Cdh1fl/fl (CKPY) and Cdh1fl/+ mice to 
trigger oncogenic Kras activation, Trp53 loss with and without loss of Cdh1 in the lungs 
(Johnson et al. 2001; Jackson et al. 2001; Jackson et al. 2005). Examination of lungs 12 
weeks post infection demonstrated a decrease in overall tumor burden in Cdh1fl/fl mice 
compared to Cdh1fl/+ mice (Figure 3-6, p=0.02). This is in marked contrast to the 
dramatic increase in tumor burden observed in the stomach. 
 
Figure 3-6. Cdh1fl/fl vs Cdh1fl/+ lung adenocarcinoma. 
(A) Tumor to lung ratio for Cdh1fl/fl (n=5) vs Cdh1fl/+ (n=4), error bars represent standard 
deviation. (B) Representative images of Cdh1fl/fl and Cdh1fl/+ lungs. 
 
Subcutaneous tumors are more similar to sarcomas than gastric cancers 
I wished to determine if these sarcomatoid subcutaneous tumors arising in 
Cdh1fl/+ and Cdh1+/+ mice were primary sarcomas of the skin or metastatic lesions from 
the stomach. Though most of the mice in which subcutaneous tumors arose lacked 
detectable gastric tumors one could not rule out the possibility of small, unidentified 
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gastric tumors that metastasized to the subcutaneous space. One could also not rule out 
the possibility that these lesions were the result of off target Cre activation in the 
subcutaneous space resulting in sarcoma formation. Microarray expression data from 
glandular stomach tissue and subcutaneous metastasis tissue from four independent 
Cdh1fl/+ mice was examined. 
Initially, I analyzed the expression of the top 10 stomach enriched genes as 
annotated by The Human Protein Atlas (Uhlén et al. 2015). Though only Gkn1 and 
Muc5ac expression were statistically significant in their differential expression, there is a 
clear trend toward lower expression of stomach specific genes in the subcutaneous 
tumors. 
 
Figure 3-7. Expression of stomach enriched genes in Cdh1fl/+ stomachs and subcutaneous 
tumors. 
 
Next, I compared two publically available microarray expression data sets from 
the Gene Expression Omnibus (Edgar, Domrachev, and Lash 2002): GSE15459, 200 
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primary gastric tumors from the Singapore patient cohort (Ooi et al. 2009), and 
GSE21050, 310 soft tissue sarcomas from the French Sarcoma Group (Chibon et al. 
2010). By comparing these data sets, I selected the top 25 genes that were more highly 
expressed in the gastric cancers and the top 25 genes that were more highly expressed in 
the sarcomas. 
Using this set of 50 genes that differentiates between sarcomas and gastric 
cancers, I performed hierarchical clustering analysis on the expression data from our 
Cdh1fl/+ stomach and subcutaneous tumor microarrays. I found that the stomach samples 
and the subcutaneous tumor samples formed distinct clusters. Further, the 25 genes more 
highly expressed in gastric cancers were more highly expressed in the stomach samples 
and the 25 genes more highly expressed in sarcomas were, for the most part, more highly 
expressed in the subcutaneous tumors (Figure 3-8, Figure 3-9). 
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Figure 3-8. Hierarchical clustering of Cdh1fl/+ stomach and subcutaneous tumor samples 
based on 50 genes that differentiate between gastric cancer and sarcomas. 
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Figure 3-9. Hierarchical clustering, for 50 genes that differentiate between gastric cancer 
and sarcomas, of Cdh1fl/+ stomachs and subcutaneous tumors as well as Cdh1fl/fl stomachs 
and metastases. 
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iv. Discussion 
E-cadherin as the gatekeeper to mutant Kras and Trp53 loss-driven gastric cancer 
Though E-cadherin is well known in cancer biology as an “invasion suppressor 
gene” (Birchmeier, Hülsken, and Behrens 1995; Pećina-Slaus 2003), here we 
demonstrate its role as a suppressor of primary tumorigenesis. In gastric parietal cells, 
despite the strong oncogenic stimulus of mutant Kras and Trp53 loss, E-cadherin 
expression dramatically decreases tumorigenesis. From these data we can definitively say 
that Cdh1 loss cooperates with oncogenic Kras expression and loss of Trp53 to promote 
primary tumor formation. The observed loss of E-cadherin expression in the tumors that 
arise in Cdh1fl/+ mice suggests that E-cadherin is a gatekeeper to tumorigenesis in gastric 
parietal cells. 
This function, however, appears to be somewhat specific to gastric parietal cells. 
In our model of lung adenocarcinoma, loss of E-cadherin reduced primary tumor 
formation. Of note, this is in contrast to the mutant C-raf driven model of lung cancer 
where Cdh1 loss accelerated tumorigenesis (Table 3-2). However, this is a poor 
comparison for two reasons: (1) the C-raf model had wild-type Trp53 and (2) oncogenic 
C-raf only models activation of one of the many pathways downstream of Kras (as I will 
discuss in Chapter 5). As discussed, the oncogenic Kras liver cancer model also displays 
synergy between oncogenic Kras and loss of Cdh1 (Nakagawa et al. 2014). However, 
loss of Trp53 paired with oncogenic Kras in the liver also accelerates tumor formation 
and is not dependent on Cdh1 loss as we see here (O’Dell et al. 2012).  
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This gatekeeper function of a tumor suppressor gene in the face of mutant Kras 
and Trp53 loss is not without precedent. Recently, a similar phenomenon has been 
observed with the adenomatous polyposis coli (Apc) tumor suppressor in colorectal 
cancer (Dow et al. 2015). They showed that Apc knock-down in Lgr5+ colon cells led to 
adenoma formation that was reversible with Apc restoration. They could drive 
adenocarcinoma development with the addition of oncogenic Kras expression and Trp53 
loss. However, even these adenocarcinomas regressed with restoration of Apc. 
APC is an important member of the canonical Wnt pathway; though not directly 
involved in the enzymatic modification of β-catenin, it is crucial in facilitating its 
destruction and regulation through a variety of mechanisms (Mohammed et al. 2016). 
Similarly, E-cadherin binds and sequesters β-catenin at adherens junctions. Presumably, 
loss of either would lead to increased β-catenin signaling which may be crucial for 
mutant Kras and Trp53 loss-driven oncogenesis in both gastric parietal cells and Lgr5+ 
colon stem cells. 
Off target Cre activation results in subcutaneous sarcomas 
The presence of subcutaneous tumors in the majority of Cdh1fl/+ and Cdh1+/+ 
mice as well as rarely in Cdh1fl/fl mice raises the question: are they independent tumors 
arising in the subcutaneous space or metastases derived from gastric cancers arising in 
these mice? These sarcomatoid lesions could be arising independently as a result of off 
target Cre expression driving expression of oncogenic Kras and loss of Trp53 in a rare 
skin cell population that expresses Atp4b for unknown reasons. It is well described that 
oncogenic Kras and loss of Trp53 is sufficient to drive sarcomagenesis in the mouse with 
 50 
a latency of 56 to 117 days (median 79 days) (Kirsch et al. 2007). This latency is 
strikingly similar to the age at which the subcutaneous tumors appear in our mice. 
The lack of detectable gastric cancer in the majority of the Cdh1fl/+ and Cdh1+/+ 
would suggest that the subcutaneous tumors arise independent of gastric tumorigenesis. 
However, we cannot rule out the possibility of small gastric lesions that we are not 
detecting that are metastasizing. Further, the reported specificity of the Atp4b-Cre to 
gastric parietal cells would argue against off-target activation. No specific data is 
available on Cre specificity in the Atp4b-Cre strain I used (Syder et al. 2004), however 
data is available on a similar strain produced by another group (Zengming Zhao et al. 
2010). This group mated their strain to a conditional Smad4 allele and screened a panel of 
tissues including skin for recombination. They only detected recombination in the 
stomach. The Human Protein Atlas has immunohistochemical staining data of a variety 
of tissues using two independent antibodies to ATP4B. They only detected expression in 
gastric parietal cells and not the skin (“The Human Protein Atlas: ATP4B,” n.d.; Uhlén et 
al. 2015). 
However, this does not rule out a very rare cell population that was not 
represented in their samples, expresses ATP4B at a level bellow their level of detection, 
or a species-specific cell population in the skin of mice that expresses ATP4B. Further, a 
hypothetical cell population may have sufficient activity at the transgenic Atp4b promoter 
to drive Cre expression but insufficient activity at the endogenous Atp4b promoter (due 
to other regulatory elements) to express ATP4B.  
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 Recent work has shown that the majority of stringently tested targeted Cre strains 
have unreported off-target activities (Heffner et al. 2012). In addition, the gene 
expression analysis I performed comparing the stomachs of Cdh1fl/+ mice to their 
subcutaneous tumors strongly suggests these tumors have an expression profile more 
consistent with sarcomas than with gastric-derived metastases. The subcutaneous tumors 
can be differentiated from the stomachs based on genes specific to sarcomas versus 
gastric cancers (Figure 3-8) and stomach-enriched genes (Figure 3-7). 
Finally, assuming the Cdh1fl/+ sub-cutaneous tumors are sarcomas arising from 
rare Cre expression in a mesenchymal skin cell, one would expect these tumors to arise in 
Cdh1fl/fl mice as well given that they use the same Atp4b-Cre transgene. In fact, 
subcutaneous tumors are rarely observed in the Cdh1fl/fl mice at a rate of about 1 in 20. As 
the subcutaneous tumors typically arise at approximately 3 months of age in the Cdh1fl/+ 
mice, one would only expect them to be seen in Cdh1fl/fl mice that live to this age. 
However, median survival of Cdh1fl/fl mice is 76.5 days, to young to see subcutaneous 
tumors arise in the majority of these mice. 
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CHAPTER 4 E-CADHERIN LOSS UPREGULATES Β-CATENIN SIGNALING 
IN THE ACKPY MOUSE MODEL OF GASTRIC CANCER 
i. Abstract 
E-cadherin has been shown to bind and inhibit the oncogenic function of β-
catenin (Gottardi, Wong, and Gumbiner 2001). Several groups have previously 
demonstrated that loss or mutation of E-cadherin alone does not increase β-catenin 
signaling in gastric and pancreatic cancer cells (Caca et al. 1999), breast cancer cells (van 
de Wetering et al. 2001) or β-cell tumors (Herzig et al. 2007) . However, in our model of 
gastric cancer, E-cadherin loss drives β-catenin activation and inhibition of β-catenin 
signaling prolonged survival of our ACKPY mice. Given these conflicting results, we 
must consider the context of this increase in β-catenin signaling in our model. Many 
studies have demonstrated cross-activation of canonical WNT signaling by the receptor 
tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway (Zeller et 
al. 2013). Taken together, these data suggest crosstalk between oncogenic Kras and loss 
of E-cadherin in our model, wherein oncogenic Kras primes the system by inactivating 
the β-catenin destruction machinery (Lemieux et al. 2015) and loss of E-cadherin releases 
β-catenin from sequestration. 
ii. Introduction 
Canonical WNT signaling, sometimes referred to as the “β-catenin dependent” 
pathway, results in β-catenin translocation to the nucleus and upregulation of target 
genes. The amount of free β-catenin is tightly regulated in the cell by phosphorylation, 
ubiquitination, and proteasomal degradation. In the absence of WNT ligands, free β-
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catenin is bound and phosphorylated by a complex consisting of Axin, Adenomatous 
polyposis coli (APC), Casein kinase 1 alpha (CK1α), and glycogen synthase kinase 3β 
(GSK3β). Phosphorylated β-catenin is recognized and ubiquitinated by the E3 ligase β-
transducin repeat-containing protein (β-TrCP) targeting β-catenin for proteasomal 
degradation (Figure 4-1A). When WNT ligands are present, they bind to the 
Frizzled(FZ)/Low-density lipoprotein receptor-related protein 5/6 (LRP5/6) receptor 
complex, leading to dissociation of the Axin/APC/CK1α/GSK3β destruction complex. 
This is achieved by the binding of Dishevelled (Dvl) to the ligand-bound Fz/LRP5/6 
receptor complex, which leads to the phosphorylation of LRP5/6 and binding of Axin to 
the receptor complex. Dissociation of the destruction complex prevents phosphorylation 
of β-catenin, results in its accumulation, and subsequent translocation to the nucleus. In 
the nucleus, it binds the T-cell factor (TCF)/lymphoid enhancing factor (LEF) 
transcription factor complex, displacing negative regulator Groucho, and activating 
transcription of target genes (Figure 4-1B) (Chiurillo 2015). 
Canonical WNT signaling has long been implicated in the development of gastric 
cancer. Many studies have shown increased expression or activating mutation of positive 
WNT regulators and decreased expression or inactivating mutation of WNT repressors in 
gastric cancer samples and cell lines (Chiurillo 2015). Several studies have demonstrated 
that H. pylori can also upregulate canonical WNT signaling (Song et al. 2015). Relevant 
to the model I present here, E-cadherin has long been known to bind cytoplasmic β-
catenin and suppress its oncogenic activity by sequestering it in the cadherin-catenin 
complex (Gottardi, Wong, and Gumbiner 2001). It has been suggested, but not shown, 
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that reciprocal regulation occurs; that loss of E-cadherin can lead to increased oncogenic 
transformation through release of free β-catenin (Gottardi, Wong, and Gumbiner 2001; 
Liu et al. 2014; Chiurillo 2015). Here I present the first direct evidence demonstrating 
that loss of E-cadherin, at least in the context of oncogenic Kras and loss of p53 in gastric 
parietal cells, is sufficient to increase β-catenin signaling. 
A B  
Figure 4-1. Canonical WNT pathway. 
(A) WNT ligand absent. (B) WNT ligand present) 
Results 
Microarray reveals upregulation of TCF/LEF targets with E-cadherin loss 
To identify differential gene expression in our model of gastric cancer, I 
performed a microarray on glandular stomach tissue from four independent Cdh1fl/fl and 
Cdh1fl/+ mice. Principal components analysis revealed two clusters: one that contained 3 
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of the Cdh1fl/+ stomachs and a second that contained all 4 of the Cdh1fl/fl stomachs. One 
of the Cdh1fl/+ stomachs did not fall distinctly within either of these groups but was closer 
to the Cdh1fl/fl stomachs (Figure 4-2A). Unsupervised hierarchical clustering analysis 
indicates that the single outlier Cdh1fl/+ stomach sample clustered more closely to Cdh1fl/fl 
stomachs rather than Cdh1fl/+ stomachs (Figure 4-2B). One interpretation of these data 
suggests that this Cdh1fl/+ outlier contained a rare Cdh1fl/+ tumor and thus clusters closer 
to the Cdh1fl/fl tumor containing stomachs than the other, tumor free, Cdh1fl/+ stomachs. 
This data correlates with the 1 in 4 frequency of stomach tumors observed in Cdh1fl/+ 
mice. Microarray data from the Cdh1fl/+ outlier was removed from future analysis due to 
the likely presence of a stomach tumor.  
 
Figure 4-2. Principal component analysis and unsupervised hierarchical clustering 
analysis of microarray data from Cdh1fl/fl and Cdh1fl/+ stomachs. 
 
To determine which pathways were differentially regulated between the two 
genotypes, I performed gene set overlap analysis (Subramanian et al. 2005) on genes 
upregulated in the Cdh1fl/fl stomachs versus Cdh1fl/+ stomachs and a publicly available 
data set of transcription factor target gene sets. The first hit was a set of genes containing 
a LEF1 binding site in their promoters, and the sixth was a set of genes containing the 
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TCF3 binding site (Table 4-1). Further, when genes upregulated in Cdh1fl/fl versus 
Cdh1fl/+ stomachs were compared to oncogenic signature gene sets, the results contained 
several genes sets whose upregulation resulted from expression of LEF1, WNT1, and 
CTNNB1 (Table 4-1). All these data are consistent with an up-regulation of β-catenin 
target genes. 
Name Description FDR q-value  
 Transcription Factor Target Gene Sets  
CTTTGT_V$LEF1_Q2 Genes with promoter regions containing the LEF1 motif 3.27 e-87 
 CAGGTG_V$E12_Q6  Genes with promoter regions containing the TCF3 motif 1.44 e
-58 
 Oncogenic Signature Gene Sets  
LEF1_UP.V1_UP Upregulated in DLD1 cells over-expressing LEF1 2.86 e
-19
 
WNT_UP.V1_UP Upregulated in C57MG cells over-expressing WNT1 1.42 e
-8
 
BCAT.100_UP.V1_UP Upregulated in HEK293 cells expressing active CTNNB1 3.83 e
-8
 
Table 4-1. Selected results from Gene Set Overlap Analysis comparing genes 
overexpressed in Cdh1fl/fl vs. Cdh1fl/+ to transcription factor target gene sets and 
oncogenic signature gene sets. 
 
Validation of β-catenin target gene regulation by E-cadherin 
To validate the microarray data, I analyzed RNA isolated from stomachs of other 
Cdh1fl/fl and Cdh1fl/+ mice for expression of several canonical WNT/β-catenin target 
genes: MYC (He et al. 1998), CCND1 (McCormick and Tetsu 1999; Shtutman et al. 
1999), AXIN2 (Yan et al. 2001; Lustig et al. 2002; Jho et al. 2002), LEF1 (Hovanes et al. 
2001; Filali et al. 2002; T. W.-H. Li et al. 2006), CD44 (Wielenga et al. 1999; Zeilstra et 
al. 2008), MMP7 (Crawford et al. 1999; Brabletz et al. 1999). All genes were 
significantly upregulated in Cdh1fl/fl compared to Cdh1fl/+ stomach tissues. 
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Figure 4-3. qPCR validated upregulation of WNT/β-catenin targets in Cdh1fl/fl over 
Cdh1fl/+ stomachs. 
 
Loss of membranous β-catenin in Cdh1fl/fl and Cdh1fl/+ tumors mirrors loss of E-cadherin 
β-catenin is normally sequestered at the plasma membrane by E-cadherin. To test 
if loss of E-cadherin alters the subcellular localization of β-catenin, I co-immunostained 
Cdh1fl/fl and Cdh1fl/+ stomachs with and without tumors for E-cadherin, β-catenin, and 
YFP. As expected, a wild-type control stomach lacked YFP but expressed E-cadherin and 
β-catenin that were localized to the plasma membrane (Figure 4-4A, white arrows). 
Conversely, Cdh1fl/fl stomachs showed loss of expression of E-cadherin and β-catenin in 
YFP+ tumors (Figure 4-4B, yellow arrows), but expression patterns were normal in YFP- 
areas (Figure 4-4B, white arrows).  
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Figure 4-4. Representative images showing loss of membranous β-catenin in Cdh1fl/fl and 
Cdh1fl/+ tumors. 
(White arrows) Retained E-cadherin and β-catenin in YFP negative areas. (Yellow 
arrows) Lost E-cadherin and β-catenin in YFP positive tumor areas. (Orange arrows) 
Retained E-cadherin and β-catenin in YFP positive non-tumor areas. 
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The Cdh1fl/+ stomach without a tumor (Figure 4-4C) and the normal area of a Cdh1fl/+ 
stomach with a tumor (Figure 4-4D) retained expression of E-cadherin and β-catenin 
throughout (Figure 4-4, orange arrows). In contrast to the benign regions, the tumor area 
of the Cdh1fl/+ stomach displayed loss of membranous expression of E-cadherin and β-
catenin (Figure 4-4E, yellow arrows). 
Inhibition of β-catenin/TCF signaling increases survival of ACKPY mice 
To test the necessity of β-catenin signaling in our ACKPY gastric cancer mouse 
model, I treated mice with the β-catenin/TCF complex inhibitor PKF118-310. Though the 
effect size is small, mice treated with the inhibitor had a statistically significant (p=0.04) 
6-day increase in median survival (78 days) over vehicle treated mice (72 days).  
 
Figure 4-5. Kaplan-Meier curve showing increased survival with PKF118-310 treatment. 
Beginning at 4-weeks of age, mice were injected 3x per week with 1 mg/kg PKF118-310 
(red, n=8) or a volumetrically equivalent does of 0.1% DMSO vehicle (black, n=13) 
intra-peritoneally. 
 
Activation of β-catenin with LiCl did not promote tumorigenesis in Cdh1fl/+ mice 
To determine if β-catenin activation was sufficient to drive tumorigenesis in 
Cdh1fl/+ mice, I treated them with the GSK3β inhibitor lithium chloride (LiCl). GSK3β is 
a key component of the degradation complex that phosphorylates β-catenin and targets it 
for ubiquitination and proteasomal degradation. Inhibition or loss of GSK3β leads to 
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increased free β-catenin that can translocate to the nucleus, bind TCF/LEF, and transcribe 
targets. My preliminary data suggest no difference in stomach tumor incidence between 
LiCl treated Cdh1fl/+ mice and vehicle treated Cdh1fl/+ mice (data not shown). However, 
interpretation of these data is limited as we were not able to confirm efficacy of the 
inhibition by assaying for destruction complex activity.  
iii. Discussion 
Though it has long been hypothesized that E-cadherin loss would lead to 
upregulation of β-catenin signaling, several studies have shown that this may not be the 
case. For example, cancer cell lines with deletion (Caca et al. 1999) or mutation (van de 
Wetering et al. 2001) of E-cadherin did not show constitutive β-catenin/TCF/LEF 
signaling. Further, in the Rip1Tag2 model of β-cell carcinogenesis, E-cadherin loss is 
rate-limiting. However, it has been shown that this loss does not upregulate β-catenin 
target genes and cannot be phenocopied by forced activation of TCF or β-catenin 
transcriptional activity (Herzig et al. 2007). Taken together, these data suggest that 
though loss of E-cadherin may release β-catenin from sequestration, the nuclear activity 
is still inhibited by a functional destruction complex (Jeanes, Gottardi, and Yap 2008). 
Here we show that loss of E-cadherin is sufficient to drive increased β-
catenin/TCF/LEF signaling in our model and that this signaling is important to the 
survival phenotype. However, the status of the β-catenin destruction complex is not 
known. Given the data suggesting E-cadherin loss alone is not sufficient to drive β-
catenin signaling, we must consider the hypothesis that other manipulation in our model 
may be affecting the destruction complex. 
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In fact, many studies have shown significant crosstalk between the 
RTK/Ras/mitogen-activated protein kinase (MAPK) pathway and canonical WNT 
signaling (Zeller et al. 2013). For example, in intestinal tumor formation, APC and Kras 
mutation are synergistic not only in promoting tumor formation but also in the activation 
of WNT signaling (Janssen et al. 2006). One potential mechanism elucidated in colorectal 
cancer cell lines reveals that oncogenic Kras, functioning through the MAPK pathway, 
can activate canonical WNT signaling by phosphorylation of LRP6 (Lemieux et al. 
2015). Additionally, in their investigation of the Trp53/Cdh1 double conditional model, 
Shimada et al did not observe any expression of β-catenin in their tumors and concluded 
that β-catenin signaling was not involved in the development of diffuse gastric cancer in 
their model (2012). 
Taken together, these data suggest that our β-catenin signaling phenotype is a 
synthetic phenotype resulting from both the loss of E-cadherin and expression of 
oncogenic Kras in our model: loss of E-cadherin releases β-catenin from sequestration 
and oncogenic Kras inhibiting the destruction complex. Further, it may suggest a reason 
why we do not see increased tumorigenesis in the LiCl treatment group. This treatment 
may be redundant in targeting the destruction complex that may already be impaired by 
oncogenic Kras. 
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CHAPTER 5 LOSS OF E-CADHERIN CORRELATES WITH UPREGULATION 
OF ONCOGENIC KRAS TARGET GENES IN THE ACKPY MOUSE MODEL 
OF GASTRIC CANCER 
i. Abstract 
Ras oncogenes directly regulate four core signaling pathways that influence 
nearly every hallmark of cancer (Hanahan and Weinberg 2000; Hanahan et al. 2011): the 
mitogen activated kinase (MAPK) pathway, the phosphatidylinositol-3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, the Ras-like GTPase 
guanine nucleotide exchange factor (Ral-GEFs) pathway, and the phospholipase C 
isoform ε (PLCε) pathway (Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011). Microarray 
data comparing gene expression in stomachs harvested from Cdh1fl/fl vs. Cdh1fl/+ mice 
correlates E-cadherin loss with the upregulation of oncogenic Kras signaling in our 
model. Gene sets regulated by MAPK activation were among those over-represented in 
our microarray analysis. However, examination of extracellular signal-related kinase 
(ERK) phosphorylation revealed that E-cadherin does not regulate MAPK activity in our 
model. The upregulation of oncogenic Kras target genes that result from the loss of E-
cadherin may alternatively be explained by E-cadherin regulation of other Kras effector 
pathways. In fact, E-cadherin loss correlated with upregulation of gene sets driven by 
activation of each of the other effector pathways.  
ii. Introduction 
The Ras family of oncogenes has been extensively studied since its discovery in 
the early 1980s (Tsuchida et al. 2016). They have been implicated in the regulation of 
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nearly all of the hallmarks of cancer as outlined by Hanahan and Weinberg (Hanahan and 
Weinberg 2000; Hanahan et al. 2011; Pylayeva-Gupta, Grabocka, and Bar-Sagi 2011). 
The four core pathways they directly regulate have been known since the early 2000s 
(Downward 2003). While their reach seems endless, new downstream effectors are still 
being discovered (F. Zhang and Cheong 2016). 
The first Ras effector discovered was the Raf/mitogen activated protein kinase 
(MAPK) pathway. Activated Ras binds and activates Raf, a kinase complex, which then 
activates MAPK/ERK Kinase (MEK) by phosphorylating it. MEK phosphorylates and 
activates the extracellular signal-related kinase (ERK), also known as MAPK. ERK 
phosphorylates a myriad of both cytoplasmic and nuclear targets, many of which are 
transcription factors (Mendoza, Er, and Blenis 2011). 
Ras also activates the lipid kinase phosphatidylinositol-3-kinase (PI3K), 
generating the signaling molecule phosphatidyl inositol 3,4,5 tri-phosphate (PIP3). PIP3 
recruits the kinase Akt to the plasma membrane where another target of PIP3, 3-
phosphoinositide-dependent kinase 1 (PDK1), and the mammalian target of rapamycin 
(mTOR) complex 2 (mTORC2) activate it by phosphorylation. Akt has many targets that 
regulate a variety of pathways; most notable is its inhibition of the tuberous sclerosis 
complex genes (TSC1/2) that inhibit the GTPase Ras homolog enriched in brain (RHEB) 
that activates mTORC1. As such, Akt disinhibits RHEB via inhibition of TSC1/2 leading 
to activation of mTORC1, a master regulator of cell survival, division, and metabolism 
(Mendoza, Er, and Blenis 2011). 
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Ras also activates the Ras-like GTPases (Rals) via their guanine nucleotide 
exchange factors (GEFs). Like Ras proteins, the Rals interact with a variety of effectors 
to influence exocytosis, endocytosis, actin organization, second messenger production, 
and transcription factor activity. One such effector pathway results in NF-κB activation. 
RalB promotes the association of Sec5 with TANK-binding kinase (TBK1), which 
increases its activity as an inhibitor of κB (IκB) kinase (IKK), thereby relieving 
inhibition of NF-κB (Neel et al. 2011). 
The fourth canonical target of Ras is phospholipase C (PLC) isoform ε, which 
increases its activity. PLC enzymes generate two important second messengers: 
diacylglycerol (DAG), which activates phosphokinase C (PKC), and inositol 1,4,5-
trisphosphate (IP3), which leads to an increase in intracellular calcium by release from 
intracellular stores and influx through cell membrane channels. Both of these pathways 
regulate a variety of pathways. As with the RalGEF pathway, the PLCε has also been 
shown to activate NF-κB (R.-Y. Zhang et al. 2016). Additionally, increased intracellular 
calcium activates calcineurin, which dephosphorylates the transcription factor nuclear 
factor of activated T cells (NFAT), exposing its nuclear localization signal and inducing 
translocation to the nucleus, thereby activating NFAT (Mognol et al. 2016). 
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Figure 5-1. Main downstream effector pathways of the Ras family of oncogenes 
(Downward 2003; F. Zhang and Cheong 2016). 
iii. Results 
Microarray analysis correlates loss of E-cadherin with upregulation of oncogenic Kras 
signaling and increased expression of MAPK target genes 
The microarray gene set overlap analysis (GSOA) data, described in Chapter 3, 
also revealed that RTK/Kras/MAPK driven gene sets were over-represented in our 
Cdh1fl/fl versus Cdh1fl/+ stomach gene set. When comparing our gene set to the collection 
of cancer hallmark gene sets, the second most significant hit was one for “genes up-
regulated by Kras activation.” Further, significant overlap was found between our gene 
set and RTK/Kras/MAPK regulated gene sets (oncogenic signature gene sets), including 
9 resulting from the over-expression of oncogenic KRAS and 4 from activation of 
RTK/MAPK components (Table 5-1). Given that both Cdh1fl/fl and Cdh1fl/+ stomachs 
express oncogenic Kras, these data suggest that E-cadherin presence or loss may regulate 
the activity of oncogenic Kras in our model. 
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Name Description FDR q-value 
Cancer Hallmark Gene Sets   
HALLMARK_KRAS_SIGNALING_UP Genes up-regulated by KRAS activation. 3.36E-61 
Oncogenic Signature   
EGFR_UP.V1_UP Up-regulated in MCF-7 cells engineered to 
express ligand-activatable EGFR 
7.54E-27 
MEK_UP.V1_UP Up-regulated in MCF-7 cells stably over-
expressing constitutively active MAP2K1 
1.30E-25 
RAF_UP.V1_UP Up-regulated in MCF-7 cells stably over-
expressing constitutively active RAF1 
1.30E-25 
KRAS.600_UP.V1_UP Up-regulated in four lineages of epithelial 
cell lines over-expressing oncogenic KRAS 
1.47E-19 
ERB2_UP.V1_UP Up-regulated in MCF-7 cells engineered to 
express ligand-activatable ERBB2 
9.62E-19 
KRAS.DF.V1_UP Up-regulated in epithelial lung cancer cell 
lines over-expressing oncogenic KRAS 
9.39E-18 
KRAS.600.LUNG.BREAST_UP.V1_UP Up-regulated in epithelial lung and breast 
cancer cell lines over-expressing oncogenic 
KRAS 
2.68E-17 
KRAS.LUNG.BREAST_UP.V1_UP Up-regulated in epithelial lung and breast 
cancer cell lines over-expressing oncogenic 
KRAS 
2.55E-15 
KRAS.BREAST_UP.V1_UP Up-regulated in epithelial breast cancer cell 
lines over-expressing oncogenic KRAS 
4.49E-11 
KRAS.LUNG_UP.V1_UP Up-regulated in epithelial lung cancer cell 
lines over-expressing oncogenic KRAS 
1.34E-10 
KRAS.300_UP.V1_UP Up-regulated in four lineages of epithelial 
cell lines over-expressing oncogenic KRAS 
8.06E-09 
KRAS.PROSTATE_UP.V1_UP Up-regulated in epithelial prostate cancer 
cell lines over-expressing oncogenic KRAS 
2.75E-08 
KRAS.50_UP.V1_UP Up-regulated in four lineages of epithelial 
cell lines over-expressing oncogenic KRAS 
2.78E-07 
Table 5-1. Gene set overlap analysis comparing cancer hallmark gene sets and oncogenic 
signature gene sets to genes up-regulated in Cdh1fl/fl versus Cdh1fl/+ stomachs. 
 
E-cadherin does not attenuate MAPK activity 
ERK, the downstream effector of the MAPK pathway, is activated by 
phosphorylation. To assess the effect of E-cadherin on the MAPK pathway activity 
downstream of oncogenic Kras, stomach tissue from Cdh1fl/fl and Cdh1fl/+ mice was 
stained by immunofluorescence (IF) for phospho-ERK (pERK) and yellow fluorescence 
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protein (YFP) expression. Preliminary data comparing two stomach samples of each 
genotype suggested a considerable increase in pERK in the Cdh1fl/fl stomachs over the 
Cdh1fl/+ stomachs (Figure 5-2A). 
For quantitative analysis, I examined two larger cohorts of mice. One cohort, 
referred to as the terminal cohort, was composed of Cdh1fl/fl mice that had reached the 
humane survival endpoint (20% loss of body weight) and Cdh1fl/+ mice that had reached 
the humane endpoint for their subcutaneous tumors (≥ 2 cm3). A second cohort was 
composed of age-matched Cdh1fl/fl and Cdh1fl/+ mice euthanized between 9 and 10 weeks 
of age. IF staining of the terminal cohort revealed a trend towards increased pERK in 
Cdh1fl/fl stomachs over Cdh1fl/+ stomachs, but this difference was not statistically 
significant (p = 0.15). However, IF staining of the age-matched cohort exhibited no such 
trend (Figure 5-2B). 
To further analyze pERK expression in tissue sections, I performed 
immunohistochemical (IHC) staining on the same cohorts.  In contrast to the IF staining, 
IHC staining of the terminal cohort indicated a trend toward increased expression of 
pERK in Cdh1fl/+ stomachs over Cdh1fl/fl stomachs (p=0.23). In the age-matched cohort, 
this finding was a statistically significant increase (p=0.01). Additionally, analysis of the 
combination of these two cohorts revealed a statistically significant increase in pERK in 
Cdh1fl/+ stomachs over Cdh1fl/fl stomachs (p=0.01, Figure 5-2C). 
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Figure 5-2. Results from pERK staining experiments in Cdh1fl/fl and Cdh1fl/+ stomachs. 
(A) Initial immunofluorescence staining for pERK (red) and YFP (green) in Cdh1fl/fl and 
Cdh1fl/+ stomachs. Counterstained with DAPI (blue), 63x. 
(B) Quantitative analysis of immunofluorescence staining for pERK+ and YFP+ overlap 
area (relative to total YFP+ area) in two Cdh1fl/fl vs. Cdh1fl/+ stomach cohorts. 
(C) Quantitative analysis of immunohistochemical staining for pERK+ (relative to total 
stomach area) in two Cdh1fl/fl vs. Cdh1fl/+ stomach cohorts, separate and combined. 
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Microarray analysis correlates loss of E-cadherin with upregulation of oncogenic Kras 
MAPK-independent effector pathways 
Name Description FDR 
q-value 
PI3K/AKT/mTOR Gene Sets   
HALLMARK_MTORC1_SIGNALING Up-regulated through activation of mTORC1 
complex. 
1.76E-08 
HALLMARK_PI3K_AKT_MTOR_SIGNALING Up-regulated by activation of the 
PI3K/AKT/mTOR pathway. 
4.54E-02 
MTOR_UP.V1_DN Down-regulated by everolimus (mTOR inhibitor) in 
prostate tissue. 
1.31E-12 
PTEN_DN.V2_UP Up-regulated in HCT116 cells upon knockdown of 
PTEN 
2.98E-11 
AKT_UP_MTOR_DN.V1_DN Down-regulated by everolimus (mTOR inhibitor) in 
mouse prostate tissue transgenically expressing 
human AKT1 
1.76E-10 
NF-κB Gene Sets   
HALLMARK_TNFA_SIGNALING_VIA_NFKB Regulated by NF-kB in response to TNF 5.52E-45 
V$NFKAPPAB_01 Genes with promoter regions containing the NFKB 
binding site 
1.57E-17 
V$NFKAPPAB65_01 Genes with promoter regions containing the RELA 
binding site 
1.42E-14 
HINATA_NFKB_IMMU_INF Immune or inflammatory genes induced by NF-KB 
in primary keratinocytes and fibroblasts. 
6.26E-07 
RELA_DN.V1_DN Genes down-regulated in HEK293 cells upon 
knockdown of RELA 
2.21E-06 
NFAT Gene Sets   
TGGAAA_V$NFAT_Q4_01 Genes with promoter regions containing the NFAT 
binding site 
1.47E-69 
V$NFAT_Q6 Genes with promoter regions containing the NFAT 
binding site 
1.17E-18 
Table 5-2. Gene set overlap analysis results for downstream KRAS pathways that are 
MAPK-independent. 
 
Further review of the microarray GSOA revealed MAPK-independent gene sets 
downstream of oncogenic KRAS also overlapped with our Cdh1fl/fl over Cdh1fl/+ stomach 
gene set. Using GSOA, our gene set overlapped with two publicly available cancer 
hallmarks gene sets upregulated by activation of the PI3K/AKT/mTOR pathway. 
Comparison of our gene sets to oncogenic signature gene sets demonstrated overlap with 
three sets of genes also upregulated by activation of the PI3K/AKT/mTOR pathway 
(Table 5-2, white). Gene sets upregulated by NF-κB were also over-represented in 
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comparison to cancer hallmarks gene sets (1 gene set), transcription factor target gene 
sets (2 gene sets), and oncogenic signature gene sets (2 gene sets) (Table 5-2, light gray). 
There was also overlap with two transcription factor target gene sets for NFAT (Table 
5-2, dark gray). 
iv. Discussion 
Investigating E-cadherin regulation of MAPK 
The suggestion that E-cadherin might negatively regulate the MAPK pathway 
downstream of oncogenic Kras in our model was intriguing. While crosstalk between E-
cadherin and receptor tyrosine kinases (RTKs) has been suggested (Andl and Rustgi 
2005) only two papers demonstrate E-cadherin-dependent down-regulation of MAPK 
(Laprise et al. 2004; Soto et al. 2008). Crosstalk between the canonical WNT and 
RTK/KRAS/MAPK pathways is well-described (Zeller et al. 2013), but only one study 
has implicated β-catenin signaling in the regulation of the pathway downstream of RTKs 
(Zeller et al. 2012). Prior to our semi-quantitative pERK staining data that suggest that 
this initial observation may not be true, we began to consider several pathways that could 
have potentially been at play. 
First, E-cadherin has been shown to bind and activate the PI3K-p85 regulatory 
subunit, resulting in activation of Akt (De Santis et al. 2009). This E-cadherin regulation 
of the PI3K/Akt pathway has been shown to inhibit MEK/ERK activity (Laprise et al. 
2004). We hypothesized that E-cadherin in Cdh1fl/+ stomachs might lead to increased 
AKT activity that might explain the inhibition of pERK in these mice. As such, I 
examined Cdh1fl/fl and Cdh1fl/+ stomach tissue for the active form of AKT (pAKT-
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Ser473) by IF. In a pilot experiment, I did not observe pAKT expression in either cohort 
(data not shown). 
Second, E-cadherin and β-catenin have been shown to influence the expression of 
several negative regulators of MAPKs (MAPK phosphatases, MKPs): dual specific 
phosphatase 6 and 14 (DUSP6/14) (Zeller et al. 2012), and sprouty homolog 2 (SPRY2) 
(Barbáchano et al. 2010). We hypothesized that E-cadherin expression or the lack of β-
catenin signaling in Cdh1fl/+ stomachs could lead to an increase in expression of a MAPK 
phosphatase that could cause a decrease in the phosphorylated state of ERK in these 
stomachs. Due to the large number of MKPs and the fact that the reported regulation by 
E-cadherin/β-catenin was at the transcriptional level, we began our examination of MKP 
expression in a panel of Cdh1fl/fl and Cdh1fl/+ stomach RNAs by qPCR. I did not observe 
increased expression in the Cdh1fl/+ RNAs of any of the 10 MAPK regulatory DUSPs 
(Kidger and Keyse 2016), 4 SPRYs, or 3 SPREDs (sprouty related EVH1 domain 
containing) (data not shown). 
Third, in the context of a mouse model of lung carcinogenesis, it is has been 
shown that BrafV600E can drive oncogene-induced senescence (OIS) that is rescued by 
canonical WNT driven cMyc expression (Juan et al. 2014). I hypothesized that KrasG12D 
in Cdh1fl/+ stomachs might similarly drive OIS that would result in an inhibition of 
MAPK activity. In Cdh1fl/fl stomachs, this could be rescued by cMyc upregulation as a 
result of E-cadherin loss-driven β-catenin signaling. This mechanism is not possible, as 
OIS is dependent on p53 activity and Trp53 is knocked out in our model. 
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Fourth, E-cadherin is known to inhibit p120-Rac1 activity. This inhibition has 
been shown to be necessary for Raf/MEK activation (Soto et al. 2008). I hypothesized 
that loss of E-cadherin in Cdh1fl/fl stomachs led to loss of inhibition of p120-Rac and 
ultimate disinhibition of Raf/MEK (re: MAPK) activity. Unfortunately, there is no way to 
assess Rac1 activity in tissue sections. 
E-cadherin does not down-regulate MAPK activity 
Ultimately, the initial observation of a decrease in pERK expression in Cdh1fl/+ 
stomachs compared to Cdh1fl/fl stomachs was not borne out upon examination of larger 
cohorts. By IF, there was no significant difference in pERK expression between the 
genotypes. However, by IHC there was a contrasting increase in pERK staining in 
Cdh1fl/+ stomachs compared to Cdh1fl/fl stomachs (or decrease in pERK staining in 
Cdh1fl/fl stomachs compared to Cdh1fl/+ stomachs). This difference is likely due to the 
lack of co-staining and subsequent controlling for YFP in the IHC analysis. 
For IF analysis, I measured the area of pERK and YFP co-expression divided by 
total YFP+ area per microscopic field (averaged over multiple fields and tissue planes). 
This controlled for the relative abundance of Cre-transformed cells of interest by 
excluding cells untransformed cells and acellular areas. I analyzed the IHC data by 
measuring the total pERK stained area per slide divided by the total tissue area per slide 
(each slide containing several tissue planes). This IHC analysis did not account for the 
area of the tissue that was Cre transformed (i.e. YFP+). This could be corrected by 
staining for YFP on a serial section and dividing the pERK stained area per slide by the 
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YFP+ area per slide. Qualitatively, I did observe greater YFP positivity throughout 
Cdh1fl/+ stomachs compared to Cdh1fl/fl stomachs that might explain this finding. 
MAPK-independent Kras pathways may drive Kras signature in microarray data 
Due to my initial observation of a decrease in pERK expression in Cdh1fl/+ 
stomachs compared to Cdh1fl/fl stomach, I focused my work and analysis on the role of 
the MAPK pathway.  However, revisiting the initial GSOA data suggests an alternative 
interpretation of the apparent effect of E-cadherin on Kras-regulated genes. The GSOA 
results not only suggested regulation of the MAPK pathway downstream of Kras, but also 
of the PI3K/Akt/mTOR, NF-κB, and PLCε/PKC/Ca2+ (i.e. NFAT) pathways. Our 
staining data suggest that E-cadherin does not negatively regulate the Ras/MAPK axis, 
but it may regulate one or more of these pathways. If yes, that regulation could explain 
the strong Kras-driven gene signature present in our Cdh1fl/fl over Cdh1fl/+ stomach gene 
set. Further experiments are necessary to confirm or refute E-cadherin regulation of these 
pathways, I will discuss that further in the following conclusions and future directions 
chapter. 
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
i. ACKPY Metastatic Model of Gastric Cancer 
Conclusions 
The ACKPY mouse model is a promising new model of metastatic gastric cancer. 
By combining genetic lesions that represent common pathways mutated in gastric cancer, 
we have generated a clinically relevant model of gastric cancer that mimics both the 
etiology of disease and the observed disease progression. Unlike most mouse models of 
gastric cancer, ours metastasizes widely, mirroring the common presentation of patients 
in the clinic with advanced disease. In contrast to other mouse models of gastric cancer, 
ours progresses quickly, allowing for timely analyses. I demonstrated the potential 
preclinical utility of our model by treating our mice with a MEK inhibitor. However, this 
model, as all models, is not without limitation and caveats. 
First, though we set out to generate a model of diffuse gastric cancer, the 
phenotype we observe is that of mixed-type, containing both intestinal-type and diffuse-
type lesions. This phenotype may be a disadvantage of the model, as it is the least 
common form of gastric cancer (Polkowski et al. 2016). Yet, this is the first mouse model 
of mixed-type gastric cancer and is therefore the only model available to study this hybrid 
form of the disease. Furthermore, it may have implications for understanding the 
differences, similarities, and distinct etiologies of intestinal- and diffuse-type cancers, as 
both types of lesions arise from the same genetic modifications in our model. The 
presence of both intestinal- and diffuse-type lesions in one model may also be an 
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advantage as treatments could be assessed as to their effect on each type of lesion in the 
same model. 
The above presumes the prevailing narrative that intestinal- and diffuse-type 
gastric cancers represent distinct diseases with differing etiologies. Intestinal-type gastric 
cancer has traditionally been associated with the Correa pathway and is thought to be 
more related to environmental effects (Correa 1992; Muñoz and Asvall 1971). The 
histologic progression to diffuse-type is less well understood (Fox and Wang 2007), and 
the etiology is less associated with environmental effects (Muñoz and Asvall 1971) but is 
known to be related to loss of expression of E-cadherin (Graziano, Humar, and Guilford 
2003). In these discussions the presence of mixed-type gastric cancer is always 
conveniently absent. 
However, H. pylori infection is strongly associated with both forms of the disease 
(Fox and Wang 2007). Further, the recent molecular classification systems developed by 
the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) do not 
categorize intestinal- and diffuse-type disease perfectly within subsets. Though both 
groups find that their classification of Laurén types is statistically significant, a thorough 
review of the data reveals a more complex picture. Additionally, mixed-type gastric 
cancer is quite evenly distributed among subtypes (Table 6-1 & Table 6-2) (Bass et al. 
2014; Cristescu et al. 2015). These data might suggest that our current classification 
scheme, based solely on histologic appearance as described by Laurén in the 1960s, does 
not actually define distinct diseases.  
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  TCGA Classification 
  Total EBV MSI GS CIN 
  n % n % n % n % n % 
Diffuse 69 23.4% 5 19.2% 6 9.4% 40 69.0% 18 12.2% 
Intestinal 196 66.4% 15 57.7% 48 75.0% 15 25.9% 118 80.3% 
Mixed 19 6.4% 3 11.5% 3 4.7% 3 5.2% 10 6.8% 
Not Specified 11 3.7% 3 11.5% 7 10.9% 0 0.0% 1 0.7% 
Table 6-1. Distribution of samples by Laurén classification within The Cancer Genome 
Atlas (TCGA) subtypes (Bass et al. 2014). 
 
  ACRG Classification 
  Total MSS/TP53- MSS/TP53+ MSI MSS/EMT 
  n % n % n % n % n % 
Diffuse 135 45.0% 42 39.3% 36 45.6% 20 29.4% 37 80.4% 
Intestinal 146 48.7% 58 54.2% 38 48.1% 42 61.8% 8 17.4% 
Mixed 17 5.7% 7 6.5% 4 5.1% 5 7.4% 1 2.2% 
Not Specified 2 0.7% 0 0.0% 1 1.2% 1 1.0% 0 0.0% 
Table 6-2. Distribution of samples by Laurén classification within The Asian Cancer 
Research Group (ACRG) subtypes (Cristescu et al. 2015). 
 
Similarly, though the cell of origin of gastric cancer is still not well-defined, the 
data implicating Mist1+ as the cell of origin demonstrates that both sub-types can 
originate from the same cell, albeit through different genetic manipulations (Hayakawa et 
al. 2015).  This is in contrast to cancers of other sites, where sub-types have been shown 
to arise from distinct cells of origin either from similar or distinct genetic manipulations 
(Blanpain 2013). Taken together with our data showing that diffuse-type and intestinal-
type lesions can arise from the same genetic background, this might suggest that these 
histologic classifications do not correlate with etiology of disease as well as was once 
thought. Our work on the cell of origin of gastric cancer deserves further investigation. 
Another caveat is the relative rarity of the specific genetic lesions we used to 
generate our model. Kras mutations occur in only 9% of TCGA cases. However, as 
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discussed in Chapter 1, if one looks at all members of the Epidermal Growth Factor 
Receptor (EGFR)/Ras/Raf families, amplification or mutation occurs in >60% of cases 
(Bass et al. 2014; Cerami et al. 2012). This analysis omits other Receptor Tyrosine 
Kinases (RTKs) that can activate Kras. Likely the percentage of tumors with Kras 
activation would only increase if other RTKs were considered. In fact, many RTKs have 
been implicated in gastric carcinogenesis (Table 6-3). Because oncogenic Kras is a 
common effector of many of these RTKs, it allows the modeling of RTK 
amplification/mutation in general rather than that of one specific RTK. However, it does 
not model all of the potential downstream effectors of RTKs. Nonetheless, one of its 
favorable attributes is its common use and the wide array of literature on which one could 
draw on while interpreting results. 
Receptor Tyrosine Kinases (RTKs) Reference 
PDGFR Platelet Derived Growth Factor Receptor (Chung and 
Antoniades 1992) IGF-1R Insulin-like Growth Factor-1 Receptor 
TGFαR Transforming Growth Factor α Receptor 
EGFR Epidermal Growth Factor Receptor (Gong et al. 2010) 
HER2 (ERBB2) Human EGF Receptor 2 
FGFR1 Fibroblast Growth Factor Receptor 1 
FGFR2α Fibroblast Growth Factor Receptor 2α 
Insulin R Insulin Receptor 
EphA4 Erythropoietin-Producing Human Hepatocellular Receptor A4 
FGFR2 Fibroblast Growth Factor Receptor 2 (Deng et al. 2012) 
EGFR Epidermal Growth Factor Receptor 
HER2 (ERBB2) Human EGF Receptor 2 
HGFR(MET) Hepatocyte Growth Factor Receptor 
Table 6-3. Receptor Tyrosine Kinases (RTKs) implicated in gastric carcinogenesis. 
 
Additionally, though mutations in CDH1 are causal in hereditary diffuse gastric 
cancer and loss of E-cadherin is common in sporadic diffuse-type gastric cancer, it is 
rarely lost or mutated in intestinal-type gastric cancer (Liu et al. 2014). However, just as 
we looked at the entire RTK/RAS/RAF pathway to argue the relevance of the inclusion 
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of oncogenic Kras in our model, so should we do the same for E-cadherin related genes. 
In fact, in the TCGA data set, one or more components of the adherens junction are 
altered in 49% of gastric cancer cases (Figure 6-1) (Bass et al. 2014; Cerami et al. 2012).  
 
Figure 6-1. Genetic alterations in adherens junction components in The Cancer Genome 
Atlas (TCGA) gastric cancer cohort (Bass et al. 2014; Cerami et al. 2012). 
 
Further, in the data available, from the cBioPortal, CDH1 and KRAS mutations or 
other alterations rarely occur together in human gastric cancer (Bass et al. 2014; Cerami 
et al. 2012). However, this may be explained by the interaction I propose here. If, for 
example, a cell losses CDH1 expression it will also lose inhibition of the KRAS 
downstream pathways, in effect activating these pathways. Thus there may not be 
evolutionary pressure to gain oncogenic mutations of KRAS. Further it is known that, at 
least in a pancreatic cancer model, oncogenic Kras inhibits E-cadherin (Rachagani et al. 
2011). Thus, a cell that acquires a KRAS mutation may disinhibit itself by inhibiting E-
cadherin, relieving the evolutionary pressure to mutate CDH1. 
Finally, though our model metastasizes widely, it does not perfectly recapitulate 
the distribution of metastasis observed in gastric cancer patients. Clinically, one does see 
local lymph node involvement as we do in our model, but the most common sites of 
spread are to the peritoneum and liver, while lung metastases are more rare (Avital et al. 
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2015). That having been said, our model is the only clinically relevant model with 
significant metastasis.	  
Future Directions 
The ACKPY model offers many avenues for future study, some of which I have 
addressed in the previous chapters. First, an exploration of the role of oncogenic Kras in 
the metastatic phenotype of our model is certainly pertinent. Whereas E-cadherin is 
typically considered an invasion suppressor gene (Birchmeier, Hülsken, and Behrens 
1995) here we see it functioning as a primary tumor suppressor. It is the addition of 
oncogenic Kras to the Trp53/Cdh1 double-conditional knockout that expands the 
metastatic range from rare micro-metastatic lesions of local lymph nodes (Shimada et al. 
2012) to highly penetrant metastases to local lymph nodes, lungs, and mediastinal lymph 
nodes, as well as rarer micro-metastases to the liver. More detailed analysis of livers may 
reveal a higher frequency of metastases, as only 3 sections of tissue 200 µm apart were 
analyzed from each liver, leaving much of the tissue uninvestigated. Further, 
investigation of other tissues such as bone and the retroperitoneum might reveal other 
sites of metastasis. 
Study of the mixed-type histology of the model may reveal insights into the 
differing etiology of intestinal- and diffuse-type lesions. This could be done through 
experiments that isolate and compare lesions of differing histology. For example, laser 
capture micro-dissection could be used followed by microarray, RNA-seq, or mass-
spectrometric analyses. 
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Much work can be done to further investigate the cell of origin of gastric cancer. 
Initial experiments should seek to determine any overlap between Mist1+, Lgr5+, and 
Atp4b+ cell populations; this could be performed easily by lineage tracing, co-
immunostaining, or flow cytometry. I hypothesize that Mist1+ or Lgr5+ stem cell-derived 
pre-parietal or parietal cells are the actual cell transformed in those models, and this 
hypothesis could also be tested using lineage tracing experiments.  
Finally, there are a variety of topics that could be studied using this model. I 
performed a pilot experiment examining the involvement of the microbiome in the 
development of gastric cancer in our mice. In a different pilot experiment, I observed a 
correlation between number of circulating tumor cells and lung macrometastases. Both 
these findings lay promising groundwork for validation and further study. 
ii. E-cadherin as Gatekeeper to Mutant Kras and p53 Loss-Driven Gastric Cancer 
Conclusions 
I present evidence that E-cadherin may act as a gatekeeper to oncogenic Kras and 
Trp53 loss-driven gastric cancer. I show that the presence of a wild-type Cdh1 allele in 
our model delays oncogenesis significantly. Further, when tumors do form, they often 
show loss of E-cadherin expression. While the preliminary data is intriguing, more 
experiments need to be performed to definitively prove this hypothesis. As discussed, this 
gatekeeper function is not without precedent, as the tumor suppressor APC acts similarly 
in a colorectal cancer model (Dow et al. 2015). Of note, the other targeted model of 
oncogenic Kras-driven gastric cancer also has deletion of APC (Hayakawa et al. 2015). 
APC and E-cadherin functionality overlap in their regulation of β-catenin (Mohammed et 
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al. 2016; Liu et al. 2014). One hypothesis that can be drawn from these data is that 
canonical WNT signaling is necessary for oncogenic Kras and Trp53 loss-driven 
tumorigenesis in the gut. 
The other finding that resulted from adding wild-type Cdh1 back to our model 
was the subcutaneous tumor phenotype. I initially assumed these lesions were metastases 
resulting from gastric tumors. However, the fact that we did not detect primary tumors of 
the stomach in the majority of the mice with subcutaneous tumors makes this 
interpretation unlikely. The sarcomatoid histology of the tumors might suggest they are 
not gastric in origin, but the gastric tumors that do rarely occur in these mice also have 
sarcomatoid features. One cannot rule out the possibility of small, sarcomatoid stomach 
lesions that metastasize early to the subcutaneous space. 
I have come to favor the alternative explanation that these are sarcomas arising 
from off-target Cre activity in the subcutaneous space. I present several additional pieces 
of evidence that suggest this, including microarray data comparing these lesions to 
human gastric cancer and sarcoma samples as well as analysis of expression of stomach-
specific genes. Additionally, the latency to formation of these tumors is similar to that of 
an oncogenic Kras and Trp53 loss-induced model of sarcoma (Kirsch et al. 2007).  
Future Directions 
Further investigation of E-cadherin as gatekeeper to oncogenic Kras and Trp53 
loss-driven gastric cancer is certainly necessary. First, quantification of loss of E-
cadherin in tumors arising in the Cdh1fl/+ and/or Cdh1+/+ must be performed. Second, the 
mechanism of loss should be investigated. Additionally, comparisons of tumor areas to 
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non-tumor areas by microarray or RNA-seq may implicate signaling pathways that are 
necessary for tumor formation. Comparison of tumor areas that have lost E-cadherin 
expression and tumor areas that retain E-cadherin to non-tumor areas may be similarly 
useful and reveal the changes, other than of E-cadherin loss, that allow tumor 
progression. Finally, generating an E-cadherin loss allele that could be restored could 
prove its gatekeeper status. One such model is a drug inducible shRNA knock-down as 
was used in the APC/Kras/Trp53 colorectal cancer paper (Dow et al. 2015). Another 
option is an XTR Cdh1 allele (Robles-Oteiza et al. 2015). Additionally, the hypothesis 
that canonical WNT signaling is necessary for oncogenic Kras and Trp53 loss-driven 
tumorigenesis in the gut could be tested in our model and/or in the APC/Kras/p53 
colorectal cancer model by breeding the conditional β-catenin allele (Brault et al. 2001) 
onto either model. 
Finally, one could pursue definitive evidence on the origin of the subcutaneous 
tumors that arise in the Cdh1fl/+ and Cdh1+/+ models. Evidence that they are sarcomas 
could be derived from Atp4b-Cre;Rosa26LSL-YFP/ + mice. Detailed examination of the skin 
by immunofluorescence for YFP expression and highly sensitive polymerase chain 
reaction (PCR) for the recombined Rosa26LSL-YFP allele could reveal a rare Cre expressing 
cell population in the subcutaneous space. Definitive proof of gastric origin (i.e. that they 
are metastases) would be more difficult and likely involve lineage tracing using a second 
marker of gastric or epithelial origin. Hypothetically, one could add a FLP recombinase 
allele (CK19-FLP) driven by the cytokeratin 19 promoter and a FRT-STOP-FRT red 
fluorescent protein (FSF-RFP) allele to the Cdh1fl/+ model. If the cutaneous tumors are 
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epithelial in lineage, they will fluoresce from both the RFP and YFP alleles. If they are 
mesenchymal derived sarcomas, they should only fluoresce from the YFP allele. 
iii. E-cadherin Loss Upregulates β-catenin Signaling in the ACKPY Mouse Model of 
Gastric Cancer 
Conclusions 
I present, to my knowledge, the first evidence that E-cadherin loss leads directly 
to the upregulation of β-catenin in vivo using microarray and qPCR for the upregulation 
of TCF/LEF and canonical WNT targets, respectively. Additionally, I demonstrate a loss 
of membranous β-catenin that correlates with loss of E-cadherin. I show that inhibition of 
this pathway prolongs survival of our ACKPY mice. Further, I present the hypothesis that 
this effect of E-cadherin loss is only possible in the context of oncogenic Kras 
suppression of the β-catenin destruction complex. This potential in vivo evidence of such 
crosstalk between oncogenic Kras and the canonical WNT pathway would itself be novel. 
However, each of these findings has limitations that bear addressing. 
First, the comparisons via microarray and qPCR were performed on whole 
glandular stomach samples. These data leave open the possibility that the comparisons 
may have been skewed by differential content of recombined tissue. For example, if the 
Cdh1fl/fl stomachs are primarily composed of recombined tissue and the Cdh1fl/+ stomachs 
have a lower content of recombined tissue, the comparison may be better characterized as 
Cdh1fl/fl tumor versus normal stomach. This is unlikely given the high burden of 
recombined tissue as observed by YFP staining (data not shown), but still a possibility. 
An ideal experiment would compare only Cre recombined (YFP+) tissue from Cdh1fl/fl 
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and Cdh1fl/+ mice. Unfortunately, my attempts to select for recombined cell populations 
by fluorescence assisted cell sorting (FACS) for YFP+ cells did not yield high enough cell 
numbers to extract good quality RNA. Alternatively, YFP+ areas could be selected by 
laser capture micro-dissection. A less ideal but simpler possibility would be to include 
YFP expression in the qPCR experiment and normalize the results to YFP content.  
Second, while I present loss of membranous β-catenin in Cdh1fl/fl and Cdh1fl/+ 
tumors, I do not show a concomitant increase in cytoplasmic or nuclear β-catenin. This is 
a common technical difficulty with immunofluorescence (IF) staining for β-catenin. One 
solution might be to attempt to increase the sensitivity for β-catenin by adding a signal 
amplification step to the protocol. Further, the use of immunohistochemical (IHC) 
methods rather than IF might allow visualization of nuclear β-catenin. However, multiple 
staining by IHC is problematic and not possible beyond two targets, so co-staining for E-
cadherin and YFP, as I do with IF, would not be possible. Staining of serial sections is a 
potential solution to this problem, though less elegant than co-staining. 
Third, while I do show that administering a commonly used β-catenin/TCF 
inhibitor (PKF118-310) prolongs survival of the ACKPY mice, I do not show that its 
effects are on-target. This could be done by assaying for the expression of canonical 
WNT targets in treated and untreated mice. However, the effect size of treatment with 
PKF118-310 is so small that choosing an appropriate time point for such analysis could 
be impossible. One might suggest increasing the dose of the inhibitor to improve the 
effect size, however higher doses are not well-tolerated due to toxicity. As outlined in the 
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previous section, addition of the conditional β-catenin allele to the model would show 
dependence on β-catenin specifically.  
Future Directions 
In the previous section, I addressed several experimental improvements that 
would more definitively show β-catenin upregulation due to E-cadherin loss in the 
ACKPY model. There are several in vitro methods that would be of use if I were able to 
isolate cell lines from both Cdh1fl/fl and Cdh1fl/+ stomach tissue. For example, expression 
analysis could be done in these cell lines, luciferase reporter technology could be used to 
show activity at β-catenin/TCF/LEF response elements, and nuclear localization of β-
catenin could be shown by cell fractionation. However, we have been unable to isolate 
cell lines from Cdh1fl/+ stomachs that are not fully transformed. One solution would be to 
re-express E-cadherin in Cdh1fl/fl cells; however, there is little novelty to that experiment 
as repression of β-catenin by E-cadherin expression is well-documented (Gottardi, Wong, 
and Gumbiner 2001). Breeding a β-catenin reporter allele onto the Cdh1fl/fl and Cdh1fl/+ 
models could demonstrate direct regulation at the level of β-catenin/TCF response 
elements. Maretto and colleagues generated such a construct utilizing the β-galactosidase 
reporter (LacZ gene) under the control of β-catenin/TCF response elements (Maretto et 
al. 2003). 
To test the role of oncogenic Kras in this process, I would perform several 
experiments. The first, and simplest, would utilize RNA already isolated from aged 
ACPY (original double conditional model) stomachs, which should contain tumors that 
lack oncogenic Kras but have E-cadherin knocked out. I would perform qPCR for 
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canonical WNT targets in these samples alongside the Cdh1fl/fl and Cdh1fl/+ models. 
Though limited by the caveats described above, if upregulation is not evident in the 
ACPY stomachs then it would suggest a role for oncogenic Kras in the upregulation of 
canonical WNT targets. This would have to be confirmed in experiments that examine 
only at recombined (YFP+) tissue. I would include ACPY stomachs in any of the other 
analyses listed above. Their inclusion in any of the studies that breed additional alleles 
onto the model would be simple, as they are always generated during breeding of the 
model. If my hypothesis that oncogenic Kras is necessary for upregulation of canonical 
WNT signaling due to E-cadherin loss is correct, one would expect ACPY tumor 
formation not to be dependent on β-catenin (in the conditional β-catenin allele 
experiments) and not to show β-catenin reporter activity (in the β-galactosidase reporter 
experiments). While in vitro methods would be of great use in testing this hypothesis, I 
have not yet been able to generate cell lines from ACPY tumors. The use of knock-downs 
(using shRNA technology) or knock-outs (using CRISPR technology) of oncogenic Kras 
in ACKPY cell lines is a potential solution for use in vitro. 
iv. Loss of E-cadherin Correlates with Upregulation of Oncogenic Kras Target 
Genes in the ACKPY Mouse Model of Gastric Cancer 
Conclusions 
I present microarray data that shows that gene sets upregulated by Kras activity 
are overrepresented in the set of genes upregulated in Cdh1fl/fl over Cdh1fl/+ stomachs. 
Further, gene sets upregulated by several of the major downstream effectors of Kras are 
also overrepresented. This is surprising given that both the Cdh1fl/fl and Cdh1fl/+ models 
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express oncogenic Kras; one would expect similar Kras activity in these two models. One 
interpretation of these data is that E-cadherin inhibits oncogenic Kras or its effector 
pathways in the Cdh1fl/+ model. This hypothesis is intriguing given our data suggesting 
that E-cadherin is a gatekeeper to oncogenesis in our model. While oncogenic Kras and 
loss of Trp53 are sufficient to drive tumorigenesis in many other models, they are not so 
in ours. Perhaps E-cadherin inhibition of oncogenic Kras is the mechanism behind this 
gatekeeper function (Figure 6-2). Finally, given the data on APC in the Kras/Trp53 
colorectal cancer model (Dow et al. 2015), the common regulation of β-catenin by APC 
and E-cadherin may mediate this inhibition throughout the gut. 
These findings and hypotheses are not without caveats. As described in the 
previous section, the microarray data is limited by the use of whole glandular stomach 
samples. Further, the microarray data showed overrepresentation of MAPK upregulated 
gene sets in our set of genes upregulated in Cdh1fl/fl over Cdh1fl/+ stomachs. However, 
these findings were not indicative of E-cadherin regulation of the MAPK pathway as 
assayed by pERK abundance. 
One further caveat is the possibility that even though Cdh1fl/+ stomachs appear to 
possess a high content of recombined cells, these cells may not be cycling as rapidly as 
those in the frank tumors of Cdh1fl/fl stomachs. Thus, Kras downstream signaling would 
be artifactually lower in Cdh1fl/+ recombined cells compared to Cdh1fl/fl recombined cells. 
This difference would still be due to the presence or absence of a wild-type Cdh1 allele. 
However, it may indicate a different mechanism of decreased tumor formation than the 
interaction between E-cadherin and Kras that I propose. Future experiments would, 
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ideally, also show equivalent proliferative activity of these cells either qualitatively by 
Ki67 staining, or quantitatively by BrdU incorporation. In an attempt to address this issue 
in the microarray I examined the expression of Mki67 and Pcna. Notably, Mki67 
expression was not statistically significantly different between Cdh1fl/+ and Cdh1fl/fl 
stomachs. Whereas Pcna was actually up by 63.6% in Cdh1fl/+ over Cdh1fl/fl stomachs (q-
value=1.48%). 
 
Figure 6-2. Hypotheses related to E-cadherin loss in the ACKPY model. 
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Future Directions 
Though I observed no difference in ERK activation between the Cdh1fl/fl and 
Cdh1fl/+ models, E-cadherin may still be regulating other pathways downstream of 
oncogenic Kras. The microarray data identified the PI3K, NF-κB, and NFAT pathways as 
other possible targets/mechanisms. Using IF or IHC, I would assay for the activation of 
the PI3K pathway via phopsho-AKT, for NF-κB nuclear versus cytoplasmic localization 
or phospho-p65 content, and for NFAT nuclear versus cytoplasmic localization in 
Cdh1fl/fl and Cdh1fl/+ tissues. Additionally, it may be worth repeating the microarray 
experiment using RNA isolated only from YFP+ areas in the Cdh1fl/fl and Cdh1fl/+ models 
(as discussed earlier, either by FACS or laser capture micro-dissection). Doing so would 
reduce background signal from non-parietal cell tissue. Further, I would ensure that all 
Cdh1fl/+ tissue was derived from stomachs that lacked tumor by saving a portion of the 
stomach for histologic analysis. 
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APPENDIX 1 MATERIALS AND METHODS 
i. Animals 
The University of Pennsylvania Animal Care and Use Committee approved all 
animal studies. Parental mouse strains, background, source, genotyping, and primary 
reference are available in Table 0-1. 
Allele Background Source Genotyping Reference 
Atp4b-Cre B6.FVB(N1) Gordon Lab 
Washington University in St. 
Louis 
5’-CAGCGGAGGGCAGATAGCAAGCAAG 
5’-CCGGTTATTCAACTTGCACC 
 
411 bp Transgene 
(Syder et 
al. 2004) 
Cdh1fl B6.129(N3) The Jackson Laboratory (005319) 5’-GGGTCTCACCGTAGTCCTCA 
5’-GATCTTTGGGAGAGCAGTCG 
 
243 bp Wild-type/310 bp Mutant 
(Boussadia 
et al. 
2002) 
KrasLSL-G12D B6.129(N10) Tyler Jacks Laboratory 
Massachusetts Institute of 
Technology 
(backcrossed to C57BL/6 in the 
Ryeom Laboratory) 
5’-GCAGGTCGAGGGACCTAATA 
5’- TGTCTTTCCCCAGCACAGT 
5’-CTGCATAGTACGCTATACCCTGT 
 
250 bp Wild-type/100 bp Mutant 
(Jackson 
et al. 
2001) 
Trp53fl B6.129(N10) Tyler Jacks Laboratory 
Massachusetts Institute of 
Technology 
(backcrossed to C57BL/6 in the 
Ryeom Laboratory) 
5’- GGTTAAACCCAGCTTGACCA 
5’- GGAGGCAGAGACAGTTGGAG 
 
270 bp Wild-type/390 bp Mutant 
(Marino et 
al. 2000) 
Rosa26LSL-
YFP 
B6.129(N?) Stanger Lab 
Perelman School of Medicine at 
the University of Pennsylvania 
5’- AAAGTCGCTCTGAGTTGTTAT 
5’- GGAGCGGGAGAAATGGATATG 
5’-AAGACCGCGAAGAGTTTGTC 
 
600 bp Wild-type/320 bp Transgene 
(Srinivas 
et al. 
2001) 
Table 0-1. Mouse strains used to generate ACKPY mice. 
 
ACKPY Breeding 
Over the course of six generations I crossed these 5 alleles into two parental 
strains: ACPY (Atp4b-Cre;Cdh1fl/fl;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP) and CKPY (KrasLSL-
G12D/+;Cdh1fl/fl;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP). When interbred, these lines produced 3 
useful genotypes: ¼ are the desired ACKPY; ¼ are the first breeder genotype, ACPY; 
and ¼ are the second breeder genotype, CKPY (Figure 0-1). Of note, the ACPY group is 
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the double conditional knockout of Cdh1 and Trp53, from Shimada et al 2012, with the 
addition of conditional YFP expression. 
 
Figure 0-1. Breeding scheme to derive ACKPY mice and relevant controls. 
 
Cdh1fl/+ and Cdh1+/+ Breeding 
To investigate the dependence of our ACKPY model on Cdh1 loss I bred one or 
two alleles of wild-type Cdh1 back onto the ACKPY mice. These Cdh1fl/+ and Cdh1+/+ 
mice were bred by crossing ACPY mice to KPY mice (KrasLSL-
G12D/+;Trp53fl/fl;Rosa26LSL-YFP/LSL-YFP) mice for one or more generations. 
Survival Analysis 
For ACKPY mice, end point was reached at natural death or humane euthanasia at 
loss of 20% maximum body weight. To account for the mixed background, ten 
independent breeding pairs were utilized, each contributing two sibling pairs of ACKPY 
and ACPY mice (excepting one breeding pair that only contributed one ACPY sibling). 
For Cdh1fl/+ and Cdh1+/+ mice, end point was reached at natural death or humane 
euthanasia at loss of 20% maximum body weight. Animals that required humane 
 
 
Atp4b-Cre;Cdh1
fl/fl
;Trp53
fl/fl
;Rosa26
LSL-YFP/LSL-YFP
 (ACPY) 
Cdh1
fl/fl
;Kras
LSL-G12D/+
;Trp53
fl/fl
;Rosa26
LSL-YFP/LSL-YFP
 (CKPY) 
¼     Atp4b-Cre;Cdh1
fl/fl
;Kras
LSL-G12D/+
;Trp53
fl/fl
;Rosa26
LSL-YFP/LSL-YFP
  
ACKPY Model of Gastric Cancer 
¼     Atp4b-Cre;Cdh1
fl/fl
;Kras
+/+
;Trp53
fl/fl
;Rosa26
LSL-YFP/LSL-YFP
  
ACPY Shimada et al Double Conditional Model (and Breeder) 
¼     Cdh1
fl/fl
;Kras
LSL-G12D/+
;Trp53
fl/fl
;Rosa26
LSL-YFP/LSL-YFP
  
CKPY, Cre- control for ACKPY (and Breeder) 
 92 
euthanasia for subcutaneous tumor burden > 2 cm3 were censored in the analysis. To 
account for the mixed background, at least 10 independent breeding pairs were utilized in 
generating the cohorts. 
Metastatic Analysis 
Ten of the ACKPY mice from the survival cohort were analyzed for metastases. 
Epigastric fat, liver, lungs, and any abnormal lesions were dissected and analyzed (see 
Histology and Immunofluorescence). 
Analysis of Disease Progression 
Five ACKPY and five CKPY matched Cre negative control mice were sacrificed 
at 3, 6, and 9 weeks. To account for mixed background, five independent sets of ACKPY 
and CKPY negative control mice were used from five independent breeding pairs. 
Stomachs were dissected out and analyzed (see Histology and Immunofluorescence). 
In vivo Drug Treatments 
Drug treatments were initiated in 4-week-old mice ACKPY mice. MEK inhibitor 
(PD0325901, APExBIO) was administered ad libitum in the mouse chow (Purina 5010) 
at 7 mg/kg (incorporation by Research Diets Inc.). PKF118-310 (EMD Millipore) was 
administered 3x weekly as an IP injection of a 0.1 mg/mL solution in 0.1% DMSO at a 
dose of 1 mg/kg, control mice received volumetrically equivalent doses of 0.1% DMSO 
via IP injection. Mice were analyzed for survival (see Survival Analysis). 
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Intra-tracheal AdenoCre Inoculation 
Viral precipitates were formed by mixing 2.5x107 pfu of AdenoCre (University of 
Iowa Viral Vector Core Facility) and 0.6 μmoles CaCl2 (Sigma) to a total volume of 60 
μL in DMEM (Gibco) per mouse and incubating at room temperature for 10 minutes. 
Mice of the indicated genotypes were anesthetized, intubated with a 22 g angiocatheter, 
and inoculated with 60 μL of viral precipitates via the catheter. 
v. Microbiome Study 
Microbiome Depletion 
Microbiome depletion was achieved by antibiotic administration via the drinking 
water ad libitum at 1 g/L ampicillin (Polyflex, Boehringer Ingelheim Vetmedica, Inc), 1 
g/L neomycin (NeoMed 325, Bimeda Inc), 1 g/L metronidazole (Watson Pharma Inc.), 
0.5 g/L vancomycin (vancomycin hydrochloride, Mylan Institutional LLC), and 4 g/L 
sucralose (Splenda, McNeil Nutritionals, LLC). 
Quantification of Microbiome Depletion  
At necropsy gastric contents and cecal contents were flash frozen. DNA was 
extracted from 50-300 mg of gastric or cecal contents using the QIAamp Fast DNA 
Stoool Mini Kit (QIAGEN) according to the manufacturers instructions. qPCR was 
performed on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) using SYBR 
Green PCR Master Mix (Thermo Fisher Scientific) according to the manufacturers 
directions  using 20 ng of stomach or cecal content DNA per 10 μL reaction. 
Amplifications were performed as technical triplicates and biological quadruplicates. 
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Generic 16S rRNA primers 5’-ACTCCTACGGGAGGCAGCAGT (UniF340) and 5’-
ATTACCGCGGCTGCTGGC (UniR514) were used for amplification (Barman et al. 
2008). 
vi. Detect of Circulating Tumor Cells 
Blood Collection and RBC Lysis 
A 1 mL insulin syringe (BD #329412) was coated with 1 mg/mL heparin (Sigma 
#H3149-250KU) in PBS (Sigma #D5652-10X1L). As much blood as possible was 
collected by cardiac puncture and transferred to an EDTA coated tube (BD #367841). 
The remainder of the procedure was carried out in the dark. 100-200 ul of blood was 
RBC lysed by the addition of 5 volumes of RBC lysis buffer (G-Biosciences #786-650) 
and incubated at room temperate for 5 min with mixing. FACS buffer (PBS + 5% FBS + 
2 mM EDTA) was added to the lysis reaction up to 3 mLs, mixed, and centrifuged at 
2400 x g for 5 min. The supernatant was removed and the cell pellet resuspended in 100 
ul FACS Buffer.  
CD45 Staining and Flow Cytometric Analysis 
1 ul of anti-CD45-APC (Biolegend	   #103112) was added to 100 ul of suspended 
cells, mixed and incubated in the darkat room temperature for 15 min. To wash, 500 ul of 
FACS buffer was added, the suspension mixed, centrifuged at 400 x g for 5 min, and the 
supernatant discarded. The cell pellet was resuspended in 300-500 ul FACS buffer. 
Immediately prior to flow cytometric analaysis 2 ul of 5 mg/mL DAPI (ThermoFisher 
Scientific #D1306) was added to the cell suspension and mixed for live/dead 
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discrimination. The samples were run on a BD FACSVerse flow cytometer and CTCs per 
sample were quantified (defined as DAPI-, CD45-, YFP+).  
vii. Histology 
Tissue Preparation 
Tissues were dissected from indicated mice, fixed in 10% formalin in phosphate 
buffered saline (PBS), and dehydrated. Stomachs were opened along the greater 
curvature, washed of contents in PBS, the forestomach stomach was removed, and the 
glandular stomach cut into two or three levels to be embedded together. The Abramson 
Family Cancer Research Institute (AFCRI) histology core facility embedded the tissues 
in paraffin, sectioned them at 5 um, and provided me with unstained slides or stained 
them with hematoxylin and eosin (H&E).  
Immunofluorescence 
Unstained sections were warmed to 55 C, de-waxed in two xylene washes for 10 
minute each, and rehydrated through an ethanol gradient (100%, 100%, 95%, 70%, 50%, 
0%, 0%, 0%, 5 minutes each). Antigen retrieval was performed in a 2100 Retriever 
(Aptum Biologics Ltd.) using Antigen Unmasking Solution (Vector Labs). Samples were 
then washed three times in H2O and equilibrated to phosphate buffered saline (PBS), 5 
minutes each. They were then permeabilized in 0.2% Triton-X in PBS for 45 minutes. 
Sections were washed three times with PBS and treated with blocking solution (10% goat 
serum and 1% bovine serum albumin in PBS) for 1 hour. Hybridization of non- mouse 
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primary antibodies was performed overnight in blocking solution at 4 C (see Table 0-2 
for antibody information and dilutions). 
For mouse antibodies, sections were triple washed with PBS for 5 min each then 
blocked with Streptavidin/Biotin Blocking Kit (Vector Labs): sections were incubated 
with streptavidin solution for 15 minutes, washed twice with PBS for 5 min each, and the 
incubation and washes repeated with biotin solution. Hybridization of mouse primary 
antibody (see Table 0-2 for antibody information and dilutions) was done using the 
Mouse on Mouse (M.O.M.) Basic Kit (Vector Labs): sections were incubated for 1 hour 
in M.O.M. Mouse Ig Blocking Reagent, washed twice in PBS for 2 minutes each, 
equilibrated to M.O.M. Diluent for 5 minutes, treated with primary antibody in M.O.M. 
Diluent for 30 minutes at room temperature, washed twice in PBS for 2 minutes, and 
incubated with M.O.M. Biotinylated Anti-Mouse IgG Reagent in M.O.M. Diluent for 10 
minutes. 
For non-mouse antibodies or continuing after hybridization to mouse antibody, 
sections were triple washed with PBS for 5 min each and then incubated with secondary 
antibody diluted 1:1000 in 1% bovine serum albumin in PBS for 2 hours at room 
temperature. They were again triple washed with PBS for 5 min each and mounted with 
Fluor-Gel II with DAPI (Electron Microscopy Sciences). 
Target Company Catalog # Dilution Host Secondary 
(Thermo Fisher Scientific Catalog #) 
YFP (anti-GFP) Abcam ab13970 1:1000 Chicken anti-Chicken Alexa Fluor 488 
(A-11039) 
E-cadherin BD 610181 1:1000 Mouse AlexaFluor 555 conjugated Streptavidin 
(S-21381) 
β-catenin CST 8480 1:100 Rabbit anti-Rabbit Alexa Fluor 594 
(A-21207) 
pERK CST 4370 1:200 Rabbit anti-Rabbit Alexa Fluor 594 
(A-21207) 
Table 0-2. Antibody information for immunofluorescence staining. 
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Immunohistochemistry 
Unstained sections were warmed to 55 C, de-waxed in two xylene treatments for 
10 minute each and rehydrated through an ethanol gradient (100%, 100%, 95%, 70%, 
50%, 0%, 0%, 0%, 5 minutes each). Antigen retrieval was performed in a 2100 Retriever 
(Aptum Biologics Ltd.) using Antigen Unmasking Solution (Vector Labs). Samples were 
then washed three times in H2O and further washed and permeabilized in Tris Buffered 
Saline (TBS, BioRad) + 0.25% Tween (BioRad), referred to as TBST, for two washes of 
5 minutes each. Sections were treated with blocking solution (10% goat serum and 1% 
bovine serum albumin in TBST) for 1 hour. Hybridization of with primary antibody was 
performed overnight in blocking solution at 4 C (see Table 0-3 for antibody information 
and dilutions). 
Sections were washed twice with TBST and once with TBS, 5 minutes each, and 
endogenous peroxidases oversaturated by incubation with 0.3% H2O2 in TBS. Samples 
were triple washed with TBST, 5 minutes each, and hybridized to secondary antibody 
(see Table 0-3) in blocking buffer for 1 hour at room temperature. Enzymatic detection 
was performed using the Vectastain ABC HRP Kit (Vector Labs) and DAB Peroxidase 
(HRP) Substrate Kit (Vector Labs). Sections were triple washed with TBST, double 
washed with TBS (5 minutes each) and hybridized to Vectastain ABC HRP reagent 
(prepared according to manufacturers instructions) for 30 minutes at room temperature. 
Slides were again washed twice with TBST and twice with TBS, 5 min each, and then 
incubated with DAB Substrate (prepared according to manufacturers instructions) for the 
time indicated in Table 0-3. Washing with H2O stopped reaction. Samples were then 
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counterstained in Hematoxylin (50:50 solution in H2O) for 3 minutes at room temperature 
and washed under running H2O for 5 minutes. Slides were dehydrated through a series of 
ethanol solutions (80%, 95%, 100%. 100%) for 5 minutes each and two xylene washes of 
20 minutes each. Sections were mounted using PROTOCOL SecureMount (Fisher) and 
coverslips. 
Target Company Catalog# Dilution Host Secondary 
Dilution (Company & Catalog #) 
Time to 
Develop 
pERK CST 4370 1:200 Rabbit Biotinylated Goat Anti-Rabbit IgG Antibody 
1:200 (Vector Labs BA-1000) 
190 sec 
Isotype CST 3900 1:2000 Rabbit 
Table 0-3. Antibodies for immunohistochemical staining. 
Image Acquisition 
Bright field and epifluorescence images were acquired on a Leica DMI6000B microscope 
and processed using the LAS-AF software or a Zeiss Axio Imager.M2 microscope and 
processed using the ZEN 2 software. Confocal images were acquired on a Leica TCS SP5 
laser scanning confocal microscope and processed using the LAS-AF software. 
viii. Cell Lines 
Derivation 
Indicated tissue was harvested from mice that had reached humane end-point. Tissues 
were minced and digested in collagenase II (2.5 mg/mL, Worthington) and DNase (0.5 
mg/mL, Worthington) in HBSS (Gibco) at 37 C for 45 minutes. Alternatively, tissue and 
collagenase II/DNase solution were placed in a C tube (Miltenyi Biotec) and a single cell 
suspension was generated using a gentleMACS Octo Dissociator with Heaters program 
“37_m_TDK_1” (Miltenyi Biotec). Excess Fetal Bovine Serum (FBS, Hyclone) was 
added to quench enzymes and digested tissue was pelleted by centrifugation. Pellet was 
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resuspended and plated in normal growth medium: Advanced DMEM (Cellgro) + 10% 
FBS + Penicillin/Streptomycin (Lonza) + L-glutamine (Gibco). After 24 hours incubation 
at 37 C under 5% CO2, adherent cells were washed three times with phosphate buffered 
saline (PBS, Sigma) and medium replaced. 
Passaging of Cell Lines 
Cell lines were maintained in Advanced DMEM (Cellgro) + 10% FBS + 
Penicillin/Streptomycin (Lonza) + L-glutamine (Gibco) on tissue culture treated plastic in 
37 C incubators under 5% CO2. Sub-cultivation was performed by washing adherent cells 
with PBS and incubating with 0.25% Trypsin-EDTA (Gibco) until detached. Trypsin was 
quenched by the addition of excess complete medium. Cells were re-plated at a sub-
culture ratio of 1:5 or higher. 
Flank Tumor Formation 
Cell lines were sub-cultured for several passages prior to use. Cells were harvested with 
0.25% Trypsin-EDTA, quenched with excess FBS, washed with PBS, and injected 
subcutaneously in the flank at 5x106 cells per 0.1 cc PBS per mouse. Tumors were 
measured every 2-3 days using digital calipers (Fisher) and tumor volume calculated as 
(0.5)*(width2)*(length). For experimental model of metastasis, flank tumors were 
resected under sterile conditions when tumor volumes were approximately 500 mm3. 
Mice were euthanized and lung tissue analyzed for metastasis three weeks post resection. 
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ix. Gene Expression Analysis 
RNA isolation 
Glandular stomachs were dissected from indicated mice, homogenized using a 
gentleMACS Dissociator with M tubes (Miltenyi Biotec) in QIAzol Lysis Reagent 
(Qiagen), and RNA isolation performed using the RNeasy Microarray Tissue Mini Kit 
with optional DNase treatment (Qiagen) according to the manufacturers protocols. 
Quantification of total RNA was performed on a NanoDrop (Thermo Fisher Scientific). 
Microarray Target Preparation and Hybridization 
The UPENN Molecular Profiling Facility provided microarray services, including 
quality control tests of the total RNA samples by Agilent Bioanalyzer and Nanodrop 
spectrophotometry. All protocols were conducted as described in the Affymetrix WT Plus 
Reagent Kit Manual and the Affymetrix GeneChip Expression Analysis Technical 
Manual. Briefly, 250ng of total RNA was converted to first-strand cDNA using reverse 
transcriptase primed by poly(T) and random oligomers that incorporated the T7 promoter 
sequence. Second-strand cDNA synthesis was followed by in vitro transcription with T7 
RNA polymerase for linear amplification of each transcript, and the resulting cRNA was 
converted to cDNA, fragmented, assessed by Bioanalyzer, and biotinylated by terminal 
transferase end labeling. Five and a half micrograms of labeled cDNA were added to 
Affymetrix hybridization cocktails, heated at 99ºC for 5 min and hybridized for 16 h at 
45ºC to Mouse Transcriptome 1.0 ST GeneChips (Affymetrix Inc., Santa Clara CA) 
using the GeneChip Hybridization oven 645. The microarrays were then washed at low 
(6X SSPE) and high (100mM MES, 0.1M NaCl) stringency and stained with 
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streptavidin-phycoerythrin. Fluorescence was amplified by adding biotinylated anti-
streptavidin and an additional aliquot of streptavidin-phycoerythrin stain. A GeneChip 
3000 7G scanner was used to collect fluorescence signal. Affymetrix Command Console 
and Expression Console were used to quantitate expression levels for targeted genes; 
default values provided by Affymetrix were applied to all analysis parameters. 
Principle Component Analysis, Hierarchical Clustering, and Heat Maps 
Principle Component Analysis was performed using Expression Console Software 
(Affymetrix). The Penn Genomic Analysis Core Bioinformatics group performed 
unsupervised hierarchical clustering of Cdh1fl/fl and Cdh1fl/+ stomach tissue expression 
data using Partek Genomics Suite (Partek Inc). Hierarchical clustering and heat map 
production for Cdh1fl/+ stomach and subcutaneous tumor expression data was performed 
using GenePattern 2.0 Software (Reich et al. 2006): HierarchicalClustering (Eisen et al. 
1998), HierarchicalClusteringViewer, and HeatMapViewer modules. 
Differential Gene Expression Analysis 
Differentially expressed genes were determined using the Transcriptome Analysis 
Console (TAC) Software (Affymetrix) with a FDR q-value cut-off of 5% and a fold-
change cut-off of 2. 
Gene Set Overlap Analysis 
Differentially expressed mouse genes were manually mapped to their human homologs 
using the HomoloGene database (http://www.ncbi.nlm.nih.gov/homologene) from the 
National Center for Biotechnology Information (NCBI) (Geer et al. 2010). Gene set 
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overlaps were computed for gene lists using the Investigate Gene Sets function 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) on the Gene Set Enrichment 
Analysis page of the Broad Institute (Subramanian et al. 2005). 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
Complementary DNA (cDNA) was synthesized using the High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific) according to the manufacturers directions 
with 2 μg RNA per 10 μL reaction. qPCR was performed on a ViiA 7 Real-Time PCR 
System (Thermo Fisher Scientific) using SYBR Green PCR Master Mix (Thermo Fisher 
Scientific) according to the manufacturers directions  using 0.5 μL cDNA per 10 μL 
reaction. Amplifications were performed as technical quadruplicates and biological 
sextuplicates. Values were normalized to HPRT expression. Mouse gene-specific primers 
(Table 0-4) were selected from PrimerBank (X. Wang and Seed 2003; Spandidos et al. 
2008; Spandidos et al. 2010). 
Gene Forward Primer Reverse Primer Amplicon 
Size 
PrimerBank 
ID 
Hprt 5’-TCAGTCAACGGGGGACATAAA 5’-GGGGCTGTACTGCTTAACCAG 142 bp 7305155a1 
Myc 5’-ATGCCCCTCAACGTGAACTTC 5’-CGCAACATAGGATGGAGAGCA 228 bp 27545183a1 
Ccnd1 5’-GCGTACCCTGACACCAATCTC 5’-CTCCTCTTCGCACTTCTGCTC 183 bp 6680868a1 
MMP7 5’-CTGCCACTGTCCCAGGAAG 5’-GGGAGAGTTTTCCAGTCATGG 175 bp 6754716a1 
Axin2 5’-TGACTCTCCTTCCAGATCCCA 5’-TGCCCACACTAGGCTGACA 105 bp 31982733a1 
Lef1 5’-TGTTTATCCCATCACGGGTGG 5’-CATGGAAGTGTCGCCTGACAG 67 bp 27735019a1 
Cd44v1 5’-CACCATTGCCTCAACTGTGC 5’-TTGTGGGCTCCTGAGTCTGA 116 bp 6491804a1 
Table 0-4. Quantitative Real-Time Polymerase Chain Reaction Primers. 
x. Quantification and Statistics 
Lung Tumor Area Quantification 
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012; 
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust 
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Threshold Color (Thresholding method: Default, Color space: HSB), Select, and Measure 
functions. Tumor area settings were Hue 205-231, Saturation 40-120, and Brightness 90-
225. Total lung area settings were Hue 0-255, Saturation 0-255, and Brightness 0-184. 
Data is represented as tumor area divided by total lung area for one section containing at 
least 4 of 5 lung lobes. 
pERK Immunofluorescence Quantification 
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012; 
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust 
Threshold Color, Select, and Measure functions. pERK and YFP overlap area settings for 
Adjust Color Threshold (Thresholding method: Default, Color space: HSB) were Hue 40-
50, Saturation 0-225, and Brightness autoset by program (with “Dark background” radio 
button selected). YFP area settings for Adjust Color Threshold (Thresholding method: 
Default, Color space: Lab) were L* auto-set by program, a* 0-150, and b* 0-225 (with 
“Dark background” radio button selected). Data is represented as pERK and YFP overlap 
area divided by YFP area for 1-2 images per tissue level over 2-3 tissue levels per 
sample. 
pERK Immunohistochemistry Quantification 
Area quantification was performed using Fiji (Schneider, Rasband, and Eliceiri 2012; 
Schindelin et al. 2012; Schindelin et al. 2015) image analysis software using the Adjust 
Threshold Color (Thresholding method: Default, Color space: HSB), Select, and Measure 
functions. pERK staining area settings were Hue 0-40, Saturation 0-255, and Brightness 
0-184. Total stomach tissue area settings were Hue 0-255, Saturation 0-255, and 
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Brightness 0-184. Data is represented as pERK staining area divided by total stomach 
tissue area for 2-3 tissue planes. 
Statistics 
Statistical analyses (other than those previously described for microarray analysis) were 
performed in Prism 5 (GraphPad Software). Survival analysis p-values were calculated 
using the Log-rank (Mantel-Cox) test. All other p-values were calculated using the 
student’s t-test (unpaired, two-tailed). 
  
 105 
BIBLIOGRAPHY 
Adler, Douglas G., Francis A. Farraye, and James M. Crawford. 2015. “Gastrointestinal 
Tract Endoscopic and Tissue Processing Techniques and Normal Histology.” In , 
edited by Robert D. Odze and John R. Goldblum, Third edit, 4–33e.3. Philadelphia: 
Saunders/Elsevier. https://www.clinicalkey.com/#!/content/book/3-s2.0-
B9781455707478000017. 
Andersson, Patrik, Jacqueline McGuire, Carlos Rubio, Katarina Gradin, Murray L 
Whitelaw, Sven Pettersson, Annika Hanberg, and Lorenz Poellinger. 2002. “A 
Constitutively Active Dioxin/aryl Hydrocarbon Receptor Induces Stomach Tumors.” 
Proceedings of the National Academy of Sciences of the United States of America 99 
(15). National Academy of Sciences: 9990–95. doi:10.1073/pnas.152706299. 
Andl, Claudia D, and Anil K Rustgi. 2005. “No One-Way Street: Cross-Talk between E-
Cadherin and Receptor Tyrosine Kinase (RTK) Signaling: A Mechanism to 
Regulate RTK Activity.” Cancer Biology & Therapy 4 (1): 28–31. 
http://www.ncbi.nlm.nih.gov/pubmed/15662113. 
Avital, Itzhak, Alexander Stojadinovic, Peter W. T. Pisters, David P. Kelsen, and 
Christopher G. Willett. 2015. “Cancer of the Stomach.” In DeVita, Hellman, and 
Rosenberg’s Cancer: Principles & Practice of Oncology, edited by Vincent T. Jr. 
DeVita, Theodore S. Lawrence, and Steven A. Rosenberg, 10th editi. Philadelphia, 
PA: Lippincott Williams & Wilkins. 
Barbáchano, A, P Ordóñez-Morán, J M García, A Sánchez, F Pereira, M J Larriba, N 
Martínez, et al. 2010. “SPROUTY-2 and E-Cadherin Regulate Reciprocally and 
 106 
Dictate Colon Cancer Cell Tumourigenicity.” Oncogene 29 (34). Nature Publishing 
Group: 4800–4813. doi:10.1038/onc.2010.225. 
Bardeesy, N., A. J. Aguirre, G. C. Chu, K.-h. Cheng, L. V. Lopez, A. F. Hezel, B. Feng, 
et al. 2006. “Both p16Ink4a and the p19Arf-p53 Pathway Constrain Progression of 
Pancreatic Adenocarcinoma in the Mouse.” Proceedings of the National Academy of 
Sciences 103 (15). National Academy of Sciences: 5947–52. 
doi:10.1073/pnas.0601273103. 
Barker, Nick, Meritxell Huch, Pekka Kujala, Marc van de Wetering, Hugo J. Snippert, 
Johan H. van Es, Toshiro Sato, et al. 2010. “Lgr5+ve Stem Cells Drive Self-
Renewal in the Stomach and Build Long-Lived Gastric Units In Vitro.” Cell Stem 
Cell 6 (1): 25–36. doi:10.1016/j.stem.2009.11.013. 
Barman, Melissa, David Unold, Kathleen Shifley, Elad Amir, Kueichun Hung, Nicolaas 
Bos, and Nita Salzman. 2008. “Enteric Salmonellosis Disrupts the Microbial 
Ecology of the Murine Gastrointestinal Tract.” Infection and Immunity 76 (3). 
American Society for Microbiology: 907–15. doi:10.1128/IAI.01432-07. 
Bass, Adam J., Vesteinn Thorsson, Ilya Shmulevich, Sheila M. Reynolds, Michael 
Miller, Brady Bernard, Toshinori Hinoue, et al. 2014. “Comprehensive Molecular 
Characterization of Gastric Adenocarcinoma.” Nature 513 (7517). Nature 
Publishing Group: 202–9. doi:10.1038/nature13480. 
Birchmeier, W, J Hülsken, and J Behrens. 1995. “E-Cadherin as an Invasion Suppressor.” 
Ciba Foundation Symposium 189: 124-36-41, 174–76. 
http://www.ncbi.nlm.nih.gov/pubmed/7587628. 
 107 
Blanpain, Cédric. 2013. “Tracing the Cellular Origin of Cancer.” Nature Cell Biology 15 
(2). Nature Research: 126–34. doi:10.1038/ncb2657. 
Boussadia, Oréda, Stefanie Kutsch, Andreas Hierholzer, Véronique Delmas, and Rolf 
Kemler. 2002. “E-Cadherin Is a Survival Factor for the Lactating Mouse Mammary 
Gland.” Mechanisms of Development 115 (1): 53–62. doi:10.1016/S0925-
4773(02)00090-4. 
Brabletz, T, A Jung, S Dag, F Hlubek, and T Kirchner. 1999. “Beta-Catenin Regulates 
the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer.” The 
American Journal of Pathology 155 (4). American Society for Investigative 
Pathology: 1033–38. http://www.ncbi.nlm.nih.gov/pubmed/10514384. 
Brault, V, R Moore, S Kutsch, M Ishibashi, D H Rowitch, A P McMahon, L Sommer, et 
al. 2001. “Inactivation of the Beta-Catenin Gene by Wnt1-Cre-Mediated Deletion 
Results in Dramatic Brain Malformation and Failure of Craniofacial Development.” 
Development (Cambridge, England) 128 (8). The Company of Biologists Ltd: 1253–
64. doi:10.1074/jbc.271.3.1520. 
Braun, Benjamin S, David A Tuveson, Namie Kong, Doan T Le, Scott C Kogan, Jacob 
Rozmus, Michelle M Le Beau, Tyler E Jacks, and Kevin M Shannon. 2004. 
“Somatic Activation of Oncogenic Kras in Hematopoietic Cells Initiates a Rapidly 
Fatal Myeloproliferative Disorder.” Proceedings of the National Academy of 
Sciences of the United States of America 101 (2). National Academy of Sciences: 
597–602. doi:10.1073/pnas.0307203101. 
Brembeck, Felix H, Franz S Schreiber, Therese B Deramaudt, Linden Craig, Ben 
 108 
Rhoades, Gary Swain, Paul Grippo, Doris A Stoffers, Debra G Silberg, and Anil K 
Rustgi. 2003. “The Mutant K-Ras Oncogene Causes Pancreatic Periductal 
Lymphocytic Infiltration and Gastric Mucous Neck Cell Hyperplasia in Transgenic 
Mice.” Cancer Research 63 (9). American Association for Cancer Research: 2005–
9. doi:10.1016/0092-8674(88)90571-5. 
Caca, K, F T Kolligs, X Ji, M Hayes, J Qian, A Yahanda, D L Rimm, J Costa, and E R 
Fearon. 1999. “Beta- and Gamma-Catenin Mutations, but Not E-Cadherin 
Inactivation, Underlie T-Cell Factor/lymphoid Enhancer Factor Transcriptional 
Deregulation in Gastric and Pancreatic Cancer.” Cell Growth & Differentiation  : The 
Molecular Biology Journal of the American Association for Cancer Research 10 (6). 
AACR: 369–76. http://www.ncbi.nlm.nih.gov/pubmed/10392898. 
Cantorna, M T, and E Balish. 1990. “Inability of Human Clinical Strains of Helicobacter 
Pylori to Colonize the Alimentary Tract of Germfree Rodents.” Canadian Journal of 
Microbiology 36 (4): 237–41. http://www.ncbi.nlm.nih.gov/pubmed/2357642. 
Caulin, Carlos, Thao Nguyen, Gene A. Lang, Thea M. Goepfert, Bill R. Brinkley, Wei-
Wen Cai, Guillermina Lozano, et al. 2007. “An Inducible Mouse Model for Skin 
Cancer Reveals Distinct Roles for Gain- and Loss-of-Function p53 Mutations.” 
Journal of Clinical Investigation 117 (7). American Society for Clinical 
Investigation: 1893–1901. doi:10.1172/JCI31721. 
Cerami, E., J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, A. Jacobsen, et 
al. 2012. “The cBio Cancer Genomics Portal: An Open Platform for Exploring 
Multidimensional Cancer Genomics Data.” Cancer Discovery 2 (5). American 
 109 
Association for Cancer Research: 401–4. doi:10.1158/2159-8290.CD-12-0095. 
Ceteci, Fatih, Semra Ceteci, Christiaan Karreman, Boris W. Kramer, Esther Asan, Rudolf 
Götz, and Ulf R. Rapp. 2007. “Disruption of Tumor Cell Adhesion Promotes 
Angiogenic Switch and Progression to Micrometastasis in RAF-Driven Murine 
Lung Cancer.” Cancer Cell 12 (2): 145–59. doi:10.1016/j.ccr.2007.06.014. 
Chan, Annie On On. 2006. “E-Cadherin in Gastric Cancer.” World Journal of 
Gastroenterology 12 (2). Baishideng Publishing Group Inc: 199–203. 
http://www.ncbi.nlm.nih.gov/pubmed/16482618. 
Chan, Iris T., Jeffery L. Kutok, Ifor R. Williams, Sarah Cohen, Lauren Kelly, Hirokazu 
Shigematsu, Leisa Johnson, et al. 2004. “Conditional Expression of Oncogenic K-
Ras from Its Endogenous Promoter Induces a Myeloproliferative Disease.” Journal 
of Clinical Investigation 113 (4). American Society for Clinical Investigation: 528–
38. doi:10.1172/JCI20476. 
Chibon, Frédéric, Pauline Lagarde, Sébastien Salas, Gaëlle Pérot, Véronique Brouste, 
Franck Tirode, Carlo Lucchesi, et al. 2010. “Validated Prediction of Clinical 
Outcome in Sarcomas and Multiple Types of Cancer on the Basis of a Gene 
Expression Signature Related to Genome Complexity.” Nature Medicine 16 (7). 
Nature Research: 781–87. doi:10.1038/nm.2174. 
Chiurillo, Miguel Angel. 2015. “Role of the Wnt/β-Catenin Pathway in Gastric Cancer: 
An in-Depth Literature Review.” World Journal of Experimental Medicine 5 (2). 
Baishideng Publishing Group Inc: 84–102. doi:10.5493/wjem.v5.i2.84. 
Chung, C K, and H N Antoniades. 1992. “Expression of c-Sis/platelet-Derived Growth 
 110 
Factor B, Insulin-like Growth Factor I, and Transforming Growth Factor Alpha 
Messenger RNAs and Their Respective Receptor Messenger RNAs in Primary 
Human Gastric Carcinomas: In Vivo Studies with in Situ Hybridiz.” Cancer 
Research 52 (12): 3453–59. http://www.ncbi.nlm.nih.gov/pubmed/1317752. 
Correa, Pelayo. 1992. “Human Gastric Carcinogenesis: A Multistep and Multifactorial 
Process First American Cancer Society Award Lecture on Cancer Epidemiology and 
Prevention 1.” CANCER RESEARCH 52: 6735–40. 
Crawford, Howard C, Barbara M Fingleton, Laura A Rudolph-Owen, Kathleen J 
Heppner Goss, Bonnee Rubinfeld, Paul Polakis, and Lynn M Matrisian. 1999. “The 
Metalloproteinase Matrilysin Is a Target of β-Catenin Transactivation in Intestinal 
Tumors.” Oncogene 18 (18). Nature Publishing Group: 2883–91. 
doi:10.1038/sj.onc.1202627. 
Cristescu, Razvan, Jeeyun Lee, Michael Nebozhyn, Kyoung-Mee Kim, Jason C Ting, 
Swee Seong Wong, Jiangang Liu, et al. 2015. “Molecular Analysis of Gastric 
Cancer Identifies Subtypes Associated with Distinct Clinical Outcomes.” Nature 
Medicine 21 (5). Nature Publishing Group: 449–56. doi:10.1038/nm.3850. 
De Santis, G, S Miotti, M Mazzi, S Canevari, and A Tomassetti. 2009. “E-Cadherin 
Directly Contributes to PI3K/AKT Activation by Engaging the PI3K-p85 
Regulatory Subunit to Adherens Junctions of Ovarian Carcinoma Cells.” Oncogene 
28 (9). Nature Publishing Group: 1206–17. doi:10.1038/onc.2008.470. 
Deng, Niantao, Liang Kee Goh, Hannah Wang, Kakoli Das, Jiong Tao, Iain Beehuat Tan, 
Shenli Zhang, et al. 2012. “A Comprehensive Survey of Genomic Alterations in 
 111 
Gastric Cancer Reveals Systematic Patterns of Molecular Exclusivity and Co-
Occurrence among Distinct Therapeutic Targets.” Gut 61 (5). BMJ Publishing 
Group Ltd and British Society of Gastroenterology: 673–84. doi:10.1136/gutjnl-
2011-301839. 
Dow, Lukas E., Kevin P. O’Rourke, Janelle Simon, Darjus F. Tschaharganeh, Johan H. 
van Es, Hans Clevers, and Scott W. Lowe. 2015. “Apc Restoration Promotes 
Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.” 
Cell 161 (7): 1539–52. doi:10.1016/j.cell.2015.05.033. 
Downward, Julian. 2003. “Targeting RAS Signalling Pathways in Cancer Therapy.” 
Nature Reviews Cancer 3 (1). Nature Publishing Group: 11–22. doi:10.1038/nrc969. 
Edgar, R., Michael Domrachev, and Alex E. Lash. 2002. “Gene Expression Omnibus: 
NCBI Gene Expression and Hybridization Array Data Repository.” Nucleic Acids 
Research 30 (1). Oxford University Press: 207–10. doi:10.1093/nar/30.1.207. 
Ehlers, S, M Warrelmann, and H Hahn. 1988. “In Search of an Animal Model for 
Experimental Campylobacter Pylori Infection: Administration of Campylobacter 
Pylori to Rodents.” Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. 
Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology 268 
(3): 341–46. http://www.ncbi.nlm.nih.gov/pubmed/3261481. 
Eisen, M B, P T Spellman, P O Brown, and D Botstein. 1998. “Cluster Analysis and 
Display of Genome-Wide Expression Patterns.” Proceedings of the National 
Academy of Sciences of the United States of America 95 (25). National Academy of 
Sciences: 14863–68. http://www.ncbi.nlm.nih.gov/pubmed/9843981. 
 112 
Ferlay, Jacques, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, 
Marise Rebelo, Donald Maxwell Parkin, David Forman, and Freddie Bray. 2015. 
“Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns 
in GLOBOCAN 2012.” International Journal of Cancer 136 (5): E359–86. 
doi:10.1002/ijc.29210. 
Ferlay, J, I Soerjomataram, M Ervik, R Dikshit, S Eser, C Mathers, M Rebelo, DM 
Parkin, D Forman, and F Bray. 2013. “GLOBOCAN 2012 v1.0.” Cancer Incidence 
and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: 
International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. 
Filali, M., Ningli Cheng, Duane Abbott, Vladimir Leontiev, and John F. Engelhardt. 
2002. “Wnt-3A/beta -Catenin Signaling Induces Transcription from the LEF-1 
Promoter.” Journal of Biological Chemistry 277 (36). American Society for 
Biochemistry and Molecular Biology: 33398–410. doi:10.1074/jbc.M107977200. 
Fox, James G., and Timothy C. Wang. 2007. Inflammation, Atrophy, and Gastric Cancer. 
Journal of Clinical Investigation. Vol. 117. American Society for Clinical 
Investigation. doi:10.1172/JCI30111. 
Fox, James G, Barbara J Sheppard, Charles A Dangler, Mark T Whary, Melanie Ihrig, 
and Timothy C Wang. 2002. “Germ-Line p53-Targeted Disruption Inhibits 
Helicobacter-Induced Premalignant Lesions and Invasive Gastric Carcinoma 
through down-Regulation of Th1 Proinflammatory Responses.” Cancer Research 62 
(3). American Association for Cancer Research: 696–702. doi:10.1016/s0092-
8674(00)81871-1. 
 113 
Geer, Lewis Y, Aron Marchler-Bauer, Renata C Geer, Lianyi Han, Jane He, Siqian He, 
Chunlei Liu, Wenyao Shi, and Stephen H Bryant. 2010. “The NCBI BioSystems 
Database.” Nucleic Acids Research 38 (Database issue). Oxford University Press: 
D492-6. doi:10.1093/nar/gkp858. 
Giraud, Andrew S., and Louise M. Judd. 2009. “Genetic Models of Gastric Cancer in the 
Mouse.” In The Biology of Gastric Cancers, edited by Timothy C. Wang, James G. 
Fox, and Andrew S. Giraud, 483–512. New York: Springer. 
Goldenring, James R., Gregory S. Ray, Robert J. Coffey, Paul C. Meunier, Patrick J. 
Haley, T.Bradford Barnes, and Bruce D. Car. 2000. “Reversible Drug–induced 
Oxyntic Atrophy in Rats.” Gastroenterology 118 (6): 1080–93. doi:10.1016/S0016-
5085(00)70361-1. 
Gong, Jian, Asahiro Morishita, Kazutaka Kurokohchi, Joji Tani, Kiyohito Kato, Hisaaki 
Miyoshi, Hideyuki Inoue, et al. 2010. “Use of Protein Array to Investigate Receptor 
Tyrosine Kinases Activated in Gastric Cancer.” International Journal of Oncology 
36 (1). Spandidos Publications: 101–6. 
Gottardi, C J, E Wong, and B M Gumbiner. 2001. “E-Cadherin Suppresses Cellular 
Transformation by Inhibiting Beta-Catenin Signaling in an Adhesion-Independent 
Manner.” The Journal of Cell Biology 153 (5). Rockefeller University Press: 1049–
60. doi:10.1083/jcb.153.5.1049. 
Graziano, Frada, B. Humar, and P. Guilford. 2003. “The Role of the E-Cadherin Gene 
(CDH1) in Diffuse Gastric Cancer Susceptibility: From the Laboratory to Clinical 
Practice.” Annals of Oncology. doi:10.1093/annonc/mdg486. 
 114 
Guilford, Parry, Justin Hopkins, James Harraway, Maybelle McLeod, Ngahiraka 
McLeod, Pauline Harawira, Huriana Taite, Robin Scoular, Andrew Miller, and 
Anthony E. Reeve. 1998. “E-Cadherin Germline Mutations in Familial Gastric 
Cancer.” Nature 392 (6674). Nature Publishing Group: 402–5. doi:10.1038/32918. 
Guilford, Parry, Bostjan Humar, and Vanessa Blair. 2010. “Hereditary Diffuse Gastric 
Cancer: Translation of CDH1 Germline Mutations into Clinical Practice.” Gastric 
Cancer 13 (1). Springer Japan: 1–10. doi:10.1007/s10120-009-0531-x. 
Han, Sang-Uk, Young-Bae Kim, Hee-Jae Joo, Ki-Baik Hahm, Won-Heung Lee, Yong-
Kwan Cho, Dae-Yong Kim, and Myung-Wook Kim. 2002. “Helicobacter Pylori 
Infection Promotes Gastric Carcinogenesis in a Mice Model.” Journal of 
Gastroenterology and Hepatology 17 (3). Blackwell Science Pty: 253–61. 
doi:10.1046/j.1440-1746.2002.02684.x. 
Hanahan, Douglas, and Robert A Weinberg. 2000. “The Hallmarks of Cancer.” Cell 100 
(1): 57–70. doi:10.1016/S0092-8674(00)81683-9. 
Hanahan, Douglas, Robert A Weinberg, J.M. Adams, S. Cory, J.A. Aguirre-Ghiso, Z. 
Ahmed, R. Bicknell, et al. 2011. “Hallmarks of Cancer: The next Generation.” Cell 
144 (5). Elsevier: 646–74. doi:10.1016/j.cell.2011.02.013. 
Hayakawa, Yoku, Hiroshi Ariyama, Jitka Stancikova, Kosuke Sakitani, Samuel Asfaha, 
Bernhard W. Renz, Zinaida A. Dubeykovskaya, et al. 2015. “Mist1 Expressing 
Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are 
Supported by a Perivascular Stem Cell Niche.” Cancer Cell 28 (6): 800–814. 
doi:10.1016/j.ccell.2015.10.003. 
 115 
Hayakawa, Yoku, James Fox, Tamas Gonda, Daniel Worthley, Sureshkumar 
Muthupalani, and Timothy Wang. 2013. “Mouse Models of Gastric Cancer.” 
Cancers 5 (1). Multidisciplinary Digital Publishing Institute: 92–130. 
doi:10.3390/cancers5010092. 
He, T C, A B Sparks, C Rago, H Hermeking, L Zawel, L T da Costa, P J Morin, et al. 
1998. “Identification of c-MYC as a Target of the APC Pathway.” Science (New 
York, N.Y.) 281 (5382). American Association for the Advancement of Science: 
1509–12. doi:10.1126/science.281.5382.1509. 
Heffner, Caleb S., C. Herbert Pratt, Randal P. Babiuk, Yashoda Sharma, Stephen F. 
Rockwood, Leah R. Donahue, Janan T. Eppig, and Stephen A. Murray. 2012. 
“Supporting Conditional Mouse Mutagenesis with a Comprehensive Cre 
Characterization Resource.” Nature Communications 3 (November). Nature 
Research: 1218. doi:10.1038/ncomms2186. 
Herzig, M, F Savarese, M Novatchkova, H Semb, and G Christofori. 2007. “Tumor 
Progression Induced by the Loss of E-Cadherin Independent of β-catenin/Tcf-
Mediated Wnt Signaling.” Oncogene 26 (16). Nature Publishing Group: 2290–98. 
doi:10.1038/sj.onc.1210029. 
Hingorani, Sunil R., Emanuel F. Petricoin, Anirban Maitra, Vinodh Rajapakse, Catrina 
King, Michael A. Jacobetz, Sally Ross, et al. 2003. “Preinvasive and Invasive Ductal 
Pancreatic Cancer and Its Early Detection in the Mouse.” Cancer Cell 4 (6): 437–50. 
doi:10.1016/S1535-6108(03)00309-X. 
Hingorani, Sunil R., Lifu Wang, Asha S. Multani, Chelsea Combs, Therese B. 
 116 
Deramaudt, Ralph H. Hruban, Anil K. Rustgi, Sandy Chang, and David A. Tuveson. 
2005. “Trp53R172H and KrasG12D Cooperate to Promote Chromosomal Instability 
and Widely Metastatic Pancreatic Ductal Adenocarcinoma in Mice.” Cancer Cell 7 
(5): 469–83. doi:10.1016/j.ccr.2005.04.023. 
Hovanes, Karine, Tony W.H. Li, Jesus E. Munguia, Trung Truong, Tatjana Milovanovic, 
J. Lawrence Marsh, Randall F. Holcombe, and Marian L. Waterman. 2001. “β-
Catenin–sensitive Isoforms of Lymphoid Enhancer Factor-1 Are Selectively 
Expressed in Colon Cancer.” Nature Genetics 28 (1). Nature Publishing Group: 53–
57. doi:10.1038/ng0501-53. 
Howson, C P, T Hiyama, and E L Wynder. 1986. “The Decline in Gastric Cancer: 
Epidemiology of an Unplanned Triumph.” Epidemiologic Reviews 8 (6): 1–27. 
http://www.ncbi.nlm.nih.gov/pubmed/3533579. 
Humar, Bostjan, Vanessa Blair, Amanda Charlton, Helen More, Iain Martin, and Parry 
Guilford. 2009. “E-Cadherin Deficiency Initiates Gastric Signet-Ring Cell 
Carcinoma in Mice and Man.” Cancer Research 69 (5). American Association for 
Cancer Research: 2050–56. doi:10.1158/0008-5472.CAN-08-2457. 
Jackson, E L, Kenneth P Olive, David A Tuveson, Roderick Bronson, Denise Crowley, 
Michael Brown, and Tyler Jacks. 2005. “The Differential Effects of Mutant p53 
Alleles on Advanced Murine Lung Cancer.” Cancer Research 65 (22). American 
Association for Cancer Research: 10280–88. doi:10.1158/0008-5472.CAN-05-2193. 
Jackson, E L, N Willis, K Mercer, R T Bronson, D Crowley, R Montoya, T Jacks, and D 
A Tuveson. 2001. “Analysis of Lung Tumor Initiation and Progression Using 
 117 
Conditional Expression of Oncogenic K-Ras.” Genes & Development 15 (24). Cold 
Spring Harbor Laboratory Press: 3243–48. doi:10.1101/gad.943001. 
Janssen, Klaus-Peter, Paola Alberici, Hafida Fsihi, Claudia Gaspar, Cor Breukel, Patrick 
Franken, Christophe Rosty, et al. 2006. “APC and Oncogenic KRAS Are 
Synergistic in Enhancing Wnt Signaling in Intestinal Tumor Formation and 
Progression.” Gastroenterology 131 (4). Elsevier: 1096–1109. 
doi:10.1053/j.gastro.2006.08.011. 
Jeanes, A, C J Gottardi, and A S Yap. 2008. “Cadherins and Cancer: How Does Cadherin 
Dysfunction Promote Tumor Progression?” Oncogene 27 (55). Nature Publishing 
Group: 6920–29. doi:10.1038/onc.2008.343. 
Jho, Eek-hoon, Tong Zhang, Claire Domon, Choun-Ki Joo, Jean-Noel Freund, and Frank 
Costantini. 2002. “Wnt/beta-catenin/Tcf Signaling Induces the Transcription of 
Axin2, a Negative Regulator of the Signaling Pathway.” Molecular and Cellular 
Biology 22 (4). American Society for Microbiology (ASM): 1172–83. 
http://www.ncbi.nlm.nih.gov/pubmed/11809808. 
Johnson, Leisa, Kim Mercer, Doron Greenbaum, Roderick T. Bronson, Denise Crowley, 
David A. Tuveson, and Tyler Jacks. 2001. “Somatic Activation of the K-Ras 
Oncogene Causes Early Onset Lung Cancer in Mice.” Nature 410 (6832). Nature 
Publishing Group: 1111–16. doi:10.1038/35074129. 
Jones, EG. 1964. “Familial Gastric Cancer.” NZ Med J 63: 287–96. 
Juan, J., T. Muraguchi, G. Iezza, R. C. Sears, and M. McMahon. 2014. “Diminished 
WNT -&gt;  -Catenin -&gt; c-MYC Signaling Is a Barrier for Malignant Progression 
 118 
of BRAFV600E-Induced Lung Tumors.” Genes & Development 28 (6). Cold Spring 
Harbor Laboratory Press: 561–75. doi:10.1101/gad.233627.113. 
Kamangar, Farin, You-Lin Qiao, John T. Schiller, Sanford M. Dawsey, Thomas Fears, 
Xui-Di Sun, Christian C. Abnet, Ping Zhao, Philip R. Taylor, and Steven D. Mark. 
2006. “Human Papillomavirus Serology and the Risk of Esophageal and Gastric 
Cancers: Results from a Cohort in a High-Risk Region in China.” International 
Journal of Cancer 119 (3). Wiley Subscription Services, Inc., A Wiley Company: 
579–84. doi:10.1002/ijc.21871. 
Kaurah, Pardeep, Andrée MacMillan, Niki Boyd, Janine Senz, Alessandro De Luca, 
Nicki Chun, Gianpaolo Suriano, et al. 2007. “Founder and Recurrent CDH1 
Mutations in Families With Hereditary Diffuse Gastric Cancer.” JAMA 297 (21). 
American Medical Association: 2360. doi:10.1001/jama.297.21.2360. 
Kidger, Andrew M., and Stephen M. Keyse. 2016. “The Regulation of Oncogenic 
Ras/ERK Signalling by Dual-Specificity Mitogen Activated Protein Kinase 
Phosphatases (MKPs).” Seminars in Cell & Developmental Biology 50: 125–32. 
doi:10.1016/j.semcdb.2016.01.009. 
Kirsch, David G, Daniela M Dinulescu, John B Miller, Jan Grimm, Philip M Santiago, 
Nathan P Young, G Petur Nielsen, et al. 2007. “A Spatially and Temporally 
Restricted Mouse Model of Soft Tissue Sarcoma.” Nature Medicine 13 (8): 992–97. 
doi:10.1038/nm1602. 
Koike, Kazuhiko, Steven H Hinrichst, Kurt J Isselbachert, and Gilbert Jay. 1989. 
“Transgenic Mouse Model for Human Gastric Carcinoma.” Medical Sciences 86: 
 119 
5615–19. 
Konda, Y, H Kamimura, H Yokota, N Hayashi, K Sugano, T Takeuchi, K. Araki, et al. 
1999. “Gastrin Stimulates the Growth of Gastric Pit with Less-Differentiated 
Features.” The American Journal of Physiology 277 (4 Pt 1). American 
Physiological Society: G773-84. doi:10.1073/pnas.92.1.160. 
La Vecchia, C, E Negri, B D’Avanzo, and S Franceschi. 1990. “Electric Refrigerator Use 
and Gastric Cancer Risk.” British Journal of Cancer 62 (1): 136–37. 
http://www.ncbi.nlm.nih.gov/pubmed/2390474. 
Laprise, Patrick, Marie-Jos�e Langlois, Marie-Jos�e Boucher, Christian Jobin, and 
Nathalie Rivard. 2004. “Down-Regulation of MEK/ERK Signaling by E-Cadherin-
Dependent PI3K/Akt Pathway in Differentiating Intestinal Epithelial Cells.” Journal 
of Cellular Physiology 199 (1). Wiley Subscription Services, Inc., A Wiley 
Company: 32–39. doi:10.1002/jcp.10432. 
Lauren, P. 1965. “The Two Histological Main Types Of Gastric Carcinoma: Diffuse and 
So-Called Intestina-Type Carcinoma. An Attempt At A Histo-Clinical 
Classification.” Acta Pathologica et Microbiologica Scandinavica 64: 31–49. 
http://www.ncbi.nlm.nih.gov/pubmed/14320675. 
Lauwers, Gregory Y. 2015. “Epithelial Neoplasms of the Stomach.” In Gastrointestinal 
Tract Endoscopic and Tissue Processing Techniques and Normal Histology, edited 
by Robert D. Odze and John R. Goldblum, Third edit, 707–721.e5. Philadelphia, 
PA: Saunders/Elsevier. https://www.clinicalkey.com/#!/content/book/3-s2.0-
B978145570747800025X?scrollTo=%2523s0045. 
 120 
Lee, A, M Chen, N Coltro, J O’Rourke, S Hazell, P Hu, and Y Li. 1993. “Long Term 
Infection of the Gastric Mucosa with Helicobacter Species Does Induce Atrophic 
Gastritis in an Animal Model of Helicobacter Pylori Infection.” Zentralblatt Für 
Bakteriologie  : International Journal of Medical Microbiology 280 (1–2): 38–50. 
http://www.ncbi.nlm.nih.gov/pubmed/8280955. 
Lee, A, J G Fox, G Otto, and J Murphy. 1990. “A Small Animal Model of Human 
Helicobacter Pylori Active Chronic Gastritis.” Gastroenterology 99 (5): 1315–23. 
http://www.ncbi.nlm.nih.gov/pubmed/2210240. 
Lee, Adrian, Jani O ’rourke, Maria Corazon De Ungria, Bronwyn Robertson, George 
Daskalopoulos, and Michael F Dixon. 1997. “A Standardized Mouse Model of 
Helicobacter Pylori Infection: Introducing the Sydney Strain.” 
GASTROENTEROLOGY 112: 1386–97. 
Lefebvre, O, M P Chenard, R Masson, J Linares, A Dierich, M LeMeur, C Wendling, et 
al. 1996. “Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the 
pS2 Trefoil Protein.” Science (New York, N.Y.) 274 (5285). American Association 
for the Advancement of Science: 259–62. doi:10.1126/science.274.5285.259. 
Lemieux, E, S Cagnol, K Beaudry, J Carrier, and N Rivard. 2015. “Oncogenic KRAS 
Signalling Promotes the Wnt/β-Catenin Pathway through LRP6 in Colorectal 
Cancer.” Oncogene 34 (38). Nature Publishing Group: 4914–27. 
doi:10.1038/onc.2014.416. 
Li, Q., S. M. Karam, and J. I. Gordon. 1995. “Simian Virus 40 T Antigen-Induced 
Amplification of Pre-Parietal Cells in Transgenic Mice.: EFFECTS ON OTHER 
 121 
GASTRIC EPITHELIAL CELL LINEAGES AND EVIDENCE FOR A p53-
INDEPENDENT APOPTOTIC MECHANISM THAT OPERATES IN A 
COMMITTED PROGENITOR.” Journal of Biological Chemistry 270 (26). 
American Society for Biochemistry and Molecular Biology: 15777–88. 
doi:10.1074/jbc.270.26.15777. 
Li, Qiang, Zhiliang Jia, Li Wang, Xiangyu Kong, Qi Li, Kun Guo, Dongfeng Tan, et al. 
2012. “Disruption of Klf4 in Villin-Positive Gastric Progenitor Cells Promotes 
Formation and Progression of Tumors of the Antrum in Mice.” Gastroenterology 
142 (3). NIH Public Access: 531–42. doi:10.1053/j.gastro.2011.11.034. 
Li, Tony W-H, Ju-Hui T Ting, Noriko N Yokoyama, Alla Bernstein, Marc van de 
Wetering, and Marian L Waterman. 2006. “Wnt Activation and Alternative 
Promoter Repression of LEF1 in Colon Cancer.” Molecular and Cellular Biology 26 
(14). American Society for Microbiology (ASM): 5284–99. 
doi:10.1128/MCB.00105-06. 
Li, XiuBin, Guan Yang, Liang Zhu, Yu-Ling Tang, Chong Zhang, Zhenyu Ju, Xiao 
Yang, and Yan Teng. 2016. “Gastric Lgr5+ Stem Cells Are the Cellular Origin of 
Invasive Intestinal-Type Gastric Cancer in Mice.” Cell Research 26 (7). Nature 
Publishing Group: 838–49. doi:10.1038/cr.2016.47. 
Liu, Xin, Kent-Man Chu, Xin Liu, and Kent-Man Chu. 2014. “E-Cadherin and Gastric 
Cancer: Cause, Consequence, and Applications.” BioMed Research International 
2014. Hindawi Publishing Corporation: 637308. doi:10.1155/2014/637308. 
Lustig, Barbara, Boris Jerchow, Martin Sachs, Sigrid Weiler, Torsten Pietsch, Uwe 
 122 
Karsten, Marc van de Wetering, et al. 2002. “Negative Feedback Loop of Wnt 
Signaling through Upregulation of conductin/axin2 in Colorectal and Liver 
Tumors.” Molecular and Cellular Biology 22 (4). American Society for 
Microbiology (ASM): 1184–93. http://www.ncbi.nlm.nih.gov/pubmed/11809809. 
Maretto, S., M. Cordenonsi, S. Dupont, P. Braghetta, V. Broccoli, A. B. Hassan, D. 
Volpin, G. M. Bressan, and S. Piccolo. 2003. “Mapping Wnt/ -Catenin Signaling 
during Mouse Development and in Colorectal Tumors.” Proceedings of the National 
Academy of Sciences 100 (6). National Academy of Sciences: 3299–3304. 
doi:10.1073/pnas.0434590100. 
Marino, Silvia, Marc Vooijs, Hanneke van der Gulden, Jos Jonkers, and Anton Berns. 
2000. “Induction of Medulloblastomas in p53-Null Mutant Mice by Somatic 
Inactivation of Rb in the External Granular Layer Cells of the Cerebellum.” Genes 
& Development 14 (8). Cold Spring Harbor Laboratory Press: 994–1004. 
doi:10.1101/GAD.14.8.994. 
Matkar, Smita S, Amy Durham, Angela Brice, Timothy C Wang, Anil K Rustgi, and 
Xianxin Hua. 2011. “Systemic Activation of K-Ras Rapidly Induces Gastric 
Hyperplasia and Metaplasia in Mice.” American Journal of Cancer Research 1 (4). 
e-Century Publishing Corporation: 432–45. 
http://www.ncbi.nlm.nih.gov/pubmed/21761008. 
McCormick, Frank, and Osamu Tetsu. 1999. “|[beta]|-Catenin Regulates Expression of 
Cyclin D1 in Colon Carcinoma Cells.” Nature 398 (6726). Nature Publishing 
Group: 422–26. doi:10.1038/18884. 
 123 
Mendoza, Michelle C, E Emrah Er, and John Blenis. 2011. “The Ras-ERK and PI3K-
mTOR Pathways: Cross-Talk and Compensation.” Trends in Biochemical Sciences 
36 (6). NIH Public Access: 320–28. doi:10.1016/j.tibs.2011.03.006. 
Mimata, Ayako, Hiroshi Fukamachi, Yoshinobu Eishi, and Yasuhito Yuasa. 2011. “Loss 
of E-Cadherin in Mouse Gastric Epithelial Cells Induces Signet Ring-like Cells, a 
Possible Precursor Lesion of Diffuse Gastric Cancer.” Cancer Science 102 (5). 
Blackwell Publishing Ltd: 942–50. doi:10.1111/j.1349-7006.2011.01890.x. 
Mito, Jeffrey K., Richard F. Riedel, Leslie Dodd, Guy Lahat, Alexander J. Lazar, 
Rebecca D. Dodd, Lars Stangenberg, et al. 2009. “Cross Species Genomic Analysis 
Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant 
Fibrous Histiocytoma.” Edited by Syed A. Aziz. PLoS ONE 4 (11). Public Library 
of Science: e8075. doi:10.1371/journal.pone.0008075. 
Mognol, G P, F R G Carneiro, B K Robbs, D V Faget, and J P B Viola. 2016. “Cell Cycle 
and Apoptosis Regulation by NFAT Transcription Factors: New Roles for an Old 
Player.” Cell Death and Disease 7 (4). Nature Publishing Group: e2199. 
doi:10.1038/cddis.2016.97. 
Mohammed, Maryam K, Connie Shao, Jing Wang, Qiang Wei, Xin Wang, Zachary 
Collier, Shengli Tang, et al. 2016. “Wnt/β-Catenin Signaling Plays an Ever-
Expanding Role in Stem Cell Self-Renewal, Tumorigenesis and Cancer 
Chemoresistance.” Genes & Diseases 3 (1). NIH Public Access: 11–40. 
doi:10.1016/j.gendis.2015.12.004. 
Muñoz, N., and J. Asvall. 1971. “Time Trends of Intestinal and Diffuse Types of Gastric 
 124 
Cancer in Norway.” International Journal of Cancer 8 (1). Wiley Subscription 
Services, Inc., A Wiley Company: 144–57. doi:10.1002/ijc.2910080118. 
Mutoh, Hiroyuki, Shinji Sakurai, Kiichi Satoh, Kiichi Tamada, Hiroto Kita, Hiroyuki 
Osawa, Takeshi Tomiyama, et al. 2004. “Development of Gastric Carcinoma from 
Intestinal Metaplasia in Cdx2-Transgenic Mice.” Cancer Research 64 (21). 
American Association for Cancer Research: 7740–47. doi:10.1158/0008-5472.CAN-
04-1617. 
Nagy, Rebecca, Kevin Sweet, and Charis Eng. 2004. “Highly Penetrant Hereditary 
Cancer Syndromes.” Oncogene 23 (38). Nature Publishing Group: 6445–70. 
doi:10.1038/sj.onc.1207714. 
Nakagawa, H., Y. Hikiba, Y. Hirata, J. Font-Burgada, K. Sakamoto, Y. Hayakawa, K. 
Taniguchi, et al. 2014. “Loss of Liver E-Cadherin Induces Sclerosing Cholangitis 
and Promotes Carcinogenesis.” Proceedings of the National Academy of Sciences 
111 (3). National Academy of Sciences: 1090–95. doi:10.1073/pnas.1322731111. 
Nam, Ki Taek, Hyuk–Joon Lee, Josane F. Sousa, Victoria G. Weis, Ryan L. O’Neal, Paul 
E. Finke, Judith Romero–Gallo, et al. 2010. “Mature Chief Cells Are Cryptic 
Progenitors for Metaplasia in the Stomach.” Gastroenterology 139 (6): 2028–
2037.e9. doi:10.1053/j.gastro.2010.09.005. 
Nam, Ki Taek, Ryan O’Neal, Yeo Song Lee, Yong Chan Lee, Robert J Coffey, and 
James R Goldenring. 2012. “Gastric Tumor Development in Smad3-Deficient Mice 
Initiates from Forestomach/glandular Transition Zone along the Lesser Curvature.” 
Laboratory Investigation 92 (6). Nature Publishing Group: 883–95. 
 125 
doi:10.1038/labinvest.2012.47. 
Neel, Nicole F, Timothy D Martin, Jeran K Stratford, Tanya P Zand, David J Reiner, and 
Channing J Der. 2011. “The RalGEF-Ral Effector Signaling Network: The Road 
Less Traveled for Anti-Ras Drug Discovery.” Genes & Cancer 2 (3). Impact 
Journals, LLC: 275–87. doi:10.1177/1947601911407329. 
Nomura, Sachiyo, Hirokazu Yamaguchi, Masako Ogawa, Timothy C Wang, Jeffrey R 
Lee, and James R Goldenring. 2005. “Alterations in Gastric Mucosal Lineages 
Induced by Acute Oxyntic Atrophy in Wild-Type and Gastrin-Deficient Mice.” 
American Journal of Physiology. Gastrointestinal and Liver Physiology 288 (2). 
American Physiological Society: G362-75. doi:10.1152/ajpgi.00160.2004. 
O’Dell, Michael R, Jing Li Huang, Christa L Whitney-Miller, Vikram Deshpande, Paul 
Rothberg, Valerie Grose, Randall M Rossi, et al. 2012. “Kras(G12D) and p53 
Mutation Cause Primary Intrahepatic Cholangiocarcinoma.” Cancer Research 72 
(6). American Association for Cancer Research: 1557–67. doi:10.1158/0008-
5472.CAN-11-3596. 
Ohtani, Naoko. 2015. “Microbiome and Cancer.” Seminars in Immunopathology 37 (1). 
Springer Berlin Heidelberg: 65–72. doi:10.1007/s00281-014-0457-1. 
Okumura, Tomoyuki, Russell E Ericksen, Shigeo Takaishi, Sophie S W Wang, Zinaida 
Dubeykovskiy, Wataru Shibata, Kelly S Betz, et al. 2010. “K-Ras Mutation 
Targeted to Gastric Tissue Progenitor Cells Results in Chronic Inflammation, an 
Altered Microenvironment, and Progression to Intraepithelial Neoplasia.” Cancer 
Research 70 (21). American Association for Cancer Research: 8435–45. 
 126 
doi:10.1158/0008-5472.CAN-10-1506. 
Ooi, Chia Huey, Tatiana Ivanova, Jeanie Wu, Minghui Lee, Iain Beehuat Tan, Jiong Tao, 
Lindsay Ward, et al. 2009. “Oncogenic Pathway Combinations Predict Clinical 
Prognosis in Gastric Cancer.” Edited by Jason G. Mezey. PLoS Genetics 5 (10). 
Public Library of Science: e1000676. doi:10.1371/journal.pgen.1000676. 
Oshima, Hiroko, Akihiro Matsunaga, Takashi Fujimura, Tetsuya Tsukamoto, Makoto M. 
Taketo, and Masanobu Oshima. 2006. “Carcinogenesis in Mouse Stomach by 
Simultaneous Activation of the Wnt Signaling and Prostaglandin E2 Pathway.” 
Gastroenterology 131 (4): 1086–95. doi:10.1053/j.gastro.2006.07.014. 
Pećina-Slaus, Nives. 2003. “Tumor Suppressor Gene E-Cadherin and Its Role in Normal 
and Malignant Cells.” Cancer Cell International 3 (1). BioMed Central: 17. 
doi:10.1186/1475-2867-3-17. 
Poh, Ashleigh R., Robert J.J. O’Donoghue, Matthias Ernst, and Tracy L. Putoczki. 2016. 
“Mouse Models for Gastric Cancer: Matching Models to Biological Questions.” 
Journal of Gastroenterology and Hepatology, January, n/a-n/a. 
doi:10.1111/jgh.13297. 
Polkowski, W, J W van Sandick, G J Offerhaus, F J ten Kate, J Mulder, H Obertop, and J 
J van Lanschot. 2016. “Prognostic Value of Laurén Classification and c-erbB-2 
Oncogene Overexpression in Adenocarcinoma of the Esophagus and 
Gastroesophageal Junction.” Annals of Surgical Oncology 6 (3): 290–97. Accessed 
August 8. http://www.ncbi.nlm.nih.gov/pubmed/10340889. 
Pylayeva-Gupta, Yuliya, Elda Grabocka, and Dafna Bar-Sagi. 2011. “RAS Oncogenes: 
 127 
Weaving a Tumorigenic Web.” Nature Reviews Cancer 11 (11). Nature Publishing 
Group: 761–74. doi:10.1038/nrc3106. 
Rachagani, S, S Senapati, S Chakraborty, M P Ponnusamy, S Kumar, L M Smith, M Jain, 
and S K Batra. 2011. “Activated KrasG12D Is Associated with Invasion and 
Metastasis of Pancreatic Cancer Cells through Inhibition of E-Cadherin.” British 
Journal of Cancer 104 (6). Nature Publishing Group: 1038–48. 
doi:10.1038/bjc.2011.31. 
Ray, Kevin C., Kayla M. Bell, Jingbo Yan, Guoqiang Gu, Christine H. Chung, M. Kay 
Washington, and Anna L. Means. 2011. “Epithelial Tissues Have Varying Degrees 
of Susceptibility to KrasG12D-Initiated Tumorigenesis in a Mouse Model.” Edited 
by Robert Oshima. PLoS ONE 6 (2). Public Library of Science: e16786. 
doi:10.1371/journal.pone.0016786. 
Redman, Robert S., Varalakshmi Katuri, Yi Tang, Allan Dillner, Bibhuti Mishra, and 
Lopa Mishra. 2005. “Orofacial and Gastrointestinal Hyperplasia and Neoplasia in 
smad4+/- and Elf+/-/smad4+/- Mutant Mice.” Journal of Oral Pathology and 
Medicine 34 (1). Munksgaard International Publishers: 23–29. doi:10.1111/j.1600-
0714.2004.00246.x. 
Reich, Michael, Ted Liefeld, Joshua Gould, Jim Lerner, Pablo Tamayo, and Jill P 
Mesirov. 2006. “GenePattern 2.0.” Nature Genetics 38 (5). Nature Publishing 
Group: 500–501. doi:10.1038/ng0506-500. 
Robles-Oteiza, Camila, Sarah Taylor, Travis Yates, Michelle Cicchini, Brian 
Lauderback, Christopher R. Cashman, Aurora A. Burds, Monte M. Winslow, Tyler 
 128 
Jacks, and David M. Feldser. 2015. “Recombinase-Based Conditional and 
Reversible Gene Regulation via XTR Alleles.” Nature Communications 6 
(November). Nature Research: 8783. doi:10.1038/ncomms9783. 
Rogers, Arlin B, Nancy S Taylor, Mark T Whary, Erinn D Stefanich, Timothy C Wang, 
and James G Fox. 2005. “Helicobacter Pylori but Not High Salt Induces Gastric 
Intraepithelial Neoplasia in B6129 Mice.” Cancer Research 65 (23). American 
Association for Cancer Research: 10709–15. doi:10.1158/0008-5472.CAN-05-1846. 
Sakagami, T, M Dixon, J O’Rourke, R Howlett, F Alderuccio, J Vella, T Shimoyama, 
and A Lee. 1996. “Atrophic Gastric Changes in Both Helicobacter Felis and 
Helicobacter Pylori Infected Mice Are Host Dependent and Separate from Antral 
Gastritis.” Gut 39 (5). BMJ Group: 639–48. 
http://www.ncbi.nlm.nih.gov/pubmed/9026476. 
Sakamoto, Kei, Yohko Hikiba, Hayato Nakagawa, Yoku Hayakawa, Ayako Yanai, 
Masao Akanuma, Keiji Ogura, et al. 2010. “Inhibitor of κB Kinase Beta Regulates 
Gastric Carcinogenesis via Interleukin-1α Expression.” Gastroenterology 139 (1): 
226–238.e6. doi:10.1053/j.gastro.2010.03.047. 
Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark 
Longair, Tobias Pietzsch, Stephan Preibisch, et al. 2012. “Fiji: An Open-Source 
Platform for Biological-Image Analysis.” Nature Methods 9 (7). Nature Research: 
676–82. doi:10.1038/nmeth.2019. 
Schindelin, Johannes, Curtis T. Rueden, Mark C. Hiner, and Kevin W. Eliceiri. 2015. 
“The ImageJ Ecosystem: An Open Platform for Biomedical Image Analysis.” 
 129 
Molecular Reproduction and Development 82 (7–8): 518–29. 
doi:10.1002/mrd.22489. 
Schneider, Caroline A, Wayne S Rasband, and Kevin W Eliceiri. 2012. “NIH Image to 
ImageJ: 25 Years of Image Analysis.” Nature Methods 9 (7). Nature Research: 671–
75. doi:10.1038/nmeth.2089. 
Scudamore, Cheryl L. 2013. “Gastrointestinal System.” In A Practical Guide to the 
Histology of the Mouse, 43–61. Chichester, UK: John Wiley & Sons, Ltd. 
doi:10.1002/9781118789568.ch3. 
Searle, P. F., D. P. Thomas, K. B. Faulkner, and J. M. Tinsley. 1994. “Stomach Cancer in 
Transgenic Mice Expressing Human Papillomavirus Type 16 Early Region Genes 
From a Keratin Promoter.” Journal of General Virology 75 (5). Microbiology 
Society: 1125–37. doi:10.1099/0022-1317-75-5-1125. 
Shimada, Shu, Ayako Mimata, Masaki Sekine, Kaoru Mogushi, Yoshimitsu Akiyama, 
Hiroshi Fukamachi, Jos Jonkers, Hiroshi Tanaka, Yoshinobu Eishi, and Yasuhito 
Yuasa. 2012. “Synergistic Tumour Suppressor Activity of E-Cadherin and p53 in a 
Conditional Mouse Model for Metastatic Diffuse-Type Gastric Cancer.” Gut 61 (3). 
BMJ Publishing Group Ltd and British Society of Gastroenterology: 344–53. 
doi:10.1136/gutjnl-2011-300050. 
Shtutman, M, J Zhurinsky, I Simcha, C Albanese, M D’Amico, R Pestell, and A Ben-
Ze’ev. 1999. “The Cyclin D1 Gene Is a Target of the Beta-catenin/LEF-1 Pathway.” 
Proceedings of the National Academy of Sciences of the United States of America 96 
(10). National Academy of Sciences: 5522–27. 
 130 
http://www.ncbi.nlm.nih.gov/pubmed/10318916. 
Siegel, Rebecca, Deepa Naishadham, and Ahmedin Jemal. 2012. “Cancer Statistics, 
2012.” CA: A Cancer Journal for Clinicians 62 (1). Wiley Subscription Services, 
Inc., A Wiley Company: 10–29. doi:10.3322/caac.20138. 
Song, Xiaowen, Na Xin, Wei Wang, Chenghai Zhao, Xiaowen Song, Na Xin, Wei Wang, 
and Chenghai Zhao. 2015. “Wnt/β-Catenin, an Oncogenic Pathway Targeted by  H. 
Pylori  in Gastric Carcinogenesis.” Oncotarget 6 (34). Impact Journals: 35579–88. 
Soto, Edwin, Masahiro Yanagisawa, Laura A. Marlow, John A. Copland, Edith A. Perez, 
and Panos Z. Anastasiadis. 2008. “p120 Catenin Induces Opposing Effects on 
Tumor Cell Growth Depending on E-Cadherin Expression.” The Journal of Cell 
Biology 183 (4). Rockefeller University Press: 737–49. doi:10.1083/jcb.200805113. 
Spandidos, Athanasia, Xiaowei Wang, Huajun Wang, Stefan Dragnev, Tara Thurber, 
Brian Seed, SA Bustin, et al. 2008. “A Comprehensive Collection of Experimentally 
Validated Primers for Polymerase Chain Reaction Quantitation of Murine Transcript 
Abundance.” BMC Genomics 9 (1). BioMed Central: 633. doi:10.1186/1471-2164-
9-633. 
Spandidos, Athanasia, Xiaowei Wang, Huajun Wang, and Brian Seed. 2010. 
“PrimerBank: A Resource of Human and Mouse PCR Primer Pairs for Gene 
Expression Detection and Quantification.” Nucleic Acids Research 38 (Database 
issue). Oxford University Press: D792-9. doi:10.1093/nar/gkp1005. 
Srinivas, S, T Watanabe, C S Lin, C M William, Y Tanabe, T M Jessell, and F 
Costantini. 2001. “Cre Reporter Strains Produced by Targeted Insertion of EYFP 
 131 
and ECFP into the ROSA26 Locus.” BMC Developmental Biology 1. BioMed 
Central: 4. http://www.ncbi.nlm.nih.gov/pubmed/11299042. 
Stange, Daniel E., Bon-Kyoung Koo, Meritxell Huch, Greg Sibbel, Onur Basak, Anna 
Lyubimova, Pekka Kujala, et al. 2013. “Differentiated Troy+ Chief Cells Act as 
Reserve Stem Cells to Generate All Lineages of the Stomach Epithelium.” Cell 155 
(2): 357–68. doi:10.1016/j.cell.2013.09.008. 
Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, 
A. Paulovich, et al. 2005. “Gene Set Enrichment Analysis: A Knowledge-Based 
Approach for Interpreting Genome-Wide Expression Profiles.” Proceedings of the 
National Academy of Sciences 102 (43). National Academy of Sciences: 15545–50. 
doi:10.1073/pnas.0506580102. 
Surveillance Research Program, National Cancer Institute. n.d. “SEER*Explorer: An 
Interactive Website for SEER Cancer Statistics [Internet].” 
Syder, Andrew J, Sherif M Karam, Jason C Mills, Joseph E Ippolito, Habib R Ansari, 
Vidya Farook, and Jeffrey I Gordon. 2004. “A Transgenic Mouse Model of 
Metastatic Carcinoma Involving Transdifferentiation of a Gastric Epithelial Lineage 
Progenitor to a Neuroendocrine Phenotype.” Proceedings of the National Academy 
of Sciences of the United States of America 101 (13). National Academy of 
Sciences: 4471–76. doi:10.1073/pnas.0307983101. 
Takasu, Shinji, Tetsuya Tsukamoto, Xue-Yuan Cao, Takeshi Toyoda, Akihiro Hirata, 
Hisayo Ban, Masami Yamamoto, et al. 2008. “Roles of Cyclooxygenase-2 and 
Microsomal Prostaglandin E Synthase-1 Expression and β-Catenin Activation in 
 132 
Gastric Carcinogenesis in N-Methyl-N-Nitrosourea-Treated K19-C2mE Transgenic 
Mice.” Cancer Science 99 (12). Blackwell Publishing Asia: 2356–64. 
doi:10.1111/j.1349-7006.2008.00983.x. 
Tatematsu, M, K Ogawa, T Hoshiya, Y Shichino, T Kato, K Imaida, and N Ito. 1992. 
“Induction of Adenocarcinomas in the Glandular Stomach of BALB/c Mice Treated 
with N-Methyl-N-Nitrosourea.” Japanese Journal of Cancer Research  : Gann 83 
(9): 915–18. http://www.ncbi.nlm.nih.gov/pubmed/1429199. 
Tatematsu, M, M Yamamoto, H Iwata, H Fukami, H Yuasa, N Tezuka, T Masui, and H 
Nakanishi. 1993. “Induction of Glandular Stomach Cancers in C3H Mice Treated 
with N-Methyl-N-Nitrosourea in the Drinking Water.” Japanese Journal of Cancer 
Research  : Gann 84 (12): 1258–64. http://www.ncbi.nlm.nih.gov/pubmed/8294216. 
Tebbutt, Niall C., Andrew S. Giraud, Melissa Inglese, Brendan Jenkins, Paul Waring, 
Fiona J. Clay, Sina Malki, et al. 2002. “Reciprocal Regulation of Gastrointestinal 
Homeostasis by SHP2 and STAT-Mediated Trefoil Gene Activation in gp130 
Mutant Mice.” Nature Medicine 8 (10). Nature Publishing Group: 1089–97. 
doi:10.1038/nm763. 
“The Human Protein Atlas: ATP4B.” n.d. 
http://www.proteinatlas.org/ENSG00000186009-ATP4B/tissue. 
Thiem, Stefan, Moritz F Eissmann, Joachim Elzer, Anna Jonas, Tracy L Putoczki, 
Ashleigh Poh, Paul Nguyen, et al. 2016. “Stomach-Specific Activation of Oncogenic 
KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric 
Tumorigenesis in a Preclinical Model.” Cancer Research 76 (8). American 
 133 
Association for Cancer Research: 2277–87. doi:10.1158/0008-5472.CAN-15-3089. 
Thompson, John, Thomas Epting, Georg Schwarzkopf, Axel Singhofen, Anne-Marie 
Eades-Perner, Herman van der Putten, and Wolfgang Zimmermann. 2000. “A 
Transgenic Mouse Line That Develops Early-Onset Invasive Gastric Carcinoma 
Provides a Model for Carcinoembryonic Antigen-Targeted Tumor Therapy.” 
International Journal of Cancer 86 (6). John Wiley & Sons, Inc.: 863–69. 
doi:10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4. 
Tomita, Hiroyuki, Shigeo Takaishi, Trevelyan R. Menheniott, Xiangdong Yang, Wataru 
Shibata, Guangchun Jin, Kelly S. Betz, et al. 2011. “Inhibition of Gastric 
Carcinogenesis by the Hormone Gastrin Is Mediated by Suppression of TFF1 
Epigenetic Silencing.” Gastroenterology 140 (3): 879–891.e18. 
doi:10.1053/j.gastro.2010.11.037. 
Tsuchida, Nobuo, Avaniyapuram Kannan Murugan, Michele Grieco, Nobuo Tsuchida, 
Avaniyapuram Kannan Murugan, and Michele Grieco. 2016. “Kirsten Ras* 
Oncogene: Significance of Its Discovery in Human Cancer Research.” Oncotarget 7 
(29). Impact Journals: 46717–33. 
Tsuzuki, T, A Egashira, H Igarashi, T Iwakuma, Y Nakatsuru, Y Tominaga, H Kawate, et 
al. 2001. “Spontaneous Tumorigenesis in Mice Defective in the MTH1 Gene 
Encoding 8-Oxo-dGTPase.” Proceedings of the National Academy of Sciences of the 
United States of America 98 (20). National Academy of Sciences: 11456–61. 
doi:10.1073/pnas.191086798. 
Uhlén, Mathias, Linn Fagerberg, Björn M. Hallström, Cecilia Lindskog, Per Oksvold, 
 134 
Adil Mardinoglu, Åsa Sivertsson, et al. 2015. “Proteomics. Tissue-Based Map of the 
Human Proteome.” Science (New York, N.Y.) 347 (6220). American Association for 
the Advancement of Science: 1260419. doi:10.1126/science.1260419. 
van de Wetering, M, N Barker, I C Harkes, M van der Heyden, N J Dijk, A Hollestelle, J 
G Klijn, H Clevers, and M Schutte. 2001. “Mutant E-Cadherin Breast Cancer Cells 
Do Not Display Constitutive Wnt Signaling.” Cancer Research 61 (1). American 
Association for Cancer Research: 278–84. doi:10.1016/s0959-437x(99)80068-9. 
Waddell, T, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold, European 
Society for Medical Oncology (ESMO), European Society of Surgical Oncology 
(ESSO), and European Society of Radiotherapy and Oncology (ESTRO). 2013. 
“Gastric Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for Diagnosis, 
Treatment and Follow-Up.” Annals of Oncology  : Official Journal of the European 
Society for Medical Oncology / ESMO 24 Suppl 6 (suppl 6). Oxford University 
Press: vi57-63. doi:10.1093/annonc/mdt344. 
Wang, Timothy C., Charles A. Dangler, Duan Chen, James R. Goldenring, Theodore 
Koh, Raktima Raychowdhury, Robert J. Coffey, et al. 2000. “Synergistic Interaction 
between Hypergastrinemia and Helicobacter Infection in a Mouse Model of Gastric 
Cancer.” Gastroenterology 118 (1): 36–47. doi:10.1016/S0016-5085(00)70412-4. 
Wang, X., and Brian Seed. 2003. “A PCR Primer Bank for Quantitative Gene Expression 
Analysis.” Nucleic Acids Research 31 (24). Oxford University Press: 154e–154. 
doi:10.1093/nar/gng154. 
Wang, Xin, Roger Willin, Marie Svensson, Asa Ljungh, and Torkel Wadstrom. 2003. 
 135 
“Two-Year Follow-up of Helicobacter Pylori Infection in C57BL/6 and Balb/cA 
Mice.” APMIS 111 (4). Munksgaard International Publishers: 514–22. 
doi:10.1034/j.1600-0463.2003.1110410.x. 
Washington, Kay. 2010. “7th Edition of the AJCC Cancer Staging Manual: Stomach.” 
Annals of Surgical Oncology 17 (12). Springer-Verlag: 3077–79. 
doi:10.1245/s10434-010-1362-z. 
Wielenga, V J, R Smits, V Korinek, L Smit, M Kielman, R Fodde, H Clevers, and S T 
Pals. 1999. “Expression of CD44 in Apc and Tcf Mutant Mice Implies Regulation 
by the WNT Pathway.” The American Journal of Pathology 154 (2). American 
Society for Investigative Pathology: 515–23. doi:10.1016/S0002-9440(10)65297-2. 
Xu, Xiaoling, Steven G Brodie, Xiao Yang, Young-Hyuck Im, W Tony Parks, Lin Chen, 
Yong-Xing Zhou, Michael Weinstein, Seong-Jin Kim, and Chu-Xia Deng. 2000. 
“Haploid Loss of the Tumor Suppressor Smad4/Dpc4 Initiates Gastric Polyposis and 
Cancer in Mice.” Oncogene 19 (15). Nature Publishing Group: 1868–74. 
doi:10.1038/sj.onc.1203504. 
Yamachika, T, H Nakanishi, K Inada, T Tsukamoto, N Shimizu, K Kobayashi, S 
Fukushima, and M Tatematsu. 1998. “N-Methyl-N-Nitrosourea Concentration-
Dependent, rather than Total Intake-Dependent, Induction of Adenocarcinomas in 
the Glandular Stomach of BALB/c Mice.” Japanese Journal of Cancer Research  : 
Gann 89 (4): 385–91. http://www.ncbi.nlm.nih.gov/pubmed/9617343. 
Yamamoto, M., Tetsuya Tsukamoto, Hiroki Sakai, Norimitsu Shirai, Hiroko Ohgaki, 
Chie Furihata, Lawrence A. Donehower, Kenji Yoshida, and Masae Tatematsu. 
 136 
2000. “p53 Knockout Mice (-/-) Are More Susceptible than (+/-) or (+/+) Mice to N-
Methyl-N-Nitrosourea Stomach Carcinogenesis.” Carcinogenesis 21 (10). Oxford 
University Press: 1891–97. doi:10.1093/carcin/21.10.1891. 
Yan, D, M Wiesmann, M Rohan, V Chan, A B Jefferson, L Guo, D Sakamoto, et al. 
2001. “Elevated Expression of axin2 and Hnkd mRNA Provides Evidence That 
Wnt/beta -Catenin Signaling Is Activated in Human Colon Tumors.” Proceedings of 
the National Academy of Sciences of the United States of America 98 (26). National 
Academy of Sciences: 14973–78. doi:10.1073/pnas.261574498. 
Yu, Sungsook, Mijeong Yang, and Ki Taek Nam. 2014. “Mouse Models of Gastric 
Carcinogenesis.” Journal of Gastric Cancer 14 (2). Korean Gastric Cancer 
Association: 67–86. doi:10.5230/jgc.2014.14.2.67. 
Zavros, Yana, Kathryn A Eaton, Weiqun Kang, Sivaprakash Rathinavelu, Vinay 
Katukuri, John Y Kao, Linda C Samuelson, and Juanita L Merchant. 2005. “Chronic 
Gastritis in the Hypochlorhydric Gastrin-Deficient Mouse Progresses to 
Adenocarcinoma.” Oncogene 24 (14). Nature Publishing Group: 2354–66. 
doi:10.1038/sj.onc.1208407. 
Zeilstra, Jurrit, Sander P J Joosten, Maarten Dokter, Eugène Verwiel, Marcel Spaargaren, 
and Steven T Pals. 2008. “Deletion of the WNT Target and Cancer Stem Cell 
Marker CD44 in Apc(Min/+) Mice Attenuates Intestinal Tumorigenesis.” Cancer 
Research 68 (10). American Association for Cancer Research: 3655–61. 
doi:10.1158/0008-5472.CAN-07-2940. 
Zeller, Eva, Katharina Hammer, Melissa Kirschnick, and Albert Braeuning. 2013. 
 137 
“Mechanisms of RAS/β-Catenin Interactions.” Archives of Toxicology 87 (4). 
Springer-Verlag: 611–32. doi:10.1007/s00204-013-1035-3. 
Zeller, Eva, Katharina Mock, Moritz Horn, Sabine Colnot, Michael Schwarz, and Albert 
Braeuning. 2012. “Dual-Specificity Phosphatases Are Targets of the Wnt/β-Catenin 
Pathway and Candidate Mediators of β-catenin/Ras Signaling Interactions.” 
Biological Chemistry 393 (10): 1183–91. doi:10.1515/hsz-2012-0130. 
Zhang, Fuquan, and Jit Kong Cheong. 2016. “The Renewed Battle against RAS-Mutant 
Cancers.” Cellular and Molecular Life Sciences 73 (9). Springer International 
Publishing: 1845–58. doi:10.1007/s00018-016-2155-8. 
Zhang, Rui-Yan, Wen-Qi Du, Ying-Chun Zhang, Jun-Nian Zheng, and Dong-Sheng Pei. 
2016. “PLCε Signaling in Cancer.” Journal of Cancer Research and Clinical 
Oncology 142 (4). Springer Berlin Heidelberg: 715–22. doi:10.1007/s00432-015-
1999-x. 
Zhao, Z., J. Zuber, E. Diaz-Flores, L. Lintault, S. C. Kogan, K. Shannon, and S. W. 
Lowe. 2010. “p53 Loss Promotes Acute Myeloid Leukemia by Enabling Aberrant 
Self-Renewal.” Genes & Development 24 (13). Cold Spring Harbor Laboratory 
Press: 1389–1402. doi:10.1101/gad.1940710. 
Zhao, Zengming, Ning Hou, Yanxun Sun, Yan Teng, and Xiao Yang. 2010. “Atp4b 
Promoter Directs the Expression of Cre Recombinase in Gastric Parietal Cells of 
Transgenic Mice.” Journal of Genetics and Genomics. Vol. 37. doi:10.1016/S1673-
8527(09)60083-7. 
 
